

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 16:53:57 ; Search time 145.923 Seconds
(without alignments)
376.380 Million cell updates/sec

Title: US-10-041-860-48
Perfect score: 672
Sequence: 1 QVLVQSGAEVKKPGASVKV.....YDYYGMDVWGQTTVTVSS 125

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2443163 seqs, 439378781 residues

Total number of hits satisfying chosen parameters: 2443163

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_21:*
1: Geneseqp1980s:*
2: Geneseqp1990s:*
3: Geneseqp2000s:*
4: Geneseqp2001s:*
5: Geneseqp2002s:*
6: Geneseqp2003as:*
7: Geneseqp2003bs:*
8: Geneseqp2004s:*
9: Geneseqp2005s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	672	100.0	125	7	Adk18776 Anti-huma
2	672	100.0	125	7	Adk18948 Anti-huma
3	672	100.0	125	7	Adk18624 Anti-huma
4	672	100.0	125	7	Adk18813 Anti-huma
5	672	100.0	125	8	Adl25392 Human mAb
6	638	94.9	125	7	Adk18614 Anti-huma
7	638	94.9	125	7	Adk18779 Anti-huma
8	638	94.9	125	7	Adk18919 Anti-huma
9	638	94.9	125	7	Adk18816 Anti-huma
10	638	94.9	125	8	Adl25444 Human mAb
11	593.5	88.3	126	7	Adk18864 Anti-huma
12	593.5	88.3	126	7	Adk18595 Anti-huma
13	593.5	88.3	126	7	Adk18777 Anti-huma
14	593.5	88.3	126	8	Adl25408 Human mAb
15	579.5	85.2	125	7	Adk18814 Anti-huma
16	575.5	85.6	126	7	Adk18925 Anti-huma
17	575.5	85.6	126	7	Adk18780 Anti-huma
18	575.5	85.6	126	7	Adk18616 Anti-huma
19	575.5	85.6	126	7	Adk18817 Anti-huma
20	575.5	85.6	126	8	Adl25448 Human mAb
21	572	85.1	127	7	Adk18620 Anti-huma
22	572	85.1	127	7	Adk18818 Anti-huma
23	572	85.1	127	7	Adk18781 Anti-huma
24	572	85.1	127	7	Adk18936 Anti-huma

25	572	85.1	127	8	Adl25456	Adl25456 Human mAb
26	567.5	84.4	126	7	Adk18597	Adk18597 Anti-huma
27	567.5	84.4	126	7	Adk18870	Adk18870 Anti-huma
28	567.5	84.4	126	7	Adk18812	Adk18812 Anti-huma
29	567.5	84.4	126	7	Adk18775	Adk18775 Anti-huma
30	567.5	84.4	126	8	Adl25412	Adl25412 Human mAb
31	561.5	83.6	122	6	ABR55829	ABR55829 Heavy chain
32	561.5	83.6	126	7	Adk18778	Adk18778 Anti-huma
33	561.5	83.6	126	7	Adk18613	Adk18613 Anti-huma
34	561.5	83.6	126	7	Adk18815	Adk18815 Anti-huma
35	561.5	83.6	126	8	Adl25464	Adl25464 Human mAb
36	558.5	83.1	145	6	ABP57367	ABP57367 Anti-TRAI
37	556.5	82.8	124	7	ADP03955	ADP03955 Murine-ex
38	556.5	82.8	576	8	ADP69325	ADP69325 Human lun
39	554	82.4	125	8	ADP22256	ADP22256 Human ant
40	553.5	82.4	126	6	ADA89120	ADA89120 MS-Pro-26
41	553.5	82.4	126	7	ADG74371	ADG74371 MSPRO hea
42	553.5	82.4	126	9	ADW38826	ADW38826 T-cell me
43	551	82.0	127	6	ADA89122	ADA89122 MS-Pro-29
44	551	82.0	127	7	ADG74373	ADG74373 MSPRO hea
45	551	82.0	127	9	ADW38827	ADW38827 T-cell me

ALIGNMENTS

RESULT 1
ADK18776
ID ADK18776 standard; protein; 125 AA.
XX
AC ADK18776;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #2.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
FN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Corvalan JRP, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
FI Bezabeh B;
DR WPI; 2003-587119/55.
XX
PT New human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D), useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer.
XX
PS Disclosure; SEQ ID NO 200; 255pp; English.
XX
CC The invention relates to a human monoclonal antibody that binds to platelet-derived growth factor-D (PDGF-D). The antibodies are useful for treating chronic and recurrent human diseases, such as inflammation, autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are useful for modulating collagen formation, and for staging various cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were generated using an active protein fragment of the gene product from the clone 30664188.0.99 arising in the conditioned medium obtained when CC HEX293 cells are transfected with the plasmid pCEP4/Sec-30664188. This CC sequence corresponds to a protein used in the invention.
XX
SQ Sequence 125 AA;

```
Query Match      100.0%; Score 672; DB 7; Length 125;
Best Local Similarity 100.0%; Pred. No. 3e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB      1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60

QY      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120
DB      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120

QY      121 VTVSS 125
DB      121 VTVSS 125

RESULT 2
ADK18948
ID  ADK18948 standard; protein; 125 AA.
XX
AC  ADK18948;
DT  06-MAY-2004 (first entry)
XX
DE  Anti-human PDGF-D antibody protein related sequence #174.
XX
DE  antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS  Homo sapiens.
XX
FN  WO2003057857-A2.
XX
PD  17-JUL-2003.
XX
PF  06-JAN-2003; 2003WO-US000398.
XX
PR  07-JAN-2002; 2002US-00041860.
XX
PA  (ABGE-) ABGENIX INC.
XX
PI  Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI  Bezabeh B;
XX
DR  WPI; 2003-587119/55.
XX
PT  New human monoclonal antibody that binds to platelet-derived growth
PT  factor-D (PDGF-D), useful for treating chronic and recurrent human
PT  diseases, such as inflammation, autoimmunity and cancer.
XX
PS  Disclosure; SEQ ID NO 372; 255pp; English.
XX
CC  The invention relates to a human monoclonal antibody that binds to
CC  platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC  treating chronic and recurrent human diseases, such as inflammation,
CC  autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC  useful for modulating collagen formation, and for staging various
CC  cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC  generated using an active protein fragment of the gene product from the
CC  clone 30664188.0.99 arising in the conditioned medium obtained when
CC  HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC  sequence corresponds to a protein used in the invention.
XX
SQ  Sequence 125 AA;

Query Match      100.0%; Score 672; DB 7; Length 125;
Best Local Similarity 100.0%; Pred. No. 3e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB      1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60

QY      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120
DB      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120

QY      121 VTVSS 125
DB      121 VTVSS 125
```

```
QY      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120
DB      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120

QY      121 VTVSS 125
DB      121 VTVSS 125

RESULT 3
ADK18624
ID  ADK18624 standard; protein; 125 AA.
XX
AC  ADK18624;
DT  06-MAY-2004 (first entry)
XX
DE  Anti-human PDGF-D antibody heavy chain protein sequence.
XX
DE  antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS  Homo sapiens.
XX
FN  WO2003057857-A2.
XX
PD  17-JUL-2003.
XX
PF  06-JAN-2003; 2003WO-US000398.
XX
PR  07-JAN-2002; 2002US-00041860.
XX
PA  (ABGE-) ABGENIX INC.
XX
PI  Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI  Bezabeh B;
XX
DR  WPI; 2003-587119/55.
XX
PT  New human monoclonal antibody that binds to platelet-derived growth
PT  factor-D (PDGF-D), useful for treating chronic and recurrent human
PT  diseases, such as inflammation, autoimmunity and cancer.
XX
PS  Disclosure; SEQ ID NO 48; 255pp; English.
XX
CC  The invention relates to a human monoclonal antibody that binds to
CC  platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC  treating chronic and recurrent human diseases, such as inflammation,
CC  autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC  useful for modulating collagen formation, and for staging various
CC  cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC  generated using an active protein fragment of the gene product from the
CC  clone 30664188.0.99 arising in the conditioned medium obtained when
CC  HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC  sequence corresponds to a protein used in the invention.
XX
SQ  Sequence 125 AA;

Query Match      100.0%; Score 672; DB 7; Length 125;
Best Local Similarity 100.0%; Pred. No. 3e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB      1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60

QY      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120
DB      61 AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMDYWGQGT 120

QY      121 VTVSS 125
DB      121 VTVSS 125
```

RESULT 4

ADK18813
ID ADK18813 standard; protein; 125 AA.

XX AC ADK18813;

XX DT 06-MAY-2004 (first entry)

XX DE Anti-human PDGF-D antibody protein related sequence #39.

XX KW antinflammatory; immunomodulator; cytostatic; gene therapy.

XX OS Homo sapiens.

XX PN WO2003057857-A2.

XX PD 17-JUL-2003.

XX PF 06-JAN-2003; 2003WO-US000398.

XX PR 07-JAN-2002; 2002US-00041860.

XX PA (ABGE-) ABGENIX INC.

XX PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;

XX DR WPI; 2003-587119/55.

XX PT New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.

XX PS Disclosure; SEQ ID NO 237; 255pp; English.

XX CC The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.

XX SQ Sequence 125 AA;

Query Match 100.0%; Score 672; DB 7; Length 125;

Best Local Similarity 100.0%; Pred. No. 3e-54;

Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATQGLEWMGWINPNSGNTDY 60

Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATQGLEWMGWINPNSGNTDY 60

QY 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYYGMDVWGQGT 120

Db 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125

Db 121 VTVSS 125

RESULT 5

ADL25392
ID ADL25392 standard; protein; 125 AA.

XX AC ADL25392;

DT 17-JUN-2004 (first entry)

XX DE Human mAb 6.4 heavy chain variable region protein SEQ ID NO:2.

XX KW antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
KW nephritis; mesangial cell proliferation inhibition;
KW mesangial proliferative glomerulonephritis; nephrotropic;
KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
KW gene therapy; human; monoclonal antibody; mAb.

XX OS Homo sapiens.

XX PN WO2004024098-A2.

XX PD 25-MAR-2004.

XX PF 16-SEP-2003; 2003WO-US029414.

XX PR 16-SEP-2002; 2002US-0411137P.

XX PA (ABGE-) ABGENIX INC.

XX PA (CURA-) CURAGEN CORP.

XX PI Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;

XX DR WPI; 2004-269881/25.

XX DR N-PSDB; ADL25391.

XX PT Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.

XX PS Disclosure; SEQ ID NO 2; 115pp; English.

XX CC The present invention describes an antibody or its binding fragment that
CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
CC useful in preparing a medicament for treating nephritis. Also described:
CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
CC of treating mesangial proliferative glomerulonephritis. The antibody has
CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
CC antidiabetic activities, and can be used in gene therapy. The antibody or
CC its binding fragment, that binds PDGF-DD, can be used in preparing a
CC medicament for treating nephritis and related disorders, e.g., mesangial
CC proliferative glomerulonephritis. The present sequence represents a human
CC monoclonal antibody (mAb) variable region sequence, which is used in the
CC exemplification of the present invention.

XX SQ Sequence 125 AA;

Query Match 100.0%; Score 672; DB 8; Length 125;

Best Local Similarity 100.0%; Pred. No. 3e-54;

Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATQGLEWMGWINPNSGNTDY 60

Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATQGLEWMGWINPNSGNTDY 60

QY 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYYGMDVWGQGT 120

Db 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125

Db 121 VTVSS 125

RESULT 6

ADK18614
ID ADK18614 standard; protein; 125 AA.

XX AC ADK18614;

DT 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody heavy chain protein sequence.
DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
KW Homo sapiens.
XX WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
XX 07-JAN-2002; 2002US-00041860.
XX (ABGE-) ABGENIX INC.
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX Disclosure; SEQ ID NO 38; 255pp; English.
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX Sequence 125 AA;
SQ
Query Match 94.9%; Score 638; DB 7; Length 125;
Best Local Similarity 94.4%; Pred. No. 4.2e-51;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTGY 60
QY 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGSYNYDYYGMDVWGQGT 120
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSEDTAIYYCARGSGYSYGYDYYGMDVWGQGT 120
QY 121 VTVSS 125
Db 121 VTVSS 125
RESULT 7
ADK18779
ID ADK18779 standard; protein; 125 AA.
XX ADK18779;
XX 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody protein related sequence #5.
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX Homo sapiens.
XX

PN WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
XX 07-JAN-2002; 2002US-00041860.
XX (ABGE-) ABGENIX INC.
XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX Disclosure; SEQ ID NO 203; 255pp; English.
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX Sequence 125 AA;
SQ
Query Match 94.9%; Score 638; DB 7; Length 125;
Best Local Similarity 94.4%; Pred. No. 4.2e-51;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTGY 60
QY 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGSYNYDYYGMDVWGQGT 120
Db 61 AQKFGQRTVMTNTSISTAYMELSLRSEDTAIYYCARGSGYSYGYDYYGMDVWGQGT 120
QY 121 VTVSS 125
Db 121 VTVSS 125
RESULT 8
ADK18919
ID ADK18919 standard; protein; 125 AA.
XX ADK18919;
XX 06-MAY-2004 (first entry)
XX Anti-human PDGF-D antibody protein related sequence #145.
XX antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX Homo sapiens.
XX WO2003057857-A2.
XX 17-JUL-2003.
XX 06-JAN-2003; 2003WO-US000398.
XX 07-JAN-2002; 2002US-00041860.
XX

PA (ABGE-) ABGENIX INC.
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
DR
XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 343; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 125 AA;
SQ

Query Match 94.9%; Score 638; DB 7; Length 125;
Best Local Similarity 94.4%; Pred. No. 4.2e-51;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINNVQRATCGGLEWGMWNPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINNVQRATCGGLEWGMWNPNSGNTGY 60

QY 61 AQKQGRVTMTSDTSTAYMELSLRSEDTAIYCVRGFGYSYNDYYGMDVWGQGT 120
DB 61 AQKQGRVTMTNTSISTAYMELSLRSEDTAIYCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125
DB 121 VTVSS 125

RESULT 9
ADK18816
ID ADK18816 standard; protein; 125 AA.
XX
AC ADK18816;
XX
DT 06-MAY-2004 (first entry)
XX
DE Anti-human PDGF-D antibody protein related sequence #42.
XX
KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS Homo sapiens.
XX
PN WO2003057857-A2.
XX
PD 17-JUL-2003.
XX
PF 06-JAN-2003; 2003WO-US000398.
XX
PR 07-JAN-2002; 2002US-00041860.
XX
XX (ABGE-) ABGENIX INC.
XX
PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;
XX WPI; 2003-587119/55.
DR
XX New human monoclonal antibody that binds to platelet-derived growth

PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.
XX
XX Disclosure; SEQ ID NO 240; 255pp; English.
XX
XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.
XX
XX Sequence 125 AA;
SQ

Query Match 94.9%; Score 638; DB 7; Length 125;
Best Local Similarity 94.4%; Pred. No. 4.2e-51;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINNVQRATCGGLEWGMWNPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINNVQRATCGGLEWGMWNPNSGNTGY 60

QY 61 AQKQGRVTMTSDTSTAYMELSLRSEDTAIYCVRGFGYSYNDYYGMDVWGQGT 120
DB 61 AQKQGRVTMTNTSISTAYMELSLRSEDTAIYCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125
DB 121 VTVSS 125

RESULT 10
ADL25444
ID ADL25444 standard; protein; 125 AA.
XX
AC ADL25444;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human mAb 1.45 heavy chain variable region protein SEQ ID NO:54.
XX
KW antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
KW nephritis; mesangial cell proliferation inhibition;
KW mesangial proliferative glomerulonephritis; nephrotropic;
KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
KW gene therapy; human; monoclonal antibody; mAb.
XX
OS Homo sapiens.
XX
PN WO2004024098-A2.
XX
PD 25-MAR-2004.
XX
PF 16-SEP-2003; 2003WO-US029414.
XX
PR 16-SEP-2002; 2002US-0411137P.
XX
XX (ABGE-) ABGENIX INC.
PA (CURA-) CURAGEN CORP.
XX
PI Floege J, Gazit-Bornstein G, Keyt B, Larochele WJ, Lichenstein H;
XX WPI; 2004-269881/25.
DR N-PSDB; ADL25443.
XX
PT Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.
XX

PS Disclosure; SEQ ID NO 54; 115pp; English.

XX The present invention describes an antibody or its binding fragment that binds platelet derived growth factor-DD (PDGF-DD), where the antibody is useful in preparing a medicament for treating nephritis. Also described:

CC (1) a method of detecting nephritis; (2) a method of treating nephritis;

CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method of treating mesangial proliferative glomerulonephritis. The antibody has

CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and

CC antidiabetic activities, and can be used in gene therapy. The antibody or

CC its binding fragment, that binds PDGF-DD, can be used in preparing a

CC medicament for treating nephritis and related disorders, e.g., mesangial

CC proliferative glomerulonephritis. The present sequence represents a human

CC monoclonal antibody (mAb) variable region sequence, which is used in the

CC exemplification of the present invention.

XX

XX Sequence 125 AA;

Query Match 94.9%; Score 638; DB 8; Length 125;

Best Local Similarity 94.4%; Pred. No. 4.2e-51;

Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATCGQGLEWMGWINPNSGNTDY 60

Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATCGQGLEWMGWINPNSGNTGY 60

Qy 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNYDYGGMDVWGQGT 120

Db 61 AQKFGQRTVTRNTSISTAYMELSLRSEDTAIVYCARGSYGYSYDYGGMDVWGQGT 120

Qy 121 VTVSS 125

Db 121 VTVSS 125

RESULT 11

ADK18864

ID ADK18864 standard; protein; 126 AA.

AC ADK18864;

XX 06-MAY-2004 (first entry)

XX Anti-human PDGF-D antibody protein related sequence #90.

XX antiinflammatory; immunomodulator; cytostatic; gene therapy.

XX Homo sapiens.

XX WO2003057857-A2.

XX 17-JUL-2003.

XX 06-JAN-2003; 2003WO-US000398.

XX 07-JAN-2002; 2002US-00041860.

XX (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;

XX Bezabeh B;

XX WPI; 2003-587119/55.

XX New human monoclonal antibody that binds to platelet-derived growth

XX factor-D (PDGF-D), useful for treating chronic and recurrent human

XX diseases, such as inflammation, autoimmunity and cancer.

XX Disclosure; SEQ ID NO 288; 255pp; English.

XX The invention relates to a human monoclonal antibody that binds to

XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for

XX treating chronic and recurrent human diseases, such as inflammation,

PS

PS Disclosure; SEQ ID NO 54; 115pp; English.

XX The present invention describes an antibody or its binding fragment that binds platelet derived growth factor-DD (PDGF-DD), where the antibody is useful in preparing a medicament for treating nephritis. Also described:

CC (1) a method of detecting nephritis; (2) a method of treating nephritis;

CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method of treating mesangial proliferative glomerulonephritis. The antibody has

CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and

CC antidiabetic activities, and can be used in gene therapy. The antibody or

CC its binding fragment, that binds PDGF-DD, can be used in preparing a

CC medicament for treating nephritis and related disorders, e.g., mesangial

CC proliferative glomerulonephritis. The present sequence represents a human

CC monoclonal antibody (mAb) variable region sequence, which is used in the

CC exemplification of the present invention.

XX

XX Sequence 125 AA;

Query Match 88.3%; Score 593.5; DB 7; Length 126;

Best Local Similarity 89.7%; Pred. No. 5.4e-47;

Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATCGQGLEWMGWINPNSGNTDY 60

Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATCGQGLEWMGWINPNSGNTGY 60

Qy 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 119

Db 61 AQKFGQRTVTRNTSISTAYMELSLRSEDTAIVYCARGLAVAGTYYYYYGGMDVWGQGT 120

Qy 120 TTVSS 125

Db 121 TTVSS 126

RESULT 12

ADK18595

ID ADK18595 standard; protein; 126 AA.

AC ADK18595;

XX 06-MAY-2004 (first entry)

XX Anti-human PDGF-D antibody heavy chain protein sequence.

XX antiinflammatory; immunomodulator; cytostatic; gene therapy.

XX Homo sapiens.

XX WO2003057857-A2.

XX 17-JUL-2003.

XX 06-JAN-2003; 2003WO-US000398.

XX 07-JAN-2002; 2002US-00041860.

XX (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;

XX Bezabeh B;

XX WPI; 2003-587119/55.

XX New human monoclonal antibody that binds to platelet-derived growth

XX factor-D (PDGF-D), useful for treating chronic and recurrent human

XX diseases, such as inflammation, autoimmunity and cancer.

XX Disclosure; SEQ ID NO 19; 255pp; English.

XX The invention relates to a human monoclonal antibody that binds to

XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for

XX treating chronic and recurrent human diseases, such as inflammation,

CC

CC The invention relates to a human monoclonal antibody that binds to

CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for

CC treating chronic and recurrent human diseases, such as inflammation,

CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are

CC useful for modulating collagen formation, and for staging various

CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were

CC generated using an active protein fragment of the gene product from the

CC clone 30664188.0.99 arising in the conditioned medium obtained when

CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This

CC sequence corresponds to a protein used in the invention.

XX

XX Sequence 126 AA;

Query Match 88.3%; Score 593.5; DB 7; Length 126;

Best Local Similarity 89.7%; Pred. No. 5.4e-47;

Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATCGQGLEWMGWINPNSGNTDY 60

Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYDINWVRQATCGQGLEWMGWINPNSGNTGY 60

Qy 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 119

Db 61 AQKFGQRTVTRNTSISTAYMELSLRSEDTAIVYCARGLAVAGTYYYYYGGMDVWGQGT 120

Qy 120 TTVSS 125

Db 121 TTVSS 126

RESULT 12

ADK18595

ID ADK18595 standard; protein; 126 AA.

AC ADK18595;

XX 06-MAY-2004 (first entry)

XX Anti-human PDGF-D antibody heavy chain protein sequence.

XX antiinflammatory; immunomodulator; cytostatic; gene therapy.

XX Homo sapiens.

XX WO2003057857-A2.

XX 17-JUL-2003.

XX 06-JAN-2003; 2003WO-US000398.

XX 07-JAN-2002; 2002US-00041860.

XX (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;

XX Bezabeh B;

XX WPI; 2003-587119/55.

XX New human monoclonal antibody that binds to platelet-derived growth

XX factor-D (PDGF-D), useful for treating chronic and recurrent human

XX diseases, such as inflammation, autoimmunity and cancer.

XX Disclosure; SEQ ID NO 19; 255pp; English.

XX The invention relates to a human monoclonal antibody that binds to

XX platelet-derived growth factor-D (PDGF-D). The antibodies are useful for

XX treating chronic and recurrent human diseases, such as inflammation,

CC

CC The invention relates to a human monoclonal antibody that binds to

CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for

CC treating chronic and recurrent human diseases, such as inflammation,

CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are

CC useful for modulating collagen formation, and for staging various

CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were

CC generated using an active protein fragment of the gene product from the

CC clone 30664188.0.99 arising in the conditioned medium obtained when

CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This

CC sequence corresponds to a protein used in the invention.

XX

SQ Sequence 126 AA;
 Query Match 88.3%; Score 593.5; DB 7; Length 126;
 Best Local Similarity 89.7%; Pred. No. 5.4e-47;
 Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;
 QY 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 QY 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAIYYCVR-GFGYSYNDYYGMDVWGQGT 119
 DB 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAVYICAREGIAVAGTYYTYGMDVWGQGT 120
 QY 120 TVTVSS 125
 DB 121 TVTVSS 126
 RESULT 13
 ADK18777
 ID ADK18777 standard; protein; 126 AA.
 AC ADK18777;
 XX 06-MAY-2004 (first entry)
 DT Anti-human PDGF-D antibody protein related sequence #3.
 DE antiinflammatory; immunomodulator; cytostatic; gene therapy.
 KW Homo sapiens.
 OS WO2003057857-A2.
 PN 17-JUL-2003.
 PD 06-JAN-2003; 2003WO-US000398.
 XX 07-JAN-2002; 2002US-00041860.
 PF (ABGE-) ABGENIX INC.
 PA Corvalan JRF, Jia X, Peng X, Yang X, Chen F, Gazit G, Weber R;
 PI Bezabeh B;
 XX WPI; 2003-587119/55.
 DR New human monoclonal antibody that binds to platelet-derived growth
 factor-D (PDGF-D), useful for treating chronic and recurrent human
 diseases, such as inflammation, autoimmunity and cancer.
 XX Disclosure; SEQ ID NO 201; 255pp; English.
 PS The invention relates to a human monoclonal antibody that binds to
 platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
 treating chronic and recurrent human diseases, such as inflammation,
 autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
 useful for modulating collagen formation, and for staging various
 cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
 generated using an active protein fragment of the gene product from the
 clone 30664188.0.99 arising in the conditioned medium obtained when
 HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
 sequence corresponds to a protein used in the invention.
 XX Sequence 126 AA;
 Query Match 88.3%; Score 593.5; DB 7; Length 126;
 Best Local Similarity 89.7%; Pred. No. 5.4e-47;
 Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;
 QY 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 QY 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAIYYCVR-GFGYSYNDYYGMDVWGQGT 119
 DB 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAVYICAREGIAVAGTYYTYGMDVWGQGT 120
 QY 120 TVTVSS 125
 DB 121 TVTVSS 126
 RESULT 14
 ADL25408
 ID ADL25408 standard; protein; 126 AA.
 AC ADL25408;
 XX 17-JUN-2004 (first entry)
 DT Human mAb 1.18 heavy chain variable region protein SEQ ID NO:18.
 DE antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
 KW nephritis; mesangial cell proliferation inhibition;
 KW mesangial proliferative glomerulonephritis; nephrotropic;
 KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
 KW gene therapy; human; monoclonal antibody; mAb.
 OS Homo sapiens.
 OS WO2004024098-A2.
 PN 25-MAR-2004.
 PD 16-SEP-2003; 2003WO-US029414.
 XX 16-SEP-2002; 2002US-041137P.
 PR (ABGE-) ABGENIX INC.
 PA (CURA-) CURAGEN CORP.
 PI Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;
 XX WPI; 2004-269881/25.
 DR N-PSDB; ADL25407.
 DR Use of an antibody or its binding fragment that binds platelet derived
 growth factor-DD (PDGF-DD) for preparing a medicament for treating
 nephritis.
 XX Disclosure; SEQ ID NO 18; 115pp; English.
 PS The present invention describes an antibody or its binding fragment that
 binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
 useful in preparing a medicament for treating nephritis. Also described:
 CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
 CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
 of treating mesangial proliferative glomerulonephritis. The antibody has
 CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
 CC antidiabetic activities, and can be used in gene therapy. The antibody or
 CC its binding fragment, that binds PDGF-DD, can be used in preparing a
 CC medicament for treating nephritis and related disorders, e.g., mesangial
 CC proliferative glomerulonephritis. The present sequence represents a human
 CC monoclonal antibody (mAb) variable region sequence, which is used in the
 CC exemplification of the present invention.
 XX Sequence 126 AA;
 Query Match 88.3%; Score 593.5; DB 8; Length 126;
 Best Local Similarity 89.7%; Pred. No. 5.4e-47;
 Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;
 QY 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 QY 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAIYYCVR-GFGYSYNDYYGMDVWGQGT 119
 DB 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAVYICAREGIAVAGTYYTYGMDVWGQGT 120
 QY 120 TVTVSS 125
 DB 121 TVTVSS 126
 RESULT 15
 ADL25408
 ID ADL25408 standard; protein; 126 AA.
 AC ADL25408;
 XX 17-JUN-2004 (first entry)
 DT Human mAb 1.18 heavy chain variable region protein SEQ ID NO:18.
 DE antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
 KW nephritis; mesangial cell proliferation inhibition;
 KW mesangial proliferative glomerulonephritis; nephrotropic;
 KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
 KW gene therapy; human; monoclonal antibody; mAb.
 OS Homo sapiens.
 OS WO2004024098-A2.
 PN 25-MAR-2004.
 PD 16-SEP-2003; 2003WO-US029414.
 XX 16-SEP-2002; 2002US-041137P.
 PR (ABGE-) ABGENIX INC.
 PA (CURA-) CURAGEN CORP.
 PI Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;
 XX WPI; 2004-269881/25.
 DR N-PSDB; ADL25407.
 DR Use of an antibody or its binding fragment that binds platelet derived
 growth factor-DD (PDGF-DD) for preparing a medicament for treating
 nephritis.
 XX Disclosure; SEQ ID NO 18; 115pp; English.
 PS The present invention describes an antibody or its binding fragment that
 binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
 useful in preparing a medicament for treating nephritis. Also described:
 CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
 CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
 of treating mesangial proliferative glomerulonephritis. The antibody has
 CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
 CC antidiabetic activities, and can be used in gene therapy. The antibody or
 CC its binding fragment, that binds PDGF-DD, can be used in preparing a
 CC medicament for treating nephritis and related disorders, e.g., mesangial
 CC proliferative glomerulonephritis. The present sequence represents a human
 CC monoclonal antibody (mAb) variable region sequence, which is used in the
 CC exemplification of the present invention.
 XX Sequence 126 AA;
 Query Match 88.3%; Score 593.5; DB 8; Length 126;
 Best Local Similarity 89.7%; Pred. No. 5.4e-47;
 Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;
 QY 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 DB 1 QVQLVQSGAEVKKPGASVKVCASGYYTFTSYDINWVRQATCGGLEWGMWNPNSGNTGY 60
 QY 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAIYYCVR-GFGYSYNDYYGMDVWGQGT 119
 DB 61 AQKQFQGRVTWTRDTSISTAYMELSSLRSEDTAVYICAREGIAVAGTYYTYGMDVWGQGT 120
 QY 120 TVTVSS 125
 DB 121 TVTVSS 126
 RESULT 16
 ADL25408
 ID ADL25408 standard; protein; 126 AA.
 AC ADL25408;
 XX 17-JUN-2004 (first entry)
 DT Human mAb 1.18 heavy chain variable region protein SEQ ID NO:18.
 DE antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
 KW nephritis; mesangial cell proliferation inhibition;
 KW mesangial proliferative glomerulonephritis; nephrotropic;
 KW antiinflammatory; dermatological; immunosuppressive; antidiabetic;
 KW gene therapy; human; monoclonal antibody; mAb.
 OS Homo sapiens.
 OS WO2004024098-A2.
 PN 25-MAR-2004.
 PD 16-SEP-2003; 2003WO-US029414.
 XX 16-SEP-2002; 2002US-041137P.
 PR (ABGE-) ABGENIX INC.
 PA (CURA-) CURAGEN CORP.
 PI Floege J, Gazit-Bornstein G, Keyt B, Larochelle WJ, Lichenstein H;
 XX WPI; 2004-269881/25.
 DR N-PSDB; ADL25407.
 DR Use of an antibody or its binding fragment that binds platelet derived
 growth factor-DD (PDGF-DD) for preparing a medicament for treating
 nephritis.
 XX Disclosure; SEQ ID NO 18; 115pp; English.
 PS The present invention describes an antibody or its binding fragment that
 binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
 useful in preparing a medicament for treating nephritis. Also described:
 CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
 CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
 of treating mesangial proliferative glomerulonephritis. The antibody has
 CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
 CC antidiabetic activities, and can be used in gene therapy. The antibody or
 CC its binding fragment, that binds PDGF-DD, can be used in preparing a
 CC medicament for treating nephritis and related disorders, e.g., mesangial
 CC proliferative glomerulonephritis. The present sequence represents a human
 CC monoclonal antibody (mAb) variable region sequence, which is used in the
 CC exemplification of the present invention.
 XX Sequence 126 AA;
 Query Match 88.3%; Score 593.5; DB

```
Db      1 QVLVQSGAEVKPCASVKVSKASGYTFTSYDINWVRQATGQGLEWNGWNPNSGNTGY 60
QY      61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 119
Db      61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 120
QY      120 TTVTVSS 125
Db      121 TTVTVSS 126

RESULT 15
ADK18814
ID  ADK18814 standard; protein; 125 AA.
XX
AC  ADK18814;
XX
DT  06-MAY-2004 (first entry)
XX
DE  Anti-human PDGF-D antibody protein related sequence #40.
XX
KW  antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX
OS  Homo sapiens.
XX
PN  WO2003057857-A2.
XX
PD  17-JUL-2003.
XX
PF  06-JAN-2003; 2003WO-US000398.
XX
PR  07-JAN-2002; 2002US-00041860.
XX
PA  (ABGE-) ABGENIX INC.
XX
PI  Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
PI  Bezabeh B;
XX
DR  WPI; 2003-587119/55.
XX
New human monoclonal antibody that binds to platelet-derived growth
factor-D (PDGF-D), useful for treating chronic and recurrent human
diseases, such as inflammation, autoimmunity and cancer.
XX
PS  Disclosure; SEQ ID NO 238; 255pp; English.
XX
The invention relates to a human monoclonal antibody that binds to
platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
treating chronic and recurrent human diseases, such as inflammation,
autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
useful for modulating collagen formation, and for staging various
cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
generated using an active protein fragment of the gene product from the
clone 30664188.0.99 arising in the conditioned medium obtained when
HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
sequence corresponds to a protein used in the invention.
XX
Sequence 125 AA;
Query Match      86.2%; Score 579.5; DB 7; Length 125;
Best Local Similarity 89.4%; Pred. No. 1.1e-45;
Matches 110; Conservative 4; Mismatches 8; Indels 1; Gaps 1;
QY      4 LVQSGAEVKPCASVKVSKASGYTFTSYDINWVRQATGQGLEWNGWNPNSGNTDYAQK 63
Db      3 LVQSGAEVKPCASVKVSKASGYTFTSYDINWVRQATGQGLEWNGWNPNSGNTGYAQK 62
QY      64 FQGRVTMTDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGTVT 122
Db      63 FQGRVTMTDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGTVT 122
QY      123 VSS 125
|||
```

Search completed: May 15, 2006, 16:58:54
Job time : 146.923 secs

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 17:04:12 ; Search time 35.4077 Seconds
(without alignments)
291.870 Million cell updates/sec

Title: US-10-041-860-48
Perfect score: 672
Sequence: 1 QVQLVQSGAEVKKPGASVKV.....YDYYGMDVWGQGTITVTVSS 125

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/1/1aa/5 COMB.pep.*
2: /cgn2_6/prodata/1/1aa/6 COMB.pep.*
3: /cgn2_6/prodata/1/1aa/H COMB.pep.*
4: /cgn2_6/prodata/1/1aa/PCTUS COMB.pep.*
5: /cgn2_6/prodata/1/1aa/RE COMB.pep.*
6: /cgn2_6/prodata/1/1aa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	541.5	80.6	120	2	US-09-025-769B-36
2	541.5	80.6	120	2	US-09-025-769B-59
3	541.5	80.6	120	2	US-09-490-070A-36
4	541.5	80.6	120	2	US-09-490-070A-59
5	541.5	80.6	120	2	US-09-490-153-36
6	541.5	80.6	120	2	US-09-490-153-59
7	541.5	80.6	120	2	US-09-490-324-36
8	541.5	80.6	120	2	US-09-490-324-59
9	528	78.6	117	2	US-09-025-769B-22
10	528	78.6	117	2	US-09-490-070A-22
11	528	78.6	117	2	US-09-490-153-22
12	528	78.6	117	2	US-09-490-324-22
13	526	78.3	470	2	US-09-859-053-28
14	513	76.3	125	2	US-09-199-149-3
15	510.5	76.0	128	1	US-08-202-047-22
16	510.5	76.0	128	2	US-08-964-690-22
17	510	75.9	129	1	US-08-561-521-45
18	510	75.9	129	2	US-08-525-539A-77
19	510	75.9	129	4	PCT-US95-01219-45
20	504	75.0	123	2	US-10-330-613A-21
21	502	74.7	123	1	US-08-477-877B-94
22	502	74.7	123	1	US-08-472-281A-94
23	502	74.7	123	1	US-08-477-989B-94
24	502	74.7	123	2	US-09-462-140D-102
25	502	74.7	123	2	US-09-462-140D-105
26	501	74.6	119	1	US-08-561-521-10
27	501	74.6	119	4	PCT-US95-01219-10

28	498	74.1	119	2	US-09-438-954-41	Sequence 41, Appl
29	496	73.8	117	2	US-08-545-809A-96	Sequence 96, Appl
30	496	73.8	117	2	US-09-515-697-96	Sequence 96, Appl
31	493.5	73.4	139	1	US-08-253-877C-19	Sequence 19, Appl
32	493.5	73.4	139	1	US-08-452-164A-19	Sequence 19, Appl
33	493.5	73.4	139	2	US-08-603-024-18	Sequence 18, Appl
34	493.5	73.4	139	2	US-08-450-809-14	Sequence 14, Appl
35	487	72.5	96	2	US-10-194-975-3	Sequence 3, Appl
36	487	72.5	121	1	US-08-202-047-23	Sequence 23, Appl
37	487	72.5	121	2	US-08-964-690-23	Sequence 23, Appl
38	482	71.7	119	1	US-08-561-521-12	Sequence 12, Appl
39	482	71.7	119	4	PCT-US95-01219-12	Sequence 12, Appl
40	481	71.6	123	1	US-08-482-882-86	Sequence 86, Appl
41	481	71.6	123	1	US-08-483-389-86	Sequence 86, Appl
42	481	71.6	123	1	US-08-487-113D-86	Sequence 86, Appl
43	481	71.6	123	1	US-08-473-503-86	Sequence 86, Appl
44	481	71.6	123	1	US-08-483-932-86	Sequence 86, Appl
45	481	71.6	123	1	US-08-720-420A-86	Sequence 86, Appl

ALIGNMENTS

RESULT 1
US-09-025-769B-36
; Sequence 36, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-025-769B-36

Query Match 80.6%; Score 541.5; DB 2; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.7e-44;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;

```
QY 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWGWINPNSGGTNY 60
QY 61 AQKFGQGRVTMTDRTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKFGQGRVTMTDRTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 115
QY 121 VTVSS 125
Db 116 VTVSS 120
RESULT 2
US-09-025-769B-59
; Sequence 59, Application US/09025769B
; Patent No. 6300064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James P. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-025-769B-59
Query Match 80.6%; Score 541.5; DB 2; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.7e-44;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;
QY 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWGWINPNSGGTNY 60
QY 61 AQKFGQGRVTMTDRTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKFGQGRVTMTDRTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 115
QY 121 VTVSS 125
```

```
Db 116 VTVSS 120
RESULT 3
US-09-490-070A-36
; Sequence 36, Application US/09490070A
; Patent No. 6696248
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Colin G. Sandercock, Esq. c/o Heller Ehrman
; STREET: 1666 K Street, N.W., Suite 300
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20006
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,070A
; FILING DATE: 24-Jan-2000
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Colin G. Sandercock, Esq.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 37629-0005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 912-2000
; TELEFAX: (202) 912-2020
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-070A-36
Query Match 80.6%; Score 541.5; DB 2; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.7e-44;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;
QY 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWGWINPNSGGTNY 60
QY 61 AQKFGQGRVTMTDRTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKFGQGRVTMTDRTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 115
QY 121 VTVSS 125
Db 116 VTVSS 120
RESULT 4
US-09-490-070A-59
; Sequence 59, Application US/09490070A
```



```
;
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,153
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769B
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
;
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
;
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 59:
US-09-490-153-59

Query Match 80.6%; Score 541.5; DB 2; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.7e-44;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
QY 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
QY 121 VTVSS 125
Db 116 VTVSS 120

RESULT 7
US-09-490-324-36
; Sequence 36, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
;
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
;
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-09-490-324-36

Query Match 80.6%; Score 541.5; DB 2; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.7e-44;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;

QY 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
QY 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
QY 121 VTVSS 125
Db 116 VTVSS 120

RESULT 8
US-09-490-324-59
; Sequence 59, Application US/09490324
; Patent No. 6828422
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
;
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/025,769
```

```

; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; STRANDEDNESS:
; MISMATCHES: 5; Indels 10; Gaps 1;
Query Match      80.6%; Score 541.5; DB 2; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.7e-44;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;
QY   1 QVQLVQSQAEEVKPKGASVKVSKCKASGYTFTSYDINWVRQATCGGLEWMGWNPNSGNITDY 60
Db   1 QVQLVQSQAEEVKPKGASVKVSKCKASGYTFTSYDINWVRQAPGGLEWMGWNPNSGGTNY 60
QY   61 AQKPGQGRVTMTRTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNDYYGMVMDVGQGTT 120
Db   61 AQKPGQGRVTMTRTSISTAYMELSSLRSEDTAVIYCARGG-----DGFYANDYGQGTIL 115
QY   121 VTVSS 125
Db   116 VTVSS 120
RESULT 9
US-09-025-769B-22
; Sequence 22, Application US/09025769B
; Patent No. 630064
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; APPLICANT: Pack, Peter
; APPLICANT: Ilag, Vic
; APPLICANT: Ge, Liming
; APPLICANT: Moroney, Simon
; APPLICANT: Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; FILING DATE: 18-FEB-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090

```


Db 61 AQKQGRVTMTDTSISTAYMELSLRSDDTAVVYCARDGDG-----GFDYWGQST 111

QY 120 TVTVSS 125
Db 112 LVTVSS 117

RESULT 13
US-09-859-053-28
; Sequence 28, Application US/09859053
; Patent No. 6803039
; GENERAL INFORMATION:
; APPLICANT: Teuji, Takashi
; APPLICANT: Tezuka, Katsunari
; APPLICANT: Hori, No. 6803039uaki
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODY AGAINST A
; TITLE OF INVENTION: COSTIMULATORY SIGNAL TRANSDUCTION MOLECULE AILIM AND
; TITLE OF INVENTION: PHARMACEUTICAL USE THEREOF
; FILE REFERENCE: 06501-079001
; CURRENT APPLICATION NUMBER: US/09/859,053
; CURRENT FILING DATE: 2001-05-16
; PRIOR APPLICATION NUMBER: JP 2001-99508
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: JP 2000-147116
; PRIOR FILING DATE: 2000-05-18
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 470
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-859-053-28

Query Match 78.3%; Score 526; DB 2; Length 470;
Best Local Similarity 79.2%; Pred. No. 2.4e-42;
Matches 99; Conservative 10; Mismatches 16; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWMGWINPNSGNTDY 60
Db 20 QVQLVQSGAEVKKPKGASVKVCKASGYTFTGYMHVVRAPQGQLEWMGWINPHSGGNTY 79
QY 61 AQKQGRVTMTDTSISTAYMELSLRSDTAIYYCVRGFGYSYNYDYGYMDVWGQGT 120
Db 80 AQKQGRVTMTDTSISTAYMELSLRSDTAIYYCVRGFGYSYNYDYGYMDVWGQGT 139
QY 121 VTVSS 125
Db 140 VTVSS 144

RESULT 14
US-09-199-149-3
; Sequence 3, Application US/09199149
; Patent No. 6160099
; GENERAL INFORMATION:
; APPLICANT: Jonak, Zdenka L.
; APPLICANT: Taylor, Alexander H.
; APPLICANT: Trulli Jr., Stephen H.
; APPLICANT: Johanson, Kyung O.
; TITLE OF INVENTION: Humanized Monoclonal Antibodies
; FILE REFERENCE: P50860
; CURRENT APPLICATION NUMBER: US/09/199,149
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 3
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Kabat VH subgroup I
US-09-199-149-3

Query Match 76.3%; Score 513; DB 2; Length 125;

Best Local Similarity 80.6%; Pred. No. 9.3e-42;
Matches 104; Conservative 8; Mismatches 9; Indels 8; Gaps 5;
QY 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYAISVVRQAPQGQLEWMGWINP-GGDTNY 59
QY 61 AQKQGRVTMTDTSISTAYMELSLRSDTAIYYCVR-GFGYS---YNYDYGYMDVWG 116
Db 60 AQKQGRVTITADTSTSTAYMELSLRSDTAIYYCARPGYGGGCGY-NYWG--VWG 116
QY 117 QGTVTVSS 125
Db 117 QGTLTVSS 125

RESULT 15
US-08-202-047-22
; Sequence 22, Application US/08202047
; Patent No. 5800815
; GENERAL INFORMATION:
; APPLICANT: CHESNUT, Robert W.
; APPLICANT: POLLEY, Margaret J.
; APPLICANT: PAULSON, James C.
; APPLICANT: JONES, S. Tarran
; APPLICANT: SALDANHA, Jose W.
; APPLICANT: BENDIG, Mary M.
; TITLE OF INVENTION: Antibodies to P-Selectin and Their Uses
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/202,047
; FILING DATE: 25-FEB-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14137-77
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 128 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; FEATURE:
; NAME/KEY: Protein
; LOCATION: 1..128
; OTHER INFORMATION: /label= HUMAN_I
US-08-202-047-22

Query Match 76.0%; Score 510.5; DB 1; Length 128;
Best Local Similarity 77.9%; Pred. No. 1.7e-41;
Matches 102; Conservative 7; Mismatches 13; Indels 9; Gaps 3;
QY 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYDINNVQATCGQGLEWMGWINP-NSGNTD 59
Db 1 QVQLVQSGAEVKKPKGASVKVCKASGYTFTSYAISVVRQAPQGQLEWMGWINPYNGDNT 60

GenCore version 5.1.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 17:19:47 ; Search time 126.073 Seconds
(without alignments)
414.273 Million cell updates/sec

Title: US-10-041-860-48
Perfect score: 672
Sequence: 1 QVQLVQSGAEVKPGASVKV.....YDYVGMVWGQTTVTVSS 125

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1867569 seqs, 417829326 residues

Total number of hits satisfying chosen parameters: 1867569

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications_AA_Main:*
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	672	100.0	125	4	US-10-041-860-48
2	672	100.0	125	4	US-10-041-860-200
3	672	100.0	125	4	US-10-041-860-237
4	672	100.0	125	4	US-10-041-860-372
5	672	100.0	125	4	US-10-041-860-383-2
6	638	94.9	125	4	US-10-041-860-38
7	638	94.9	125	4	US-10-041-860-203
8	638	94.9	125	4	US-10-041-860-240
9	638	94.9	125	4	US-10-041-860-343
10	638	94.9	125	4	US-10-041-860-354
11	593.5	88.3	126	4	US-10-041-860-19
12	593.5	88.3	126	4	US-10-041-860-201
13	593.5	88.3	126	4	US-10-041-860-288
14	593.5	88.3	126	4	US-10-041-860-238
15	579.5	86.2	125	4	US-10-041-860-218
16	575.5	85.6	126	4	US-10-041-860-40
17	575.5	85.6	126	4	US-10-041-860-204
18	575.5	85.6	126	4	US-10-041-860-241
19	575.5	85.6	126	4	US-10-041-860-349
20	575.5	85.6	126	4	US-10-041-860-358
21	572	85.1	127	4	US-10-041-860-44
22	572	85.1	127	4	US-10-041-860-205
23	572	85.1	127	4	US-10-041-860-242
24	572	85.1	127	4	US-10-041-860-360
25	572	85.1	127	4	US-10-041-860-366
26	567.5	84.4	126	4	US-10-041-860-21
27	567.5	84.4	126	4	US-10-041-860-199

28	567.5	84.4	126	4	US-10-041-860-236
29	567.5	84.4	126	4	US-10-041-860-294
30	567.5	84.4	126	4	US-10-041-860-383-22
31	562.5	83.7	124	4	US-10-309-762-125
32	561.5	83.6	122	4	US-10-269-805-61
33	561.5	83.6	126	4	US-10-041-860-37
34	561.5	83.6	126	4	US-10-041-860-202
35	561.5	83.6	126	4	US-10-041-860-239
36	561.5	83.6	126	4	US-10-041-860-239
37	558.5	83.1	145	4	US-10-478-056-29
38	554	82.4	125	5	US-10-727-155-162
39	553.5	82.4	126	5	US-10-734-661A-101
40	551.5	82.1	118	4	US-10-309-762-124
41	551	82.0	127	5	US-10-734-661A-103
42	548.5	81.6	255	6	US-11-090-847-79
43	547.5	81.5	128	4	US-10-371-942-46
44	544	81.0	476	3	US-09-747-669-3
45	544	81.0	476	4	US-10-290-703-3

ALIGNMENTS

RESULT 1
US-10-041-860-48
; Sequence 48, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-48
Query Match 100.0%; Score 672; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 8.6e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 QVQLVQSGAEVKPGASVKVSKASGYFTFTSYDINVRQATGQGLEWMGNINPNSGNTDY 60
DB 1 QVQLVQSGAEVKPGASVKVSKASGYFTFTSYDINVRQATGQGLEWMGNINPNSGNTDY 60
QY 61 AQKFGQVTRTRDTSISTAYMELSLRSEDTAIYYCVRGFGVSYNDYYGMDVWGQGT 120
DB 61 AQKFGQVTRTRDTSISTAYMELSLRSEDTAIYYCVRGFGVSYNDYYGMDVWGQGT 120
QY 121 VTSS 125
DB 121 VTSS 125
RESULT 2
US-10-041-860-200
; Sequence 200, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi

```
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 200
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-200

Query Match      100.0%; Score 672; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 8.6e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60
Db      1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60

Qy      61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db      61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

Qy      121 VTVSS 125
Db      121 VTVSS 125

RESULT 3
US-10-041-860-237
; Sequence 237, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 237
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-237

Query Match      100.0%; Score 672; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 8.6e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60
Db      1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60

Qy      61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db      61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

Qy      121 VTVSS 125
Db      121 VTVSS 125

RESULT 4
US-10-041-860-372
; Sequence 372, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 372
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-372

Query Match      100.0%; Score 672; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 8.6e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60
Db      1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60

Qy      61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
Db      61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

Qy      121 VTVSS 125
Db      121 VTVSS 125

RESULT 5
US-10-665-383-2
; Sequence 2, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: Larochele, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-2
```

```
Query Match          100.0%; Score 672; DB 4; Length 125;
Best Local Similarity 100.0%; Pred. No. 8.6e-54;
Matches 125; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60

QY 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
DB 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125
DB 121 VTVSS 125

RESULT 6
US-10-041-860-38
; Sequence 38, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-38
```

```
Query Match          94.9%; Score 638; DB 4; Length 125;
Best Local Similarity 94.4%; Pred. No. 1.1e-50;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTGY 60

QY 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
DB 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125
DB 121 VTVSS 125

RESULT 7
US-10-041-860-39
; Sequence 203, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
```

```
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 203
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-203
```

```
Query Match          94.9%; Score 638; DB 4; Length 125;
Best Local Similarity 94.4%; Pred. No. 1.1e-50;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTGY 60

QY 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
DB 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125
DB 121 VTVSS 125
```

```
RESULT 8
US-10-041-860-240
; Sequence 240, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 240
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-240
```

```
Query Match          94.9%; Score 638; DB 4; Length 125;
Best Local Similarity 94.4%; Pred. No. 1.1e-50;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTGY 60

QY 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120
DB 61 AQKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGFGYSYNDYYGMDVWGQGT 120

QY 121 VTVSS 125
DB 121 VTVSS 125
```

```
RESULT 9
US-10-041-860-343
; Sequence 343, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 343
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-343

Query Match      94.9%; Score 638; DB 4; Length 125;
Best Local Similarity 94.4%; Pred. No. 1.1e-50;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWNPNSGNTDY 60
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWNPNSGNTGY 60
Qy      61 AQKFGQGRVTMTTRDTSISTAYMELSSLRSEDTAIYYCVRGFGSYNYDYGGMDVWGQGT 120
Db      61 AQKFGQGRVTMTTRNTSISTAYMELSSLRSEDTAVYVCARGSGSYGYDYGGMDVWGQGT 120
Qy      121 TVTVSS 125
Db      121 TVTVSS 125

RESULT 10
US-10-041-860-343
; Sequence 343, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 343
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-343

Query Match      94.9%; Score 638; DB 4; Length 125;
Best Local Similarity 94.4%; Pred. No. 1.1e-50;
Matches 118; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWNPNSGNTDY 60
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWNPNSGNTGY 60
Qy      61 AQKFGQGRVTMTTRDTSISTAYMELSSLRSEDTAIYYCVRGFGSYNYDYGGMDVWGQGT 120
Db      61 AQKFGQGRVTMTTRNTSISTAYMELSSLRSEDTAVYVCARGSGSYGYDYGGMDVWGQGT 120
Qy      121 TVTVSS 125
Db      121 TVTVSS 125

RESULT 11
US-10-041-860-19
; Sequence 19, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-19

Query Match      88.3%; Score 593.5; DB 4; Length 126;
Best Local Similarity 89.7%; Pred. No. 1.3e-46;
Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

Qy      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWNPNSGNTDY 60
Db      1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWNPNSGNTGY 60
Qy      61 AQKFGQGRVTMTTRDTSISTAYMELSSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 119
Db      61 AQKFGQGRVTMTTRNTSISTAYMELSSLRSEDTAVYVCAREGIAVAGTYYYYYGGMDVWGQGT 120
Qy      120 TVTVSS 125
Db      121 TVTVSS 126

RESULT 12
US-10-041-860-201
; Sequence 201, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
```

```
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 201
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-201

Query Match      88.3%; Score 593.5; DB 4; Length 126;
Best Local Similarity 89.7%; Pred. No. 1.3e-46;
Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

QY 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTGY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYIYGMVWGQQT 119
Db 61 AQKFGQRTVMTTRNTSISTAYMELSLRSEDTAIYYCAREGIAVAGTYYYYYGMVWGQQT 120

QY 120 TVTVSS 125
Db 121 TVTVSS 126
```

```
RESULT 13
US-10-041-860-288
; Sequence 288, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 288
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-288

Query Match      88.3%; Score 593.5; DB 4; Length 126;
Best Local Similarity 89.7%; Pred. No. 1.3e-46;
Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

QY 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTGY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYIYGMVWGQQT 119
Db 61 AQKFGQRTVMTTRNTSISTAYMELSLRSEDTAIYYCAREGIAVAGTYYYYYGMVWGQQT 120

QY 120 TVTVSS 125
Db 121 TVTVSS 126
```

```
RESULT 14
US-10-665-383-18
; Sequence 18, Application US/10665383
; Publication No. US20040141969A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRochele, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; FILE REFERENCE: ABGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665,383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 126
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-18
```

```
Query Match      88.3%; Score 593.5; DB 4; Length 126;
Best Local Similarity 89.7%; Pred. No. 1.3e-46;
Matches 113; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

QY 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTGY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYIYGMVWGQQT 119
Db 61 AQKFGQRTVMTTRNTSISTAYMELSLRSEDTAIYYCAREGIAVAGTYYYYYGMVWGQQT 120

QY 120 TVTVSS 125
Db 121 TVTVSS 126
```

```
RESULT 15
US-10-041-860-238
; Sequence 238, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ABGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 238
; LENGTH: 125
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-238
```

```
Query Match      86.2%; Score 579.5; DB 4; Length 125;
Best Local Similarity 89.4%; Pred. No. 2.5e-45;
Matches 110; Conservative 4; Mismatches 8; Indels 1; Gaps 1;

QY 4 LVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTDYAQK 63
Db 3 LVQSGAEVKPKGASVKVSKASGYTFTSYDINWVRQATQGGLEWMGWNPNSGNTGYAQK 62

QY 64 FQGRVTMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYIYGMVWGQQT 122
```

Db 63 PQGRVTMTNTSISTAYMELSLRSEDTAVYYCAREGIAVAGTYYYYYGMVDVNGOGTTVT 122

Qy 123 VSS 125

Db 123 VSS 125

Search completed: May 15, 2006, 17:25:06
Job time : 127.073 secs

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 17:21:22 ; Search time 19.8498 Seconds
(without alignments)
295.651 Million cell updates/sec

Title: US-10-041-860-48

Perfect score: 672

Sequence: 1 QVQLVQSGAEVKPGASVKV.....YDYYGMDVWGQGTITVTVSS 125

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 250354 seqs, 4694837 residues

Total number of hits satisfying chosen parameters: 250354

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:*

- 1: /SIDSS/prodata/1/pubpaa/US08_NEW_PUB.pep1.*
- 2: /SIDSS/prodata/1/pubpaa/US06_NEW_PUB.pep.*
- 3: /SIDSS/prodata/1/pubpaa/US07_NEW_PUB.pep.*
- 4: /SIDSS/prodata/1/pubpaa/US08_NEW_PUB.pep.*
- 5: /SIDSS/prodata/1/pubpaa/PCT_NEW_PUB.pep.*
- 6: /SIDSS/prodata/1/pubpaa/US09_NEW_PUB.pep1.*
- 7: /SIDSS/prodata/1/pubpaa/US09_NEW_PUB.pep1.*
- 8: /SIDSS/prodata/1/pubpaa/US10_NEW_PUB.pep.*
- 9: /SIDSS/prodata/1/pubpaa/US10_NEW_PUB.pep1.*
- 10: /SIDSS/prodata/1/pubpaa/US11_NEW_PUB.pep.*
- 11: /SIDSS/prodata/1/pubpaa/US11_NEW_PUB.pep1.*
- 12: /SIDSS/prodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	ID	Description
1	561.5	83.6	122	9 US-10-982-440-61
2	558.5	83.1	145	9 US-10-721-763-29
3	546.5	81.3	124	11 US-11-040-159-8
4	541.5	80.6	120	9 US-10-834-397-36
5	541.5	80.6	120	9 US-10-834-397-59
6	536.5	79.8	247	11 US-11-054-515-1729
7	536.5	79.8	247	11 US-11-266-444-1729
8	536	79.8	125	9 US-10-982-440-45
9	534.5	79.5	249	11 US-11-054-515-919
10	534.5	79.5	249	11 US-11-266-444-919
11	528	78.6	117	9 US-10-834-397-22
12	527.5	78.5	122	10 US-11-211-917-110
13	524.5	78.1	245	11 US-11-054-515-1896
14	524.5	78.1	245	11 US-11-266-444-1896
15	524	78.0	255	11 US-11-054-515-1407
16	524	78.0	255	11 US-11-266-444-1407
17	523.5	77.9	247	11 US-11-054-515-927
18	523.5	77.9	247	11 US-11-054-515-948
19	523.5	77.9	247	11 US-11-266-444-927
20	523.5	77.9	247	11 US-11-266-444-948
21	520	77.4	256	11 US-11-054-515-1301

22	520	77.4	256	11	US-11-266-444-1301	Sequence 1301, Ap
23	519.5	77.3	251	11	US-11-054-515-1921	Sequence 1921, Ap
24	519.5	77.3	251	11	US-11-266-444-1921	Sequence 1921, Ap
25	519.5	77.3	253	11	US-11-054-515-3244	Sequence 3244, Ap
26	518.5	77.2	120	9	US-10-982-440-47	Sequence 47, Appl
27	518.5	77.2	238	11	US-11-054-515-1907	Sequence 1907, Ap
28	518.5	77.2	238	11	US-11-266-444-1907	Sequence 1907, Ap
29	517.5	77.0	249	11	US-11-054-515-1635	Sequence 1635, Ap
30	517.5	77.0	249	11	US-11-266-444-1635	Sequence 1635, Ap
31	516	76.8	125	11	US-11-096-074-58	Sequence 58, Appl
32	516	76.8	125	11	US-11-095-822-58	Sequence 58, Appl
33	515.5	76.7	249	11	US-11-054-515-1290	Sequence 1290, Ap
34	515.5	76.7	249	11	US-11-054-515-1299	Sequence 1299, Ap
35	515.5	76.7	249	11	US-11-266-444-1290	Sequence 1290, Ap
36	515.5	76.7	249	11	US-11-266-444-1299	Sequence 1299, Ap
37	515.5	76.7	252	11	US-11-054-515-1875	Sequence 1875, Ap
38	515.5	76.7	252	11	US-11-266-444-1875	Sequence 1875, Ap
39	515	76.6	251	11	US-11-054-515-1806	Sequence 1806, Ap
40	515	76.6	251	11	US-11-266-444-1806	Sequence 1806, Ap
41	513.5	76.4	241	11	US-11-054-515-2031	Sequence 2031, Ap
42	513.5	76.4	241	11	US-11-266-444-2031	Sequence 2031, Ap
43	512	76.2	248	11	US-11-054-515-1721	Sequence 1721, Ap
44	512	76.2	248	11	US-11-266-444-1721	Sequence 1721, Ap
45	511.5	76.1	249	11	US-11-054-515-926	Sequence 926, App

ALIGNMENTS

RESULT 1
US-10-982-440-61
; Sequence 61, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; APPLICANT: Graham, Kevin
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 61
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-61

Query Match 83.6%; Score 561.5; DB 9; Length 122;
Best Local Similarity 86.4%; Pred. No. 2.3e-44;
Matches 108; Conservative 5; Mismatches 9; Indels 3; Gaps 1;
QY 1 QVQLVQSGAEVKPGASVKASVKKSGSYFTFTSYDINWVRQATGQGLEWMGNWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKPGASVKASVKKSGSYFTFTSYDINWVRQATGQGLEWMGNWNPNSGNTGY 60
QY 61 AOKFGRTVMTDTSISTAYMELSLRSEDYAIYCVGFGYSYNDYYGMDVWGQGT 120
Db 61 AOKFGRTVMTDTSISTAYMELSLRSEDYAIYCVGFGYSYNDYYGMDVWGQGT 117
QY 121 VTVSS 125
Db 118 VTVSS 122

RESULT 2
US-10-721-763-29
; Sequence 29, Application US/10721763
; Publication No. US20050249729A1
; GENERAL INFORMATION:
; APPLICANT: KIRIN BEER KABUSHIKI KAISHA

```

; TITLE OF INVENTION: ANTI TRAIL-R ANTIBODY
; FILE REFERENCE: PH-1573-PCT
; CURRENT APPLICATION NUMBER: US/10/721,763
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: JP2001-150213
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: JP2001-243040
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: JP2001-314489
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 145
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-721-763-29

Query Match      83.1%; Score 558.5; DB 9; Length 145;
Best Local Similarity 83.3%; Pred. No. 5.1e-44;
Matches 105; Conservative 9; Mismatches 11; Indels 1; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60
Db 20 QVQLVQSGAEVKKPGASVKVCKTSGYFTTYKINWVRQAPGQGLEWGWNPDPDSTGY 79

Qy 61 AQKFGQGRVTMTSDTSISTAYMELSLRSEDATAIYYCVRGFGY-SYNDYYGMDVWGQGT 119
Db 80 PQKFGQGRVTMTSDTSISTAYMELSLRSEDATAVYYCARSGYSGYRDYYGMDVWGQGT 139

Qy 120 TVTVSS 125
Db 140 TVTVSS 145

RESULT 3
US-11-040-159-8
; Sequence 8, Application US/11040159
; Publication No. US2005025552A1
; GENERAL INFORMATION:
; APPLICANT: Flynn, Peter
; APPLICANT: Luehrsén, Kenneth
; APPLICANT: Balint, Robert F.
; APPLICANT: Het, Jeng-Hong
; APPLICANT: Bebbington, Christopher R.
; APPLICANT: Yarranton, Geoffrey T.
; APPLICANT: KaloBios, Inc.
; TITLE OF INVENTION: Antibody Specificity Transfer Using Minimal Essential
; FILE REFERENCE: 021167-001730US
; CURRENT APPLICATION NUMBER: US/11/040,159
; CURRENT FILING DATE: 2005-01-20
; PRIOR APPLICATION NUMBER: US 60/537,364
; PRIOR FILING DATE: 2004-01-20
; PRIOR APPLICATION NUMBER: US 60/546,216
; PRIOR FILING DATE: 2004-02-23
; NUMBER OF SEQ ID NOS: 133
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 124
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: BA130-5-E10 Vh human
; OTHER INFORMATION: variable region containing minimal essential binding
; OTHER INFORMATION: specificity domain (MBSD) in heavy chain CDR3 from murine
; OTHER INFORMATION: anti-PcrV antibody M166 and complete human J-region (JH6)
US-11-040-159-8

Query Match      81.3%; Score 546.5; DB 11; Length 124;
Best Local Similarity 83.2%; Pred. No. 5.4e-43;
Matches 104; Conservative 8; Mismatches 12; Indels 1; Gaps 1;

; TITLE OF INVENTION: Proteolipin (Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSER: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 36:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 120 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 36:
US-10-834-397-36

Query Match      80.6%; Score 541.5; DB 9; Length 120;
Best Local Similarity 84.0%; Pred. No. 1.5e-42;
Matches 105; Conservative 5; Mismatches 10; Indels 5; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQATGQGLEWGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVCKASGYTFTSYDINWVRQAPGQGLEWGWINPNSGNTY 60
```



```
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1729
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-1729

Query Match          79.8%; Score 536.5; DB 11; Length 247;
Best Local Similarity 81.6%; Pred. No. 8.7e-42;
Matches 102; Conservative 8; Mismatches 14; Indels 1; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYVHWHVRQAPGQGLEWMGWINPNSGNTY 60

Qy 61 AQKQGRVTMTDRTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKQGRVTMTDRTSISTAYMELSLRSLRSDTAIVYVCARGY-YDILTGYDYADFIDWKGTM 119

Qy 121 VTVSS 125
Db 120 VTVSS 124

RESULT 8
US-10-982-440-45
; Sequence 45, Application US/10982440
; Publication No. US20060018909A1
; GENERAL INFORMATION:
; APPLICANT: Oliner, John
; TITLE OF INVENTION: Angiopoietin-2 Specific Binding Agents
; FILE REFERENCE: 04-881-A
; CURRENT APPLICATION NUMBER: US/10/982,440
; CURRENT FILING DATE: 2004-11-04
; PRIOR APPLICATION NUMBER: 60/620,161
; PRIOR FILING DATE: 2004-10-19
; NUMBER OF SEQ ID NOS: 215
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 45
; LENGTH: 125
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-982-440-45

Query Match          79.8%; Score 536; DB 9; Length 125;
Best Local Similarity 81.6%; Pred. No. 4.9e-42;
Matches 102; Conservative 7; Mismatches 16; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTY 60

Qy 61 AQKQGRVTMTDRTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYYGMDVWGQGT 120
Db 61 AQKQGRVTMTDRTSTSTAYMELSLRSDTAIVYVCARDRGIAARSAYYYGMDVWGQGT 120

Qy 121 VTVSS 125
Db 121 VTVSS 125

RESULT 9
US-11-054-515-919
```

```
; Sequence 919, Application US/11054515
; Publication No. US20050255532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 919
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-054-515-919

Query Match          79.5%; Score 534.5; DB 11; Length 249;
Best Local Similarity 81.7%; Pred. No. 1.3e-41;
Matches 103; Conservative 8; Mismatches 14; Indels 1; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPGSSVKVSCKVSGTFTSSYALSWVRQAPGQGLEWMGNPNNSGNTGY 60

Qy 61 AQKQGRVTMTDRTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYY-YGMDVWGQGT 119
Db 61 AQKQGRVTMTDRTSISTAYMELSLRSEDTAIVYVCARGTYDILTGYFHYGMDVWGQGT 120

Qy 120 VTVSS 125
Db 121 VTVSS 126

RESULT 10
US-11-266-444-919
; Sequence 919, Application US/11266444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulator
; FILE REFERENCE: PF523P1D1
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
```

```
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 919
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-266-444-919

Query Match          79.5%; Score 534.5; DB 11; Length 249;
Best Local Similarity 81.7%; Pred. No. 1.3e-41;
Matches 103; Conservative 8; Mismatches 14; Indels 1; Gaps 1;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATCGQGLEWGMWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGSSVKVSKSGTFTSYAISWVRQAPGQGLEWGMWNPNSGNTGY 60

QY 61 AQKFGQRTVMTSDTSISTAYMELSLRSEDTAIYVCVRGFGYSYNDYI-YGMQVWGQGT 119
Db 61 AQKFGQRTVMTTRNTSISTAYMELSLRSEDTAIYVCARGTYVDILTGFHYGMDVWGQGT 120

QY 120 TVTVSS 125
Db 121 TVTVSS 126

RESULT 11
US-10-834-397-22
; Sequence 22, Application US/10834397
; Publication No. US20060003334A1
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 117 amino acids
; TYPE: amino acid

; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-834-397-22

Query Match          78.6%; Score 528; DB 9; Length 117;
Best Local Similarity 82.5%; Pred. No. 2.5e-41;
Matches 104; Conservative 5; Mismatches 7; Indels 10; Gaps 2;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATCGQGLEWGMWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYIHHWVRQAPGQGLEWGMWNPNSGNTNY 60

QY 61 AQKFGQRTVMTSDTSISTAYMELSLRSEDTAIYVCVR-GFGYSYNDYIYGMQVWGQGT 119
Db 61 AQKFGQRTVMTSDTSISTAYMELSLRSDDTAVYVCARDGDG-----GFDYWGQGT 111

QY 120 TVTVSS 125
Db 112 LVTVSS 117

RESULT 12
US-11-211-917-110
; Sequence 110, Application US/11211917
; Publication No. US20060093600A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/11/211,917
; CURRENT FILING DATE: 2005-08-25
; PRIOR APPLICATION NUMBER: US/10/292,088
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 110
; LENGTH: 122
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-211-917-110

Query Match          78.5%; Score 527.5; DB 10; Length 122;
Best Local Similarity 79.7%; Pred. No. 2.9e-41;
Matches 102; Conservative 7; Mismatches 10; Indels 9; Gaps 2;

QY 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTSYDINWVRQATCGQGLEWGMWNPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKGASVKVSKASGYTFTGYIHHWVRQAPGQGLEWGMWNPNSGGTNY 60

QY 61 AQKFGQRTVMTSDTSISTAYMELSLRSEDTAIYVCVRGF---GVSYNDYIYGMQVWGQ 117
Db 61 AQKFGQRTVMTSDTSISTAYMELSLRSDDTAVYVCARGYCTNGVGYTFDY-----WQ 114

QY 118 GTTVTVSS 125
Db 115 GTTVTVSS 122

RESULT 13
US-11-054-515-1896
; Sequence 1896, Application US/11054515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
```

```
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1896
; LENGTH: 245
; TYPE: PRF
; ORGANISM: Homo sapiens
US-11-054-515-1896

Query Match      78.1%; Score 524.5; DB 11; Length 245;
Best Local Similarity 81.7%; Pred. No. 1.le-40;
Matches 103; Conservative 6; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYAMHWVRQAPGQRLWGWINAGNNTKY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYVYGMVWGQGT 119
Db 61 SQKFGQRTVITRDTSTASTAYMELSLRSEDTAIYYCAREGPG-----YYTGMVWGQGT 114

QY 120 TTVTVSS 125
Db 115 MVTVSS 120

RESULT 14
US-11-266-444-1896
; Sequence 1896, Application US/11/266,444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1896

Query Match      78.1%; Score 524.5; DB 11; Length 245;
Best Local Similarity 81.7%; Pred. No. 1.le-40;
Matches 103; Conservative 6; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYAMHWVRQAPGQRLWGWINAGNNTKY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYVYGMVWGQGT 119
Db 61 SQKFGQRTVITRDTSTASTAYMELSLRSEDTAIYYCAREGPG-----YYTGMVWGQGT 114

QY 120 TTVTVSS 125
Db 115 MVTVSS 120

US-11-054-515-1896
; Sequence 1896, Application US/11/054,515
; Publication No. US2005025532A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind Blys
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1407
; LENGTH: 255
; TYPE: PRF
; ORGANISM: Homo sapiens
US-11-054-515-1407

Query Match      78.0%; Score 524; DB 11; Length 255;
Best Local Similarity 76.9%; Pred. No. 1.2e-40;
Matches 103; Conservative 6; Mismatches 11; Indels 14; Gaps 2;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTDYLYLHWVRQAPGQRLWGWINPNSGGTNY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRFGFGYSYNYDY-----YVG 111
Db 61 AQMFGQRTVMTTRDTSISTASMELSLRSEDTAIYYCAR-----VNADYDILTYGPRDYG 115

QY 112 MDVWGQGTTVTVSS 125
```

```
; FILE REFERENCE: PF523P3
; CURRENT APPLICATION NUMBER: US/11/054,515
; CURRENT FILING DATE: 2005-02-10
; PRIOR APPLICATION NUMBER: 60/543,296
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: 60/580,347
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 10/293,418
; PRIOR FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: 60/331,469
; PRIOR FILING DATE: 2001-11-16
; PRIOR APPLICATION NUMBER: 60/340,817
; PRIOR FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 09/880,748
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 3247
; SEQ ID NO 1896
; LENGTH: 245
; TYPE: PRF
; ORGANISM: Homo sapiens
US-11-054-515-1896

Query Match      78.1%; Score 524.5; DB 11; Length 245;
Best Local Similarity 81.7%; Pred. No. 1.le-40;
Matches 103; Conservative 6; Mismatches 10; Indels 7; Gaps 2;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYAMHWVRQAPGQRLWGWINAGNNTKY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYVYGMVWGQGT 119
Db 61 SQKFGQRTVITRDTSTASTAYMELSLRSEDTAIYYCAREGPG-----YYTGMVWGQGT 114

QY 120 TTVTVSS 125
Db 115 MVTVSS 120

US-11-054-515-1896
; Sequence 1896, Application US/11/266,444
; Publication No. US20060062789A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: Antibodies that Immunospecifically Bind to B Lymphocyte Stimulat
; FILE REFERENCE: PF523PDI
; CURRENT APPLICATION NUMBER: US/11/266,444
; CURRENT FILING DATE: 2005-11-04
; PRIOR APPLICATION NUMBER: 09/880,746
; PRIOR FILING DATE: 2001-06-15
; PRIOR APPLICATION NUMBER: 60/212,210
; PRIOR FILING DATE: 2000-06-16
; PRIOR APPLICATION NUMBER: 60/240,816
; PRIOR FILING DATE: 2000-10-17
; PRIOR APPLICATION NUMBER: 60/276,248
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/277,379
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: 60/293,499
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 3239
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1896

Query Match      78.0%; Score 524; DB 11; Length 255;
Best Local Similarity 76.9%; Pred. No. 1.2e-40;
Matches 103; Conservative 6; Mismatches 11; Indels 14; Gaps 2;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTDYLYLHWVRQAPGQRLWGWINPNSGGTNY 60

QY 61 AQKFGQRTVMTTRDTSISTAYMELSLRSEDTAIYYCVRFGFGYSYNYDY-----YVG 111
Db 61 AQMFGQRTVMTTRDTSISTASMELSLRSEDTAIYYCAR-----VNADYDILTYGPRDYG 115

QY 112 MDVWGQGTTVTVSS 125
```

Db 116 MDVWGKGTWTVSS 129

Search completed: May 15, 2006, 17:25:50
Job time : 20.8498 secs

THIS PAGE LEFT BLANK

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 16:59:17 ; Search time 25.2146 Seconds
(without alignments)
476.989 Million cell updates/sec

Title: US-10-041-860-48
Perfect score: 672
Sequence: 1 QVQLVQSGAEVKPKGASVKV.....YDYFGMDVWGQGTGTTVTSS 125
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 seqs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80.*
1: pir1.*
2: pir2.*
3: pir3.*
4: pir4.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	557	82.9	127	2 S34014	Ig heavy chain V r
2	537.5	80.0	136	2 S31600	Ig heavy chain V r
3	534	79.5	129	2 S46393	Ig heavy chain V r
4	516.5	76.9	118	2 S36265	Ig heavy chain V r
5	515	76.6	123	2 D33548	Ig heavy chain V-1
6	514	76.5	129	2 S36260	Ig heavy chain V r
7	511.5	76.1	135	2 S49530	anti-Sm antibody V
8	510.5	76.0	132	2 S31596	Ig heavy chain V r
9	500	74.4	131	2 S26792	Ig heavy chain V r
10	499	74.3	119	2 PH0961	Ig heavy chain V r
11	496.5	73.9	110	2 PH1670	Ig heavy chain V r
12	496	73.8	98	2 S26918	Ig heavy chain V r
13	495.5	73.7	132	2 PH0954	Ig heavy chain V r
14	495.5	73.7	171	2 S23623	Ig heavy chain V r
15	494.5	73.6	118	2 PH1666	Ig heavy chain V r
16	493.5	73.4	136	2 PH0960	Ig heavy chain V r
17	488.5	72.7	143	1 ELHUND	Ig heavy chain pre
18	488	72.6	127	2 PH0955	Ig heavy chain V r
19	487.5	72.5	124	2 S19665	Ig heavy chain V r
20	486	72.3	133	2 C33548	Ig heavy chain V-1
21	486	72.3	627	2 S14683	Ig mu chain precu
22	484	72.0	142	2 A32483	Ig heavy chain V r
23	480	71.4	122	2 S36271	Ig heavy chain V r
24	480	71.4	160	2 PL0105	anti-PR2 erythrocy
25	477.5	71.1	126	2 B33548	Ig heavy chain V-1
26	476.5	70.9	114	2 PH1667	Ig heavy chain V r
27	473.5	70.5	128	2 PH0952	Ig heavy chain V r
28	472.5	70.3	120	2 S31999	Ig heavy chain V r
29	468	69.6	109	2 PH1668	Ig heavy chain V r

30	465	69.2	98	2 S26938	Ig heavy chain V r
31	465	69.2	117	2 S31680	Ig heavy chain V r
32	465	69.2	117	2 S18551	Ig heavy chain V r
33	465	69.2	126	2 I44151	Ig heavy chain V r
34	463	68.9	104	2 S69899	Ig heavy chain V r
35	462	68.8	121	2 S20783	Ig heavy chain V r
36	460.5	68.5	122	2 PH0958	Ig heavy chain V r
37	457	68.0	98	2 S26912	Ig heavy chain V r
38	456	67.9	125	2 PH0957	Ig heavy chain V r
39	455.5	67.8	120	2 S26789	Ig heavy chain V r
40	454.5	67.6	132	2 S46394	Ig heavy chain V r
41	454	67.6	129	2 A33548	Ig heavy chain V-1
42	452.5	67.3	110	2 PH1669	Ig heavy chain V r
43	449	66.8	125	2 S68170	Ig heavy chain V r
44	448.5	66.7	116	2 PH0959	Ig heavy chain V r
45	446.5	66.4	135	2 B32274	Ig heavy chain pre

ALIGNMENTS

RESULT 1

S34014
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 02-Dec-1993 #sequence_revision 10-Nov-1995 #text_change 16-Aug-1996
C:Accession: S34014; S30535
R:Marieette, X.; Tsapis, A.; Brouet, J.C.
Eur. J. Immunol. 23, 846-851, 1993
A>Title: Nucleotide sequence analysis of the variable domains of four human monoclonal
A:Reference number: S34001; MUID:93209281; PMID:7681398
A:Accession: S34014
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-127 <MAR>
A:Cross-references: UNIPARC:UPI0000176D31; EMBL:Z18321
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>

Query Match 82.9%; Score 557; DB 2; Length 127;
Best Local Similarity 82.7%; Pred. No. 1.4e-42;
Matches 105; Conservative 10; Mismatches 10; Indels 2; Gaps 1;

QY	1	QVQLVQSGAEVKPKGASVKVCKASGYFTSDINWVRQATGQGLEWGMWNPNSGNTDY	60
Db	1	QVQWVQSGAEVKPKGASVKVCKASGYFTSYDINWVRQATGQGLEWGMWNPSSGNTCY	60
QY	61	AQKFGQRTVTRDTSISTAYMELSSLRSEDTAIYYCVR--GFGYSYNDYYGMDVWGQG	118
Db	61	AQKPKGRVTMTNTSISTAYMELSSLRSEDTAVYFCARALSIGVAVIRGYVYALDVWGQG	120
QY	119	TTVTSS	125
Db	121	TTVSVS	127

RESULT 2

S31600
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31600
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnel, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31600
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-136 <CUI>
A:Cross-references: UNIPARC:UPI0000116453; EMBL:Z14165; NID:G30994; PIDN:CAA78534.1; PIR
C:Superfamily: immunoglobulin V region; immunoglobulin homology


```
Query Match          76.5%; Score 514; DB 2; Length 129;
Best Local Similarity 78.3%; Pred. No. 9.3e-39;
Matches 101; Conservative 8; Mismatches 16; Indels 4; Gaps 2;

QY 1 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSDINWVRQATCGGLEWGWGWINPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSDINWVRQATCGGLEWGWGWINPNSGNTDY 60
QY 61 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYCVR-GFGVSYNYD---YYGMDVWG 116
DB 61 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYCVR-GFGVSYNYD---YYGMDVWG 116
QY 117 QGFTVTVSS 125
DB 121 KGTTVTVSS 129

RESULT 7
S49530
anti-Sm antibody VH chain (VH1/DK1 or DM1/JH4b) - human
C:Species: Homo sapiens (man)
C>Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 23-Jul-1999
C:Accession: S49530
R:Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994
A:Description: Molecular characterization of natural human anti-Sm autoantibodies.
A:Reference number: S48797
A:Accession: S49530
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-135 <MAH>
A:Cross-references: UNIPARC:UPI00001166PF; EMBL:Z46348; NID:G560839; PIDN:CAA86467.1; PI
A:Superfamily: immunoglobulin V region; immunoglobulin homology
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match          76.1%; Score 511.5; DB 2; Length 135;
Best Local Similarity 79.4%; Pred. No. 1.6e-38;
Matches 100; Conservative 6; Mismatches 9; Indels 11; Gaps 2;

QY 1 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSDINWVRQATCGGLEWGWGWINPNSGNTDY 60
DB 20 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTGYTHWVRQAPQGGLWGMWNPNSGGTNY 79
QY 61 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYCVRG-FGVSYNIDYYGMDVWGQGT 119
DB 80 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYCARARTGNY-----WGQGT 129
QY 120 TTVTSS 125
DB 130 LVTVSS 135

RESULT 8
S31596
Ig heavy chain V region - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 22-Nov-1993 #sequence_revision 10-Nov-1995 #text_change 23-Jul-1999
C:Accession: S31596
R:Cuisinier, A.M.; Gauthier, L.; Boubli, L.; Fougereau, M.; Tonnelles, C.
submitted to the EMBL Data Library, June 1992
A:Description: Mechanisms that generate human immunoglobulin diversity operate from the
A:Reference number: S31585
A:Accession: S31596
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-132 <CUI>
A:Cross-references: UNIPARC:UPI0000116454; EMBL:Z14166; NID:G30996; PIDN:CAA78535.1; PID
A:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:34-117/Domain: immunoglobulin homology <IMM>

Query Match          76.0%; Score 510.5; DB 2; Length 132;
Matches 100; Conservative 6; Mismatches 9; Indels 11; Gaps 2;
```

```
Best Local Similarity 79.2%; Pred. No. 1.9e-38;
Matches 99; Conservative 6; Mismatches 7; Indels 13; Gaps 1;

QY 1 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSDINWVRQATCGGLEWGWGWINPNSGNTDY 60
DB 20 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSDINWVRQATCGGLEWGMWNPNSGNTGY 79
QY 61 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYCVRGFGVSYNYDYYGMDVWGQGT 120
DB 80 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYLAKA-----PANGQGT 126
QY 121 VTVSS 125
DB 127 VTVSS 131
```

```
RESULT 9
S26792
Ig heavy chain V region - human
C:Species: Homo sapiens (man)
C>Date: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 20-Jun-2000
C:Accession: S26792
R:Mortari, F.; Newton, J.A.; Wang, J.Y.; Schroeder Jr., H.W.
Eur. J. Immunol. 22, 241-245, 1992
A:Title: The human cord blood antibody repertoire. Frequent usage of the V(H)7 gene fam
A:Reference number: S26786; MUID:92111632; PMID:1730251
A:Accession: S26792
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-131 <MOR>
A:Cross-references: UNIPARC:UPI0000115FC3; EMBL:X61012; NID:G32804; PIDN:CAA43346.1; PI
A:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>
```

```
Query Match          74.4%; Score 500; DB 2; Length 131;
Best Local Similarity 72.5%; Pred. No. 1.6e-37;
Matches 95; Conservative 13; Mismatches 17; Indels 6; Gaps 2;

QY 1 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSDINWVRQATCGGLEWGWGWINPNSGNTDY 60
DB 1 QVQLVQSGAEVKKPKGASVKVSKCKASGYTFTSTAMNVRQAPQGGLWGMWINTGNPT 60
QY 61 AQKFGQGRVTMTDTSISTAYMELSLRLSDTAIYYCVR-GFGYSY-----NYDYYGMDV 114
DB 61 AQGFTGRFVSIDTSVSTAYLQISLKAEDTAIYYCARDNRGYSYDFWMSGYFYIYMDV 120
QY 115 WQGGTTVTVSS 125
DB 121 WKGTTTVTVSS 131
```

```
RESULT 10
PH0961
Ig heavy chain V region (G6+ T-L33) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 16-Aug-1996
C:Accession: PH0961
R:Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A:Title: Evidence for somatic selection of natural autoantibodies.
A:Reference number: PH0952; MUID:92202880; PMID:1552291
A:Accession: PH0961
A>Status: nucleic acid sequence not shown
A:Molecule type: DNA
A:Residues: 1-119 <MAR>
A:Cross-references: UNIPARC:UPI0000176CES
A:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
F:15-98/Domain: immunoglobulin homology <IMM>
F:31-35/Region: complementarity-determining 1
F:36-50/Region: framework 2
```

F;51-67/Region: complementarity-determining 2
F;68-98/Region: framework 3
F;99-107/Region: complementarity-determining 3

Query Match 74.3%; Score 499; DB 2; Length 119;
Best Local Similarity 79.2%; Pred. No. 1.8e-37;
Matches 99; Conservative 6; Mismatches 14; Indels 6; Gaps 1;

Qy

1 QVQLVQSGLAEVKKPGASVKSKASYGTFYSDINWRQATQGLEWGMNPNSGNTDY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
|||:

Dd

1 QVQLVQSGLAEVKKPGSSVKSKASGTFSSVAISWRQAPGGLEWGMGIPIFGTANY 60
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

[illegible]

Qy 121 vvvss 125
|||
Db 115 vvvss 119

RESULT 11
DH1670

ig heavy chain V region (clone 2A12) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C:Accession: D01670

J. Exp. Med. 178, 331-336, 1993
E. Hillson, J.L.; Karr, N.S.; Opplinger, I.R.; Mannik, M.; Sasso, E.H.
A>Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. Reference number: 8415388
A>Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. Reference number: 8415388
A>Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. Reference number: 8415388

A:Accession: PH1670
A:Molecule type: mRNA
A:Residues: 1-110 <HIL>
A:Genbank accession: U01949C.U01949C.1.769EB

A: Experimental source: B cell
C: Superfamily: immunoglobulin V region; immunoglobulin homology
C: Keywords: heterotetramer; immunoglobulin

Query Match	73.9%;	Score 496.5;	DB 2;	Length 110;
Best Local Similarity	82.1%;	Pred. No. 2.8e-37;		

QY 9 AEVKPGASVKVSCKASGYTFTSYDINWVRQATCGGLEWGWINPNSGNTDYAQKFQGRV 68

QY 69 TWTRDTISISTAYMELSSLSRSEDTAIYYCVRGFGYSYNDYYGVMDVWGOGTTTVVSS 125

RESULT 12

IG heavy chain V region (DP-15) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 22-Nov-1993 #sequence revision 10-Nov-1995 #text change 23-Jul-1999

Reederson, J.M.A.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
R.; Tomlinson, I.M.; Walter, G.; Marks, J.D.; Llewellyn, M.B.; Winter, G.
J. Mol. Biol. 227, 776-798, 1992

A:Accession: S26918
A:Status: preliminary
A:Molecule type: DNA

A; References: 1-50
 A; Cross-references: UNIPARC:UPI0000031F36; ENBL:Z12317; NTD:G32857; PIDN:CAA78187.1; PIDN:CAA78187.2
 C; Superfamily: immunoglobulin V region; immunoglobulin homology
 C; Keywords: heterotetramer; immunoglobulin

Query Match 73.8%; Score 496; DB 2; Length 98;

Best Local Similarity 94.9%; Pred. No. 2.8e-37;
 Matches 93; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy

1 QVQLVQSGAEVKKPGASVKISCKASGFTFTSYDINWVRQATGCGLEWMGWNPNSGNTDY 60
| | | | | | | | | | | | | | | | | | : | | | |
| | | | | | | | | | | | | | | | | | | | | |

pB

1 QVQLVQSGAEVKKPGASVKISCKASGFTFTSYDINWVRQATGCGLEWMGWNPNSGNTGY 60
| | | | | | | | | | | | | | | | | | : | | | |

QY		61 A QKFGQVRVTTRDTSTISAYMELSSLEDTAIYYCVR 98 :
Db		61 AOKFGRVTTNRNTSISTAYMELSSLEDTAIVYCVR 98 :

PH0954
Ig heavy chain V region (G6+ CLL-HEN) - human (fragment)
C:Species: Homo sapiens (man)

C:\Accession: PH0954
R,Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175: 983-991, 1992
Cdate: 1/-Apr-1993 #sequence_revision 17-Apr-1993 #seq_change 10 Aug 1993

A;Title: Evidence for somatic selection of natural autoantibodies
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0954
A;Status: nucleic acid sequence not shown

A; Molecule type: DNA
A; Residues: 1-132 <MAR>
A; Cross-references: UNIPARC:UPI0000176CDE
C; Superfamily: immunoglobulin V region; immunoglobulin homology

C; Keywords: heterotetramer; immunoglobulin F; 1-30/Region: framework 1 F; 15-98/Domain: immunoglobulin homology <IMM> F; 31-35/Region: complementarity-determining 1

F:36-50/Region: framework 2
F:51-67/Region: complementarity-determining 2
F:58-98/Region: framework 3
F:99-120/Region: complementarity-determining 3

Query Match	73.7%	Score 495.5;	DB 2;	Length 132;
Best Local Similarity	75.9%	Pred. NO. 4.2e-37;		
Matches 101: Conservative		6: Mismatches	17: Indels	9: Gaps

Qy 1 QVQLVQSGAEVKKPKGASVKVSKASGVTFTSYDINWVRQATGGGLEWVGWNPNSGNTDY 60

QY 61 A Q F Q G R V T W T R D T S I S T A Y M E L S S L R S E D T A I Y Y C V R G F - - - - - G V S Y N D Y Y Y G M 112

[illegible]

RESULT 14
S23623
Ig heavy chain V region precursor - human (fragment
1-100)
Name: S23623 (man)

CjDate: 13-Jan-1995 #sequence_revision 13-Jan-1995 #text_change 23-Jul-1995
CjAccession: S23623
RjOwner: T.; Lu, E.W.; Huang, D.F.; Soto-Gil, R.W.; Defetos, M.; Kozin, F.; C
T. Date: Mod 175 831-842 1002

A:Title: Genetic analysis of self-associating immunoglobulin G rheumatoid factors from A:Reference number: S23623; MUID:92156804; PMID:1740665
A:Accession: S23623
A:Accession: S23623

A:Molecule type: DNA
A:Residues: 1-171 <OLG>
A:Cross-references: UNIPARC:UPI0000115P93; EMBL:X59702; NID:g32010; PIDN:CAA42223.1; PIDN:CAA42223.1; UniProtKB:Q6V8K1; UniProtKB:Q6V8K1; UniProtKB:Q6V8K1; UniProtKB:Q6V8K1

C;Keywords: heterotetramer; immunoglobulin F;34-117/Domain: immunoglobulin homology <IMM>

```
Query Match      73.7%; Score 495.5; DB 2; Length 171;
Best Local Similarity 70.9%; Pred. No. 5.5e-37;
Matches 95; Conservative 9; Mismatches 13; Indels 17; Gaps 2;

Qy 1 QVQLVQSGAEVKPKGASVKSCASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
Db 20 QVQLVQSGAEVKPKGASVKSCASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 79
Qy 61 AQKFGQRVTMTSDTISTAYMELSSLRSEDTAIYVCVRGFGYSYNDYYYG----- 111
Db 80 GQKFGQRVTMTSDTISTAYMELSSLRSEDTAIYVCVRGFGYSYNDYYYG----- 111
Qy 112 MDVWGQGTITVTVSS 125
Db 132 FDIWGQGTITVTVSS 145

RESULT 15
PHI666
Ig heavy chain V region (clone 6C9) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 24-Feb-1994 #sequence_revision 24-Feb-1994 #text_change 16-Aug-1996
C:Accession: PHI666
R: Hillson, J.L.; Karr, N.S.; Oppiger, I.R.; Mannik, M.; Sasso, E.H.
J. Exp. Med. 178, 331-336, 1993
A: Title: The structural basis of germline-encoded VH3 immunoglobulin binding to staphylo-
A: Reference number: PHI642; MUID: 93301610; PMID: 8315388
A: Accession: PHI666
A: Molecule type: mRNA
A: Residues: 1-118 <HIL>
A: Cross-references: UNIPARC:UPI0000176BE7
A: Experimental source: B cell
C: Superfamily: immunoglobulin V region; immunoglobulin homology
C: Keywords: heterotetramer; immunoglobulin
P: 7-90/Domain: immunoglobulin homology <IMM>

Query Match      73.6%; Score 494.5; DB 2; Length 118;
Best Local Similarity 80.5%; Pred. No. 4.5e-37;
Matches 95; Conservative 6; Mismatches 16; Indels 1; Gaps 1;

Qy 9 AEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDYAQKFGGRV 68
Db 1 AEVKKPGASVKSCASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDYAQKFGGRV 60
Qy 69 TMTSDTISTAYMELSSLRSEDTAIYVCVR-GFGYSYNDYYGMDVWGQGTITVTVSS 125
Db 61 TITSDTISTAYMELSSLRSEDTAIYVCARVTLGGIKFYFYGGNDVWGQGTITVTVSS 118
```

Search completed: May 15, 2006, 17:04:50
Job time : 26.2146 secs

THIS PAGE LEFT BLANK

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035020; AAD56256.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1_1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13205 MW; 13E64F5345F4A16E CRC64;

Query Match 73.5%; Score 494; DB 2; Length 119;
Best Local Similarity 76.0%; Pred. No. 2,8e-41;
Matches 95; Conservative 10; Mismatches 14; Indels 6; Gaps 1;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGAELVKKPGASVKVSCKASGYTFTGYTHWVRQAPGQGLEWMGWINPNSWTNY 60
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

Qy 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVRGFGYSNYDYGVMDVWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 AOKFQGRVTMTDTSISTAYMELSLRSDDTAVYYCARGGRLGMLF-----DPWQQT 114
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

Qy 121 VTVSS 125
Db 115 VTVSS 119
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

RESULT 3
ID Q9UL95 HUMAN PRELIMINARY; PRT; 125 AA.
AC Q9UL95;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin heavy chain variable region
DE (Fragment)
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RL fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035019; AAD56255.1; -; mRNA.
DR HSSP; P01751; INQB.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1_1
FT NON_TER 125
SQ SEQUENCE 125 AA; 13516 MW; 0D3CD5C23248EAC CRC64;

Query Match 73.5%; Score 494; DB 2; Length 125;
```

```
Best Local Similarity 76.0%; Pred. No. 3e-41;
Matches 95; Conservative 9; Mismatches 21; Indels 0; Gaps 0;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 EVQLVESGAELVKKPGASVKVSCKASGYTFTGYTHWVRQAPGQGLEWMGWINPNSGGTNY 60
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

Qy 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVRGFGYSNYDYGVMDVWGQGT 120
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 AOKFQGRVTMTDTSISTAYMELSLRSDDTAVYYCARSGGRIAAAGDAFDWGQGT 120
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

Qy 121 VTVSS 125
Db 121 VTVSS 125
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

RESULT 4
ID Q65ZC8 HUMAN PRELIMINARY; PRT; 244 AA.
AC Q65ZC8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Single-chain Fv (Fragment)
DE Name=acFv;
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=97362799; PubMed=9219263; DOI=10.1038/nbt0797-629;
RA Kontermann R.E., Wing M.G., Winter G.;
RT "Complement recruitment using bispecific diabodies."
RL Nat. Biotechnol. 15:629-631(1997).
DR EMBL; Y13057; CAA73500.1; -; mRNA.
DR InterPro; IPR003599; IG.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00409; IGV; 2.
DR SMART; SM00406; IGV; 2.
DR PROSITE; PS50835; IG_LIKE; 2.
FT NON_TER 1_1
FT NON_TER 244
FT NON_TER 244
SQ SEQUENCE 244 AA; 26127 MW; 4B1F17868338F2BF CRC64;

Query Match 73.1%; Score 491; DB 2; Length 244;
Best Local Similarity 75.4%; Pred. No. 1.3e-40;
Matches 95; Conservative 13; Mismatches 12; Indels 6; Gaps 2;

Qy 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWINPNSGNTDY 60
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 1 QVQLVQSGAEVKKPGDSVKVSCKASGYTFTSDYHMHVVRQAPGQGLEWMGWIDPNNGDTFR 60
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

Qy 61 AOKFQGRVTMTDTSISTAYMELSLRSEDTAIYVCVR-GRFGYSNYDYGVMDVWGQGT 119
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 61 AOKFQGRVTMTDTSISAAAYMEVSLRSDDTAVYYCAREGTGSA-----IYGMVWGQGT 115
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

Qy 120 VTVSS 125
Db 116 LVTSS 121
||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:

RESULT 5
ID HVIC_HUMAN STANDARD; PRT; 147 AA.
AC P01744;
DT 21-JUL-1986 (Rel. 01, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE IG heavy chain V-I region ND precursor (Fragments)
DE Homo sapiens (Human).
```



```
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00409; IG; 4.
DR SMART; SM00407; IGC1; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER
SQ SEQUENCE 498 AA; 54125 MW; 40B3208A84E03B46 CRC64;

Query Match 71.2%; Score 478.5; DB 2; Length 498;
Best Local Similarity 74.6%; Pred. No. 5e-39;
Matches 94; Conservative 11; Mismatches 18; Indels 3; Gaps 2;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATCGQGLEWGWNPNSGNTDY 60
DB |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
35 QVQLVQSGADVKKPGASVKVSCKASGYTFTSYFFHWVRQAPGQGPPEWMGMINPRDGSTKY 94
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AOKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 119
DB |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
95 AQRFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVR-GFGYSYNYDYGGMDVWGQGT 152
|||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 120 TTVTVSS 125
DB |||||
153 LVTVSS 158

RESULT 8
Q9BRV24 HUMAN PRELIMINARY; PRT; 497 AA.
AC Q8WY24;
DT 01-MAR-2002 (TREMBlrel. 20, Created)
DT 01-MAR-2002 (TREMBlrel. 20, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE SMC66 protein.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Zheng S., Shao X., Cao J., Geng L., Fang Y., Dong Q.;
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF283666; AAL36987.1; -; mRNA.
DR HSSP; P01876; 10W0.
DR SMR; Q8WY24; 267-475.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain.
SQ SEQUENCE 497 AA; 53666 MW; F24D08DFA5A663E5 CRC64;

Query Match 70.5%; Score 474; DB 2; Length 497;
Best Local Similarity 70.0%; Pred. No. 1.4e-38;
Matches 91; Conservative 13; Mismatches 16; Indels 10; Gaps 2;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATCGQGLEWGWNPNSGNTDY 60
DB |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QQLVQSGAEVTKPGASVKVSCKASGYTFTSYDINWVRQAPGQGLEWGWNPQTGNTF 79
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AOKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVR-----GFGYSYNYDYGGMDVW 115
DB |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 AOKFGQRTVMTDTSINTAYMVLSTLSDTAIYFCARGNLRGGRGFGYNW-----FDPW 134
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 116 GQGTITVTVSS 125
DB |||||
135 GHGTLTVTVSS 144
```

```
RESULT 9
Q9BRV0 HUMAN PRELIMINARY; PRT; 500 AA.
AC Q9BRV0;
DT 01-JUN-2001 (TREMBlrel. 17, Created)
DT 01-JUN-2001 (TREMBlrel. 17, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE MGC27165 protein.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
KLausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
ALtschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heide F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
STapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
BRawstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
FAhey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
WHiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.N.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
and mouse cDNA sequences".
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RA Strausberg R.;
RL Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC005951; AA05951.1; -; mRNA.
DR HSSP; P01876; 10W0.
DR SMR; Q9BRV0; 25-300, 270-478.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003597; IG cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00835; IG LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Immunoglobulin domain; Repeat.
SQ SEQUENCE 500 AA; 54154 MW; 0A9BF43F2A3CC6D9 CRC64;

Query Match 70.0%; Score 470.5; DB 2; Length 500;
Best Local Similarity 71.9%; Pred. No. 3.1e-38;
Matches 92; Conservative 11; Mismatches 22; Indels 3; Gaps 2;

QY 1 QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATCGQGLEWGWNPNSGNTDY 60
DB |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVHLVQSGAEVSPGASVRSCKTSYGAFHTSYIIWVRQAPGQGLEWGWISPSDNTRF 79
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 61 AOKFGQRTVMTDTSISTAYMELSLRSEDTAIYYCVRGF-GYS--YNYDYGGMDVWGO 117
DB |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 AKTQGRVTLTDTSTSTVYVYMLRSLRSDDTAVYVCARRYCSYSSCONDYTYTYMDVWVGK 139
|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:

QY 118 GTTVTVSS 125
```



```
DB 140 GTTVTVSS 147
|||||
NCBI_TaxID=10090;
OX [1]
RN NUCLEOTIDE SEQUENCE.
RA Song X.T., Peng Z.Q., Guan X.H.;
RT "Amplification, cloning and sequence analysis of the heavy chain
RT variable region gene of monoclonal anti-idiotypic antibody NP30 of
RT Schistosoma japonicum.";
RL Submitted (JUN-2000) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF282622; AAG01452.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q9GYZ2; 1-119.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 119
SQ SEQUENCE 119 AA; 13567 MW; BA893873FD5FA6AB CRC64;

Query Match 67.7%; Score 455; DB 2; Length 119;
Best Local Similarity 69.6%; Pred. No. 2.2e-37;
Matches 87; Conservative 14; Mismatches 16; Indels 6; Gaps 1;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATCGQGLEWGWNPNSGNTDY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 QVQLVESGAELVRKPKASVRSKASGYTFTGYTMWVRQAPGQGHLEWIGYINPSRGYNY 60
QY 61 AQKFGQRTVMTDTSISTAYMELSLRSRSDTAIYYCVRGFGYSYNYDYGYGMDVWGQGT 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
61 NQKFKDRVTMTTDSKSFSTAYMDLSRLSADSASVYVCAR-----YYDHYCLDYGWQGT 114

QY 121 VTVSS 125
Db |||||
115 VTVSS 119

RESULT 12
QSN091.HUMAN
ID Q6N091 HUMAN PRELIMINARY; PRT; 500 AA.
AC Q6N091.
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein DKFZp686C02220 (Fragment).
GN Name=DKFZp686C02220;
OS Homo sapiens (Human);
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Human rectum tumor;
RG The German Human cDNA Consortium;
RA Wambutt R., Heubner D., Mewes H.W., Weil B., Amid C., Osanger A.,
RA Fobo G., Han M., Wiemann S.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640625; CAB45779.1; -; mRNA.
DR HSSP; P01751; 1A6W.
DR SMR; Q6N091; 270-478.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; Cl-set; 2.
DR SMART; SM00409; IGV; 4.
DR SMART; SM00407; IGV; 3.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
FT NON_TER 1
FT NON_TER 11

RESULT 10
QSN030.HUMAN
ID Q6N030 HUMAN PRELIMINARY; PRT; 518 AA.
AC Q6N030.
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DE Hypothetical protein DKFZp686I15212.
GN Name=DKFZp686I15212;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Rectum tumor;
RG The German cDNA Consortium;
RA Poustka A., Albert R., Moosmayer P., Schupp I., Wellenreuther R.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JAN-2005) to the EMBL/GenBank/DBJ databases.
DR EMBL; BX640724; CAB45841.1; -; mRNA.
DR HSSP; P01861; 1A0Q.
DR InterPro; IPR000005; HTHARAC.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig.cl.
DR InterPro; IPR003006; IG_MHC.
DR InterPro; IPR003596; IG_v.
DR Pfam; PF07654; Cl-set; 3.
DR SMART; SM00409; IGV; 3.
DR SMART; SM00407; IGV; 3.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS00041; HTH ARAC FAMILY_1; UNKNOWN_1.
DR PROSITE; PS50835; IG_LIKE; 4.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 518 AA; 57019 MW; 93B5F98613BF6382 CRC64;

Query Match 68.1%; Score 457.5; DB 2; Length 518;
Best Local Similarity 71.2%; Pred. No. 6.4e-37;
Matches 89; Conservative 10; Mismatches 23; Indels 3; Gaps 1;

QY 1 QVQLVQSGAEVKKPKASVKVSKASGYTFTSYDINWVRQATCGQGLEWGWNPNSGNTDY 60
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
20 QVHLVQSGAEVKKPKASVKVSKASGYTFTNFINWVRQAPGQSLWGWINTGNTKY 79
QY 61 AQKFGQRTVMTDTSISTAYMELSLRSRSDTAIYYCVRGFGYSYNYDYGYGMDVWGQGT 120
Db |||||:|||||:|||||:|||||:|||||:|||||:|||||:
80 SQKFGQRTVMTDTSISTAYMELSLRSRSDTAIYVCARDAPQGVTTTF---DYWGQGT 136

QY 121 VTVSS 125
Db |||||
137 VTVSS 141

RESULT 11
Q9GYZ2.MOUSE
ID Q9GYZ2.MOUSE PRELIMINARY; PRT; 119 AA.
AC Q9GYZ2.
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DE Monoclonal anti-idiotypic Schistosoma japonicum antibody NP30 heavy
DE chain variable region (Fragment).
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC Muridae; Murinae; Mus.
```

```

SQ SEQUENCE 500 AA; 54160 MW; 3C423A17D65A41E4 CRC64;
Query Match 66.4%; Score 446; DB 2; Length 500;
Best Local Similarity 69.8%; Pred. No. 8.7e-36;
Matches 88; Conservative 12; Mismatches 22; Indels 4; Gaps 2;

QY 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
DB 38 QVQLVQSGAEVKKPGASVKVSKASGYTFTSDHSITLWLRQAPGQGLEWIGWISAYSGQTY 97

QY 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVRGFGY-SYNYDYIYCMGVGQGT 119
DB 98 AQNLQGRVTMTDTSISTAYMELSLRSDDTAVYYCAKQDSYTIIPNDAPH---IWGQGT 154

QY 120 TVTVSS 125
DB 155 MVTVSS 160

RESULT 13
HV1G HUMAN STANDARD; PRT; 117 AA.
AC P23083;
DT 01-NOV-1991 (Rel. 20, Created)
DT 01-NOV-1991 (Rel. 20, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region V35 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=88296408; PubMed=2841108;
RA Matsuda F., Lee K.H., Nakai S., Sato T., Kodaira M., Zong S.Q.,
RA Ohno H., Fukuhara S., Honjo T.;
RT "Dispersed localization of D segments in the human immunoglobulin
RT heavy-chain locus.";
RL EMBO J. 7:1047-1051(1988).
RN [2]
RP NUCLEOTIDE SEQUENCE OF 20-116.
RX PubMed=7681398;
RA Mariette X., Tsapis A., Brouet J.C.;
RT "Nucleotide sequence analysis of the variable domains of four human
RT monoclonal IgM with an antibody activity to myelin-associated
RT glycoprotein.";
RL Eur. J. Immunol. 23:846-851(1993).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; X07448; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR PIR; S00476; HVHJ35.
DR HSSP; P01751; 1NOB.
DR SMR; P23083; 20-117.
DR Ensembl; ENSG00000130076; Homo sapiens.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region V35.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117

```

```

SQ SEQUENCE 117 AA; 13009 MW; B561CE63F8CE97BD CRC64;
Query Match 65.6%; Score 441; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 5.2e-36;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
DB 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTGYVHWVRQAPGQGLEWGRINPNSGGTY 79

QY 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVR 98
DB 80 AQKFGQRTVTRDTSISTAYMELSLRSDDTAVYYCAR 117

RESULT 14
HV1B HUMAN STANDARD; PRT; 117 AA.
AC P01743;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig heavy chain V-I region HG3 precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN NUCLEOTIDE SEQUENCE.
RP MEDLINE=83144028; PubMed=6298778;
RA Rechavi G., Ram D., Glazer L., Zakut R., Givol D.;
RT "Evolutionary aspects of immunoglobulin heavy chain variable region
RT (VH) gene subgroups.";
RL Proc. Natl. Acad. Sci. U.S.A. 80:855-859(1983).
CC -1- SIMILARITY: Contains 1 Ig-like (immunoglobulin-like) domain.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC EMBL; J00240; AAA52988.1; -; Genomic_DNA.
DR PIR; A02024; HVHUG.
DR HSSP; P01751; 1NOB.
DR SMR; P01743; 20-116.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 19
FT CHAIN 20 117 Ig heavy chain V-I region HG3.
FT DOMAIN 20 >117 Ig-like.
FT NON_TER 117 117
SQ SEQUENCE 117 AA; 12946 MW; 2D3F92FC60CD1FE7 CRC64;
Query Match 65.5%; Score 440; DB 1; Length 117;
Best Local Similarity 85.7%; Pred. No. 6.6e-36;
Matches 84; Conservative 5; Mismatches 9; Indels 0; Gaps 0;

QY 1 QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWGWGWINPNSGNTDY 60
DB 20 QVQLVQSGAEVKKPGASVKVSKASGYTFTNSYVHWVRQAPGQGLEWGRINPNSGGTSY 79

QY 61 AQKFGQRTVTRDTSISTAYMELSLRSEDTAIYYCVR 98
DB 80 AQKFGQRTVTRDTSISTAYMELSLRSDTAIYYCAR 117

```

Search completed: May 15, 2006, 17:03:57
Job time : 161.408 secs

THIS PAGE LEFT BLANK

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: May 15, 2006, 16:53:57 ; Search time 126.077 Seconds
(without alignments)
376.380 Million cell updates/sec
Title: US-10-041-860-49
Perfect score: 558
Sequence: 1 EXVLQSPGTLSPGERAT.....CQQYGSPCSFQGTGLKLIK 108
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 2443163 seqs, 439378781 residues
Total number of hits satisfying chosen parameters: 2443163
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
Database : A_Geneseq 21:.*
1: Geneseqp1980s:.*
2: Geneseqp1990s:.*
3: Geneseqp2000s:.*
4: Geneseqp2001s:.*
5: Geneseqp2002s:.*
6: Geneseqp2003as:.*
7: Geneseqp2003bs:.*
8: Geneseqp2004s:.*
9: Geneseqp2005s:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	558	100.0	108	ADK18625	Adk18625 Anti-huma
2	558	100.0	108	ADK18951	Adk18951 Anti-huma
3	558	100.0	108	ADK18835	Adk18835 Anti-huma
4	558	100.0	108	ADK18801	Adk18801 Anti-huma
5	558	100.0	108	ADL25394	Adl25394 Human mAb
6	535	95.9	108	ADY26769	Ady26769 Anti-NGF-
7	535	95.9	108	ADY26816	Ady26816 Human ant
8	535	95.9	128	ADZ57709	Adz57709 Germline
9	535	95.9	129	AAR38672	Aar38672 vk325-Jk2
10	533	95.5	108	ADP03986	Adp03986 Murine-ex
11	533	95.5	130	ABJ36930	Abj36930 Anti-CD40
12	533	95.5	384	AAM24101	Aam24101 Human BGT
13	532	95.3	108	ADQ16703	Adq16703 Modified
14	532	95.3	108	ADV44439	Adv44439 PAX116 va
15	532	95.3	108	AEb12911	Aeb12911 Antibody
16	532	95.3	109	ADP46971	Adp46971 Murine li
17	532	95.3	112	ADV44477	Adv44477 Anti-teta
18	532	95.3	120	ADP40551	Adp40551 3E1/4G11
19	532	95.3	130	AEb12948	Aeb12948 Antibody
20	532	95.3	215	ADQ16702	Adq16702 Modified
21	532	95.3	215	ADV44438	Adv44438 PAX116 va
22	532	95.3	215	AEb12910	Aeb12910 Antibody
23	532	95.3	239	ADV44458	Adv44458 Anti-teta
24	532	95.3	239	AEb12929	Aeb12929 Antibody

25	531	95.2	108	9	ADZ42030	Adz42030 Ig L chai
26	531	95.2	108	9	ADZ42032	Adz42032 Ig L chai
27	531	95.2	108	9	ADZ42034	Adz42034 Ig L chai
28	531	95.2	108	9	AEA89845	Aea89845 Anti-IFN
29	530	95.0	384	4	AAU14462	Aau14462 Human nov
30	530	95.0	384	4	AAU14463	Aau14463 Human nov
31	530	95.0	384	4	AAU14461	Aau14461 Human nov
32	530	95.0	384	4	AAU14464	Aau14464 Human nov
33	530	95.0	384	8	ADH80782	Adh80782 Human pol
34	529	94.8	108	8	ADS84382	Ads84382 Human ant
35	529	94.8	108	8	ADP68524	Adp68524 Anti-EPO-
36	528	94.6	108	9	AEA89846	Aea89846 Anti-IFN
37	528	94.6	384	8	ADH80779	Adh80779 Human pol
38	528	94.6	384	8	ADH80781	Adh80781 Human pol
39	528	94.6	385	8	ADH80780	Adh80780 Human pol
40	526	94.3	108	6	AAE38059	Aae38059 Human 17G
41	526	94.3	108	9	ADY70202	Ady70202 Human mon
42	526	94.3	109	6	ADA89268	Ada89268 Human ant
43	526	94.3	109	8	ADP47295	Adp47295 Human pho
44	526	94.3	109	9	AEA41084	Aea41084 Germline
45	526	94.3	235	9	AEA41059	Aea41059 Anti-M-CS

ALIGNMENTS

RESULT 1
ADK18625
ID ADK18625 standard; protein; 108 AA.
XX AC ADK18625;
XX DT 06-MAY-2004 (first entry)
XX DE Anti-human PDGF-D antibody light chain protein sequence.
XX KW antiinflammatory; immunomodulator; cytostatic; gene therapy.
XX OS Homo sapiens.
XX PN WO2003057857-A2.
XX PD 17-JUL-2003.
XX PF 06-JAN-2003; 2003WO-US000398.
XX PR 07-JAN-2002; 2002US-00041860.
XX PA (ABGE-) ABGENIX INC.
XX PI Corvalan JRF, Jia X, Feng X, Yang X, Chen F, Gazit G, Weber R;
XX PI Bezabeh B;
XX DR WPI; 2003-587119/55.
XX PT New human monoclonal antibody that binds to platelet-derived growth
XX PT factor-D (PDGF-D), useful for treating chronic and recurrent human
XX PT diseases, such as inflammation, autoimmunity and cancer.
XX PT Disclosure; SEQ ID NO 49; 255pp; English.
XX CC The invention relates to a human monoclonal antibody that binds to
XX CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
XX CC treating chronic and recurrent human diseases, such as inflammation,
XX CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
XX CC useful for modulating collagen formation, and for staging various
XX CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
XX CC generated using an active protein fragment of the gene product from the
XX CC clone 30664188.0.99 arising in the conditioned medium obtained when
XX CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
XX CC sequence corresponds to a protein used in the invention.
SQ Sequence 108 AA;

KW antiinflammatory; immunomodulator; cytostatic; gene therapy.

XX Homo sapiens.

XX WO2003057857-A2.

XX 17-JUL-2003.

XX 06-JAN-2003; 2003WO-US000398.

XX 07-JAN-2002; 2002US-00041860.

XX (ABGE-) ABGENIX INC.

XX Corvalan JRF, Jia X, Peng X, Yang X, Chen F, Gazit G, Weber R;
PI Bezabeh B;

XX WPI; 2003-587119/55.

XX New human monoclonal antibody that binds to platelet-derived growth
PT factor-D (PDGF-D), useful for treating chronic and recurrent human
PT diseases, such as inflammation, autoimmunity and cancer.

XX Disclosure; SEQ ID NO 225; 255pp; English.

XX The invention relates to a human monoclonal antibody that binds to
CC platelet-derived growth factor-D (PDGF-D). The antibodies are useful for
CC treating chronic and recurrent human diseases, such as inflammation,
CC autoimmunity and cancer. The PDGF-D nucleic acids and polypeptides are
CC useful for modulating collagen formation, and for staging various
CC cancers. Antibodies to platelet-derived growth factor-D (PDGF-D) were
CC generated using an active protein fragment of the gene product from the
CC clone 30664188.0.99 arising in the conditioned medium obtained when
CC HEK293 cells are transfected with the plasmid pCEP4/Sec-30664188. This
CC sequence corresponds to a protein used in the invention.

XX Sequence 108 AA;

Query Match 100.0%; Score 558; DB 7; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.1e-35;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGAPRLLIYATSSRATGIP 60

DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGAPRLLIYATSSRATGIP 60

QY 61 DRFSGSGSTDTLTISRLEPEDFAVYCCQYGSFPCSPFGQGTKLEIK 108

DB 61 DRFSGSGSTDTLTISRLEPEDFAVYCCQYGSFPCSPFGQGTKLEIK 108

RESULT 5

ADL25394

ID ADL25394 standard; protein; 108 AA.

XX AC

XX ADL25394;

XX 17-JUN-2004 (first entry)

XX Human mAb 6.4 light chain variable region protein SEQ ID NO:4.

XX antibody; binding fragment; platelet derived growth factor-DD; PDGF-DD;
KW nephritis; mesangial cell proliferation inhibition;
KW mesangial proliferative glomerulonephritis; nephrotropic;
KW antinflammatory; dermatological; immunosuppressive; antidiabetic;
KW gene therapy; human; monoclonal antibody; mAb.

XX Homo sapiens.

XX WO2004024098-A2.

XX 25-MAR-2004.

XX

PF 16-SEP-2003; 2003WO-US029414.

XX 16-SEP-2002; 2002US-0411137P.

XX (ABGE-) ABGENIX INC.

XX (CURA-) CURAGEN CORP.

XX Floege J, Gazit-Bornstein G, Keyt B, Laroche WJ, Lichenstein H;

XX WPI; 2004-269881/25.

XX N-PSDB; ADL25393.

XX Use of an antibody or its binding fragment that binds platelet derived
PT growth factor-DD (PDGF-DD) for preparing a medicament for treating
PT nephritis.

XX Disclosure; SEQ ID NO 4; 115pp; English.

XX The present invention describes an antibody or its binding fragment that
CC binds platelet derived growth factor-DD (PDGF-DD), where the antibody is
CC useful in preparing a medicament for treating nephritis. Also described:
CC (1) a method of detecting nephritis; (2) a method of treating nephritis;
CC (3) a method of inhibiting mesangial cell proliferation; and (4) a method
CC of treating mesangial proliferative glomerulonephritis. The antibody has
CC nephrotropic, antiinflammatory, dermatological, immunosuppressive and
CC antidiabetic activities, and can be used in gene therapy. The antibody or
CC its binding fragment, that binds PDGF-DD, can be used in preparing a
CC medicament for treating nephritis and related disorders, e.g., mesangial
CC proliferative glomerulonephritis. The present sequence represents a human
CC monoclonal antibody (mAb) variable region sequence, which is used in the
CC exemplification of the present invention.

XX Sequence 108 AA;

Query Match 100.0%; Score 558; DB 8; Length 108;

Best Local Similarity 100.0%; Pred. No. 4.1e-35;

Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGAPRLLIYATSSRATGIP 60

DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGAPRLLIYATSSRATGIP 60

QY 61 DRFSGSGSTDTLTISRLEPEDFAVYCCQYGSFPCSPFGQGTKLEIK 108

DB 61 DRFSGSGSTDTLTISRLEPEDFAVYCCQYGSFPCSPFGQGTKLEIK 108

RESULT 6

ADY26769

ID ADY26769 standard; protein; 108 AA.

XX AC

XX ADY26769;

XX 19-MAY-2005 (first entry)

XX Anti-NGF-antibody light chain variable region SEQ ID NO 84.

XX analgesic; gene therapy; antibody engineering; pharmaceutical; pain;
KW neurological disease; NGF; nerve growth factor;
KW light chain variable region.

XX Homo sapiens.

XX WO2005019266-A2.

XX 03-MAR-2005.

XX 15-JUL-2004; 2004WO-US022876.

XX 15-JUL-2003; 2003US-0487431P.

XX (AMGE-) AMGEN INC.

XX

PI Wild KD, Treanor JJS, Huang H, Inoue H, Zhang TJ, Martin F;
XX WPI; 2005-202606/21.
XX
XX New human anti-nerve growth factor (NGF) neutralizing antibodies useful
PT for manufacturing a medicament for treating painful disorders (e.g. acute
PT pain) or conditions associated with increased expression or sensitivity
PT to NGF.
XX
XX Claim 33; SEQ ID NO 84; 190pp; English.
PS
XX The invention describes an isolated human antibody that interacts with or
XX binds specifically to human nerve growth factor (NGF) and neutralize the
CC function of NGF. Also described are: methods of treating a condition
CC caused by increased expression of NGF or increased sensitivity to NGF in
CC a patient; methods for detecting NGF in a biological sample; an NGF
CC specific binding agent comprising any of the 59 amino acid sequences
CC comprising, for e.g. 123, 107 or 14 amino acids, as mentioned in the
CC specification, and where the binding agent can bind to NGF; a
CC pharmaceutical composition comprising a pharmaceutical carrier and a
CC medicament for treating a painful disorder or condition associated with
CC increased expression of NGF or increased sensitivity to NGF, the
CC medicament comprising a pharmaceutical amount of a monoclonal antibody or
CC its immunologically functional immunoglobulin fragment, or pharmaceutical
CC salts of the monoclonal antibody or the fragment, where the monoclonal
CC antibody is at least one of the monoclonal antibody cited above, and a
CC pharmaceutical carrier, diluent or excipient; a nucleic acid molecule or
CC polynucleotide that encodes the above antibody or binding agent; an
CC isolated cell line that produces the above antibody or binding agent; an
CC expression vector comprising the above polynucleotide; and a host cell
CC comprising the nucleic acid or expression vector. The composition
CC (including the antibody) and methods are useful for manufacturing a
CC medicament for treating a painful disorder (e.g. acute pain, dental pain,
CC or pain from trauma or cancer), or a condition associated with increased
CC expression of NGF or increased sensitivity to NGF. This is the amino acid
CC sequence of a human NGF antibody light chain variable region.
XX
XX Sequence 108 AA;
SQ
Query Match 95.9%; Score 535; DB 9; Length 108;
Best Local Similarity 96.3%; Pred. No. 2.3e-33;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIIYVASSRATGIP 60
QY 61 DRFSGSGSDFTLTISRLEPEDFAVYYCQQYGSSPFTFGQGTKLEIK 108
Db 61 DRFSGSGSDFTLTISRLEPEDFAVYYCQQYGSSPFTFGQGTKLEIK 108
RESULT 7
ADY26816
ID ADY26816 standard; protein; 108 AA.
XX
XX ADY26816;
AC
XX
XX 19-MAY-2005 (first entry)
DT
XX Human anti-NGF-antibody light chain SEQ ID NO 131.
DE
XX analgesic; gene therapy; antibody engineering; pharmaceutical; pain;
KW neurological disease; NGF; nerve growth factor; light chain.
KW
XX Homo sapiens.
OS
XX WO2005019266-A2.
PN
XX 03-MAR-2005.
PD
XX 15-JUL-2004; 2004WO-US022876.
PF

XX
XX 15-JUL-2003; 2003US-0487431P.
PR (AMGE-) AMGEN INC.
PA
XX Wild KD, Treanor JJS, Huang H, Inoue H, Zhang TJ, Martin F;
PI WPI; 2005-202606/21.
XX
XX New human anti-nerve growth factor (NGF) neutralizing antibodies useful
PT for manufacturing a medicament for treating painful disorders (e.g. acute
PT pain) or conditions associated with increased expression or sensitivity
PT to NGF.
XX
XX Claim 33; SEQ ID NO 131; 190pp; English.
PS
XX The invention describes an isolated human antibody that interacts with or
XX binds specifically to human nerve growth factor (NGF) and neutralize the
CC function of NGF. Also described are: methods of treating a condition
CC caused by increased expression of NGF or increased sensitivity to NGF in
CC a patient; methods for detecting NGF in a biological sample; an NGF
CC specific binding agent comprising any of the 59 amino acid sequences
CC comprising, for e.g. 123, 107 or 14 amino acids, as mentioned in the
CC specification, and where the binding agent can bind to NGF; a
CC pharmaceutical composition comprising a pharmaceutical carrier and a
CC medicament for treating a painful disorder or condition associated with
CC increased expression of NGF or increased sensitivity to NGF, the
CC medicament comprising a pharmaceutical amount of a monoclonal antibody or
CC its immunologically functional immunoglobulin fragment, or pharmaceutical
CC salts of the monoclonal antibody or the fragment, where the monoclonal
CC antibody is at least one of the monoclonal antibody cited above, and a
CC pharmaceutical carrier, diluent or excipient; a nucleic acid molecule or
CC polynucleotide that encodes the above antibody or binding agent; an
CC isolated cell line that produces the above antibody or binding agent; an
CC expression vector comprising the above polynucleotide; and a host cell
CC comprising the nucleic acid or expression vector. The composition
CC (including the antibody) and methods are useful for manufacturing a
CC medicament for treating a painful disorder (e.g. acute pain, dental pain,
CC or pain from trauma or cancer), or a condition associated with increased
CC expression of NGF or increased sensitivity to NGF. This is the amino acid
CC sequence of a human NGF antibody light chain.
XX
XX Sequence 108 AA;
SQ
Query Match 95.9%; Score 535; DB 9; Length 108;
Best Local Similarity 96.3%; Pred. No. 2.3e-33;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIIYVASSRATGIP 60
QY 61 DRFSGSGSDFTLTISRLEPEDFAVYYCQQYGSSPFTFGQGTKLEIK 108
Db 61 DRFSGSGSDFTLTISRLEPEDFAVYYCQQYGSSPFTFGQGTKLEIK 108
RESULT 8
ADZ57709
ID ADZ57709 standard; protein; 128 AA.
XX
XX ADZ57709;
AC
XX
XX 30-JUN-2005 (first entry)
DT
XX Germline antibody A27Vk3, Jk2 light chain protein.
DE
XX antibody engineering; cytostatic; vulnery; vasotropic; cardiant;
KW monoclonal antibody; heavy chain; light chain; wound healing; skin ulcer;
KW gastrointestinal ulcer; ischemia; transplant rejection; angioplasty;
KW myocardial infarction; reperfusion injury; restenosis; arthritis;
KW vascular disease; cancer; retinopathy; endometriosis; arthritis;
KW

KW Alzheimers disease; tumor; glioblastoma; sarcoma; carcinoma; diagnosis;
 KW antibody.
 XX
 XX Homo sapiens.
 XX GB2404660-A.
 XX 09-FEB-2005.
 XX 04-AUG-2004; 2004GB-00017384.
 XX 04-AUG-2003; 2003US-0492432P.
 XX (PFIZ) PFIZER PROD INC.
 XX (ABGE-) ABGENIX INC.
 XX Michaud NR, Kajiji S, Borzillo G, Bedian V, Coleman K, Green LL;
 XX Jia X;
 XX WPI; 2005-145169/16.
 XX Human monoclonal antibody or antigen-binding portion that specifically
 PT binds to c-Met, useful for treating cancer by inhibiting c-Met or for
 PT promoting tissue regeneration and wound healing by activating c-Met.
 XX
 XX Example 2; SEQ ID NO 18; 128pp; English.
 XX The invention relates to a human monoclonal antibody (I) or its antigen-
 CC binding portion that specifically binds to c-Met, comprises a heavy chain
 CC having a fully defined sequence (S1) of 13.3.2 heavy chain, where X2 is
 CC lysine and X4 is threonine, and a light chain having a fully defined
 CC sequence (S2) of 13.3.2 light chain, where X8 is threonine, where both
 CC chains are without a signal sequence. All the sequences are fully defined
 CC in the specification. (I) is useful for the manufacture of a medicament
 CC for treating a hyperproliferative disorder in a subject, where the
 CC antibody or its portion is a c-Met antagonist. (I) is useful for
 CC manufacture of a medicament for promoting wound healing or tissue
 CC regeneration in a subject, where the antibody, antigen-binding portion or
 CC the composition activates c-Met. (I) which has a c-Met agonist activity
 CC is useful in tissue regeneration or wound healing (skin ulcers or gastric
 CC ulcers), or treating ischemia associated with kidney transplant
 CC rejection, or attenuating toxicity associated with cyclosporin treatment
 CC after transplant surgery, for treating myocardial infarction, cardiac
 CC ischemia due to reperfusion injury, restenosis after angioplasty or
 CC vascular diseases. (I) which has a c-Met antagonist activity is useful
 CC for treating cancers of brain, lung, squamous cell, bladder, neck, liver,
 CC prostate, etc., proliferative vitreoretinopathy, proliferative diabetic
 CC retinopathy, endometriosis, and arthritis, for inhibiting plaque
 CC formation in Alzheimer's disease, inhibiting cellular mitogenic
 CC responses, or for treating tumor, glioblastoma, sarcomas, or carcinomas.
 CC (I) is useful for detecting c-Met in a biological sample in vitro or in
 CC vivo, thus useful for diagnosing c-Met-expressing tumor. (I) has
 CC selectivity for c-Met that is at least 100 times greater than their
 CC selectivity for insulin like growth factor I receptor. This sequence
 CC corresponds to the amino acid sequence for a germline antibody light
 CC chain used in the invention.
 XX
 XX Sequence 128 AA;

Query Match 95.9%; Score 535; DB 9; Length 128;
 Best Local Similarity 96.3%; Pred. No. 2.7e-33;
 Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLITYATSSRATGIP 60
 DB 21 EIVLTQSPGTLISLPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLITYAGSSRATGIP 80
 QY 61 DRFGSGSGGTDTLTISRLEPEDFAVYVYQQYGGSPFCSPGQGTKEIK 108
 DB 81 DRFGSGSGGTDTLTISRLEPEDFAVYVYQQYGGSPFTFGQGTKEIK 128

RESULT 9

AAR38672
 ID AAR38672 standard; protein; 129 AA.
 XX
 AC AAR38672;
 XX
 DT 25-MAR-2003 (revised)
 DT 01-NOV-1993 (first entry)
 XX
 DE vk325-Jk2.
 XX Monoclonal antibody; MAb; envelope; glycoprotein; gp120; HIV; AIDS; CD4;
 KW receptor; hybridoma; polymerase chain reaction; PCR; heavy; light; chain;
 KW epitope; immune deficiency.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Region 1..116
 FT /label= vk325
 FT Peptide 1..20
 FT /label= sig_peptide
 FT Misc-difference 1
 FT /note= "Met encoded by ATC (sic)"
 FT Protein 21..129
 FT /label= mat_protein
 FT Misc-difference 35
 FT /note= "Pro encoded by GCA (sic)"
 FT Region 44..55
 FT /label= CDR1
 FT Region 71..77
 FT /label= CDR2
 FT Misc-difference 99
 FT /note= "Leu encoded by GTG (sic)"
 FT Region 110..117
 FT /label= CDR3
 FT Misc-difference 113
 FT /note= "Gly encoded by GAT (sic)"
 FT Misc-difference 114
 FT /note= "Ser encoded by AAC (sic)"
 FT Misc-difference 116
 FT /note= "Pro encoded by GTT (sic)"
 FT Region 117..129
 FT /label= Jk2
 XX WO9312232-A1.
 XX 24-JUN-1993.
 XX 10-DEC-1992; 92WO-US010928.
 XX 10-DEC-1991; 91US-00804652.
 XX (DAND) DANA FARRER CANCER INST INC.
 XX (NEW-) NEW ENGLAND DEACONNESS HOSPITAL CORP.
 XX Marasco WA, Sodroski JG, Posner MR, Haseltine WA;
 XX WPI; 1993-214174/26.
 XX N-PSDB; AAQ42706.
 XX DNA segments encoding monoclonal antibody - which binds to gp120 and
 PT neutralises HIV, for treating AIDS, and for diagnosing and monitoring HIV
 PT infection.
 XX Disclosure; Page 74-75; 109pp; English.
 XX The nucleotide sequence of F105 V_k (AAQ42707 - sequence differs from
 CC other F105 V_k sequences given elsewhere in the specification) was
 CC compared with germline gene Humvk325 (AAQ42706), showing 97.7%
 CC similarity. By nucleotide sequence analysis, F105 appears to be derived
 CC from a member of the V_k III subgroup gene family. (Updated on 25-MAR-2003
 CC to correct PN field.)
 XX

```
SQ Sequence 129 AA;
Query Match          95.9%; Score 535; DB 2; Length 129;
Best Local Similarity 96.3%; Pred. No. 2.7e-33;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 80

Qy 61 DRFSGSGGTDFLTISRLEPEDFAVYVYCOQYSSPCSFQGGTKLEIK 108
Db 81 DRFSGSGGTDFLTISRLEPEDFAVYVYCOQYSSPCSFQGGTKLEIK 128

RESULT 10
ADP03986
ID ADP03986 standard; protein; 108 AA.
XX
AC ADP03986;
XX
DT 29-JUL-2004 (first entry)
XX
DE Murine-expressed anti-human CA IX monoclonal antibody VL protein SEQ 156.
XX
KW monoclonal antibody; carbonic anhydrase IX; CA IX tumour antigen;
KW cytosolic; colorectal neoplasm; renal cell carcinoma;
KW cervical intraepithelial squamous neoplasia;
KW cervical intraepithelial glandular neoplasia; breast cancer;
KW gene therapy; murine; mouse; human; light chain variable domain.
XX
OS Unidentified.
XX
FN WO2003048328-A2.
XX
PD 12-JUN-2003.
XX
PF 02-DEC-2002; 2002WO-US038550.
XX
PR 03-DEC-2001; 2001US-0337275P.
XX
PA (ABGE-) ABGENIX INC.
XX
PI Gudas J, Foltz I, Handa M, Gallo M;
XX
WPI; 2003-523295/49.
XX
New anti-CA IX monoclonal antibody, useful for treating a tumor e.g.,
PT colorectal neoplasms, colorectal tumors, cervical carcinoma, cervical
PT intraepithelial squamous and glandular neoplasia or esophageal tumors.
XX
Example 2; SEQ ID NO 156; 89pp; English.
XX
The invention relates to a novel isolated monoclonal antibody (mAb)
CC comprising a heavy chain polypeptide and light chain polypeptide having a
CC sequence chosen from one of 53 fully defined amino acid sequences given
CC in the specification, where the antibody specifically binds carbonic
CC anhydrase IX (CA IX) tumour antigen. The antibody of the invention
CC demonstrates cytostatic activity and may be useful for treating a tumour,
CC such as colorectal neoplasm, renal cell carcinoma, cervical carcinoma,
CC cervical intraepithelial squamous and glandular neoplasia, oesophageal
CC tumour or breast cancer, possibly via gene therapy. The current sequence
CC is that of a murine-expressed anti-human CA IX monoclonal antibody VL
CC (light chain variable domain) protein of the invention. The protein was
CC generated via the introduction of the human CA IX protein into a
CC transgenic mouse strain.
XX
SQ Sequence 108 AA;
Query Match          95.5%; Score 533; DB 7; Length 108;
Best Local Similarity 95.4%; Pred. No. 3.2e-33;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 80

Qy 61 DRFSGSGGTDFLTISRLEPEDFAVYVYCOQYSSPCSFQGGTKLEIK 108
Db 81 DRFSGSGGTDFLTISRLEPEDFAVYVYCOQYSSPCSFQGGTKLEIK 128

RESULT 11
ABJ36930
ID ABJ36930 standard; protein; 130 AA.
XX
AC ABJ36930;
XX
DT 01-MAY-2003 (first entry)
XX
DE Anti-CD40 monoclonal antibody related protein SEQ ID No 46.
XX
KW Antiallergic; haemostatic; immunomodulator; cytostatic; antibody;
KW human CD40; IL-12; LPS; lipopolysaccharide; IFNgamma; interferon gamma;
KW dendritic cell; high G28-5; CD95 expression; high G28-5; B cell line;
KW immunoadjuvant; anti-tumour agent; immunosuppressant; allergy;
KW autoimmune disease; coagulation factor VIII inhibitor; anti-CD40.
XX
OS Unidentified.
XX
FN WO200288186-A1.
XX
PD 07-NOV-2002.
XX
PF 26-APR-2002; 2002WO-JP004292.
XX
PR 27-APR-2001; 2001WO-US013672.
XX
PR 11-MAY-2001; 2001JP-00142482.
XX
PR 05-OCT-2001; 2001JP-00310535.
XX
PR 26-OCT-2001; 2001US-00040244.
XX
PA (KIRI ) KIRIN BEER KK.
XX
PI Mikayama T, Yoshida H, Force WR, Chen X, Takahashi N;
XX
WPI; 2003-120463/11.
XX
N-PSDB; ABT31872.
XX
Anti-CD40 monoclonal antibody with antagonist/agonist activity to CD40,
PT or functional fragment, is useful in the treatment of e.g. autoimmune
PT diseases or cancer.
XX
Claim 25; Page 51; 94pp; Japanese.
XX
The invention relates to an antibody to human CD40, or its functional
CC fragment, has at least one of the following properties: acting on
CC dendritic cells to produce IL-12 in the presence of LPS
CC (lipopolysaccharide) and IFNgamma (interferon gamma); acting on dendritic
CC cells to activate maturity of the dendritic cells with high G28-5
CC antibody; and activating CD95 expression with high G28-5 antibody against
CC B cell line. Such antibodies or functional fragments can be used as
CC immunoadjuvants, anti-tumour agents, immunosuppressants, and as remedies
CC for autoimmune diseases, allergy or coagulation factor VIII inhibitors
CC syndrome. This sequence represents a protein relating to the anti-CD40
CC monoclonal antibody of the invention
XX
SQ Sequence 130 AA;
Query Match          95.5%; Score 533; DB 6; Length 130;
Best Local Similarity 95.4%; Pred. No. 3.8e-33;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 80
```

QY 61 DRFGSGSGTDFLTISRLEPEDFAVYCCQYSSPCSFQGTGKLEIK 108
 DB 81 DRFGSGSGTDFLTISRLEPEDFAVYCCQYSSPITFGQTRLEIK 128

RESULT 12

AAW24101
 ID AAW24101 standard; protein; 384 AA.

AC AAW24101;

DT 12-OCT-2001 (first entry)

DE Human EST encoded protein SEQ ID NO: 1626.

XX Human; sheep; pig; cow; fruit fly; yeast; hamster; macaque; horse;
 KW tomato; monkey; dog; sea urchin; expressed sequence tag; EST;
 KW diagnostics; forensic test; gene mapping; genetic disorder; biodiversity;
 KW gene therapy; nutrition.

XX Homo sapiens.

XX WO200154477-A2.

XX 02-AUG-2001.

XX 25-JAN-2001; 2001WO-US002687.

XX 25-JAN-2000; 2000US-00491404.

XX 17-JUL-2000; 2000US-00617746.

XX 03-AUG-2000; 2000US-00631451.

XX 15-SEP-2000; 2000US-00663870.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Zhou P, Qian XB, Wang Z, Chen R, Asundi V;

PI Cao Y, Drmanac RA, Zhang J, Werhman T;

XX WPI; 2001-476164/51.

XX N-PSDB; AAH98760.

XX Isolated polypeptide for treatment of diseases, diagnostics, raising
 PT antibodies and research use.

XX Claim 20; Page 1102-1103; 1275pp; English.

XX The present invention provides the protein and coding sequences of novel
 CC proteins from a variety of organisms, including human, dog, cat, horse,
 CC cow, pig, hamster, monkey, macaque, yeast, bacteria, fruit fly, sea
 CC urchin and tomato. These were derived from expressed sequence tags (ESTs)
 CC from the organism of interest. They can be used in diagnostics,
 CC forensics, gene mapping, identification of mutations, to assess
 CC biodiversity and for nutritional purposes. The present sequence is a
 CC protein of the invention

XX Sequence 384 AA;

Query Match 95.5%; Score 533; DB 4; Length 384;

Best Local Similarity 95.4%; Pred. No. 1e-32;

Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKPGQAPRLLIYATSSRATGIP 60

DB 167 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKPGQAPRLLIYATSSRATGIP 226

QY 61 DRFGSGSGTDFLTISRLEPEDFAVYCCQYSSPCSFQGTGKLEIK 108

DB 227 DRFGSGSGTDFLTISRLEPEDFAVYCCQYSSPITFGQTRLEIK 274

RESULT 13

ADQ16703
 ID ADQ16703 standard; protein; 108 AA.

XX ADQ16703;
 AC 09-SEP-2004 (first entry)
 DT Modified immunoglobulin clone 116 LC variable region SEQ ID NO:123.
 DE immunoglobulin; complementarity determining region; CDR; peptide mimetic;
 KW erythropoietin; EPO; thrombopoietin; TPO; immunosuppressive;
 KW immunotherapy; thrombocytopenia.

XX Synthetic.

XX WO2004050017-A2.

XX 17-JUN-2004.

XX 17-NOV-2003; 2003WO-US036894.

XX 02-DEC-2002; 2002US-00307724.

XX (ALEX-) ALEXION PHARM INC.

XX Bowdish KS, Frederickson S, Renshaw M;

XX WPI; 2004-460973/43.

XX New immunoglobulin molecule comprising a region, where two
 PT complementarity determining regions (CDRs) are replaced with EPO mimetic
 PT or a TPO mimetic, useful for treating thrombocytopenia.

XX Example 8; SEQ ID NO 123; 107pp; English.

XX The invention relates to a novel immunoglobulin molecule or its fragment
 CC comprising a region where amino acid residues corresponding to at least a
 CC portion of a two complementarity determining regions (CDRs) are replaced
 CC with a peptide mimetic selected from an erythropoietin (EPO) mimetic and
 CC a thrombopoietin (TPO) mimetic. An immunoglobulin molecule of the
 CC invention has immunosuppressive activity, and may have a use in
 CC immunotherapy. The immunoglobulin molecule is useful for diagnosing or
 CC treating thrombocytopenia as a result of chemotherapy, bone marrow
 CC transplantation, or chronic diseases such as idiopathic thrombocytopenia.
 CC The present sequence represents immunoglobulin clone 116 light chain
 CC variable region.

XX Sequence 108 AA;

Query Match 95.3%; Score 532; DB 8; Length 108;

Best Local Similarity 95.4%; Pred. No. 3.9e-33;

Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKPGQAPRLLIYATSSRATGIP 60

DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKPGQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDFLTISRLEPEDFAVYCCQYSSPCSFQGTGKLEIK 108

DB 61 DRFGSGSGTDFLTISRLEPEDFAVYCCQYSSPITFGQTRLEIK 108

RESULT 14

ADV44439

ID ADV44439 standard; protein; 108 AA.

XX ADV44439;

XX 10-MAR-2005 (first entry)

XX pAX116 variable light chain variable region.

XX anti-HIV; cytostatic; gene therapy; antibody engineering; diagnosis;
 KW HIV-infection; anti-HIV; chemotherapy; bone marrow transplantation;
 KW transplant rejection; prophylaxis; myeloproliferative disorder;

KW hematological disease; pAX116.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004108078-A2.
XX
XX 16-DEC-2004.
XX
XX 26-MAY-2004; 2004WO-US016574.
XX
XX 02-JUN-2003; 2003US-00452590.
XX
XX (ALEX-) ALEXION PHARM INC.
XX
XX Bowdish KS, Frederickson S, Renshaw M, Orencia C;
XX WPI; 2005-031588/03.
XX
XX New immunoglobulin molecule comprises a region where amino acid residues
PT corresponding to a portion of complementarity determining region (CDR) is
PT replaced with a peptide mimetic, useful for treating, e.g. HIV-infected
PT patients.
XX
XX Example 8; SEQ ID NO 123; 139pp; English.
XX
XX The invention describes an immunoglobulin molecule or its fragment
CC comprising: a region where amino acid residues corresponding to at least
CC a portion of two CDRs are replaced with a peptide mimetic selected from
CC an EPO mimetic or a TPO mimetic; or a region where amino acid residues
CC corresponding to at least a portion of a CDR is replaced by a peptide
CC mimetic including SEQ ID NO. 126 (not defined in the specification),
CC where X at each occurrence represents any amino acid. Also described are:
CC a nucleic acid encoding an immunoglobulin molecule or its fragment; an
CC expression vector comprising the nucleic acid of (1); a host cell
CC transformed with the expression vector of (2); producing an
CC immunoglobulin molecule or its fragment; and a composition comprising the
CC immunoglobulin or its fragment and a pharmaceutical carrier. Also
CC disclosed are: engineering immunoglobulin molecules or fragments;
CC creation of a library of monoclonal antibodies; stimulating
CC proliferation, differentiation, or growth of megakaryocytes; and
CC activating a homodimeric receptor protein. The immunoglobulin molecules
CC are useful for treating HIV-infected patients, patients undergoing
CC chemotherapy, bone marrow transplant patients, stem cell transplant
CC patients, or patients suffering from myeloproliferative disorders. This
CC is the amino acid sequence of modified anti-tetanus toxoid antibody
CC pAX116 light chain variable region. The heavy chain of pAX116 comprises
CC two agonist TPO-mimetic peptides.
XX
SQ Sequence 108 AA;

Query Match 95.3%; Score 532; DB 9; Length 108;
Best Local Similarity 95.4%; Pred. No. 3.9e-33;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSGTSLSPGERATLSCRASQSVSSYLAWYQQKPKQAPRLIYATSSRATGIP 60
|||||
DB 1 EIVLTQSGTSLSPGERATLSCRASQSVSSYLAWYQQKPKQAPRLIYATSSRATGIP 60
|||||

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYVCOQYGSSPCSGQGTKEIK 108
|||||
DB 61 DRFGSGSGTDFTLTISRLEPEDFAVYVCOQYGSSPWTFGQGTKEIK 108
|||||

RESULT 15
AEB12911
ID AEB12911 standard; protein; 108 AA.
XX
AC AEB12911;
XX
DT 08-SEP-2005 (first entry)
XX
DE Antibody pAXB116 light chain variable region.

XX
KW Antibody; phage display; protein therapy; antibody engineering;
KW hematopoiesis; immunotherapy; Cardiant; Antidiabetic; Anorectic;
KW cardiac failure; diabetes; obesity; light chain; tetanus toxoid; TPO;
KW thrombopoietin.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2005060642-A2.
XX
XX 07-JUL-2005.
XX
XX 15-DEC-2004; 2004WO-US041946.
XX
XX 15-DEC-2003; 2003US-00737290.
XX
XX (ALEX-) ALEXION PHARM INC.
XX
XX Bowdish KS, Frederickson S, Renshaw M, Orencia C;
XX WPI; 2005-479402/48.
XX
XX New immunoglobulin molecule comprising a region where amino acid residues
PT corresponding to at least a portion of a complementarity determining
PT region is replaced with a peptide, for treating congestive heart failure,
PT diabetes or obesity.
XX
XX Example 8; SEQ ID NO 123; 152pp; English.
XX
XX The invention relates to an immunoglobulin (Ig) molecule or its fragment
CC comprising a region where amino acid residues corresponding to at least a
CC portion of a complementarity determining regions (CDR) is replaced with a
CC peptide selected from human brain natriuretic protein (hBNP), hBNP
CC mimetics, glycogen phosphorylase (GLP)-1, GLP-1 mimetics, GLP-2, GLP-2
CC mimetics, exendin, exendin mimetics, glucagons, glucagon mimetics and
CC PACAP-38. Also included are a nucleic acid encoding the immunoglobulin
CC molecule, an expression vector comprising the nucleic acid, a host cell
CC transformed with the expression vector, producing an immunoglobulin
CC molecule (or its fragment, comprising culturing the host cell under
CC conditions suitable for expression of the immunoglobulin or its
CC fragment), a composition comprising an immunoglobulin (or its fragment)
CC and a pharmaceutically acceptable carrier, treating congestive heart
CC failure (comprising administering to the subject an immunoglobulin
CC molecule or fragment comprising a region where amino acid residues
CC corresponding to at least a portion of a CDR is replaced with a peptide
CC selected from hBNP and hBNP mimetics), treating diabetes or obesity
CC (comprising administering to a subject an immunoglobulin molecule or its
CC fragment comprising a region where amino acid residues corresponding to
CC at least a portion of a CDR is replaced with a peptide selected from GLP-
CC 1, GLP-1 mimetics, GLP-2, GLP-2 mimetics, exendin, exendin mimetics,
CC glucagons, glucagon mimetics and PACAP-38), preserving/improving beta-
CC cell function (comprising administering to a subject an immunoglobulin
CC molecule or fragment comprising a region where amino acid residues
CC corresponding to at least a portion of a CDR is replaced with GLP-1),
CC inducing endothelial-dependent relaxation of precontracted pulmonary
CC artery rings (comprising administering to a subject an immunoglobulin
CC molecule or fragment thereof comprising a region where amino acid
CC residues corresponding to at least a portion of a CDR is replaced with
CC GLP-1) and administering to a subject an immunoglobulin molecule or its
CC fragment (comprising a region where amino acid residues corresponding to
CC at least a portion of a complementarity determining regions (CDR) is
CC replaced with a thiazolidinedione derivative), regulating adiponectin
CC expression (comprising administering to a subject an immunoglobulin
CC molecule or its fragment comprising a region where amino acid residues
CC corresponding to at least a portion of a CDR is replaced with a
CC thiazolidinedione derivative). The immunoglobulin is an anti-tetanus
CC toxoid antibody (TT) where the heavy chain CDR2 and/or CDR3 are fully or
CC partially replaced with a peptide listed above or (as described in the
CC examples) a thrombopoietin (TPO) mimetic, erythropoietin (EPO) mimetic
CC or ANP (atrial natriuretic peptide). The molecule, composition and
CC methods are useful for treating congestive heart failure, diabetes or
CC obesity. The present sequence represents a light chain of the anti-

CC tetanus toxoid Fab antibody with engrafted TPO mimetic peptides in place
 CC of one or more of its CDRs.

XX
 SQ Sequence 108 AA;

Query Match 95.3%; Score 532; DB 9; Length 108;
 Best Local Similarity 95.4%; Pred. No. 3.9e-33;
 Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;
 QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
 |||||
 Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
 |||||
 QY 61 DRPFGSGGTDFTLTISRLEPEDFAVYCCQYGGSPFCFQGTKEIK 108
 |||||
 Db 61 DRPFGSGGTDFTLTISRLEPEDFAVYCCQYGGSPFTFGQTKVEIK 108
 |||||

Search completed: May 15, 2006, 16:58:53
 Job time : 128.077 secs

THIS PAGE LEFT BLANK

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 17:04:12 ; Search time 30.5923 Seconds
(without alignments)
291.870 Million cell updates/sec

Title: US-10-041-860-49
Perfect score: 558
Sequence: 1 EIVLTQSPGTLSPGERAT.....CQYGSPPCSFGQGTKLEIK 108

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 572060 seqs, 82675679 residues

Total number of hits satisfying chosen parameters: 572060

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /cgn2_6/prodata/1/iaa/5 COMB.pep.*
2: /cgn2_6/prodata/1/iaa/6 COMB.pep.*
3: /cgn2_6/prodata/1/iaa/H COMB.pep.*
4: /cgn2_6/prodata/1/iaa/PCTUS COMB.pep.*
5: /cgn2_6/prodata/1/iaa/RE COMB.pep.*
6: /cgn2_6/prodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	530	95.0	108	1	US-08-232-081B-42
2	529	94.8	109	2	US-09-025-769B-16
3	529	94.8	109	2	US-09-490-070A-16
4	529	94.8	109	2	US-09-490-153-16
5	529	94.8	109	2	US-09-490-324-16
6	525	94.1	108	1	US-08-488-113B-150
7	525	94.1	108	1	US-08-477-484B-150
8	525	94.1	108	1	US-08-646-360-150
9	525	94.1	108	2	US-08-839-765-150
10	525	94.1	108	2	US-09-136-389-150
11	525	94.1	108	2	US-09-610-838-150
12	525	94.1	108	2	US-09-711-485-150
13	524.5	94.0	226	2	US-09-456-090A-50
14	524.5	94.0	226	2	US-09-456-090A-86
15	524.5	94.0	226	2	US-09-453-234-50
16	524.5	94.0	226	2	US-09-453-234-86
17	521	93.4	235	2	US-09-472-087-14
18	521	93.4	235	2	US-09-472-087-65
19	518.5	92.9	226	2	US-09-456-090A-80
20	518.5	92.9	226	2	US-09-453-234-80
21	518.5	92.9	236	2	US-09-859-053-34
22	518	92.8	108	2	US-09-240-274-178
23	518	92.8	108	2	US-09-848-798-178
24	513.5	92.0	236	2	US-09-859-053-38
25	512.5	91.8	226	2	US-09-456-090A-74
26	512.5	91.8	226	2	US-09-453-234-74
27	511.5	91.7	226	2	US-09-456-090A-42

28	511.5	91.7	226	2	US-09-453-234-42	Sequence 42, Appl
29	511	91.6	129	1	US-08-480-774A-4	Sequence 4, Appl
30	508	91.0	108	1	US-07-634-278-86	Sequence 86, Appl
31	508	91.0	108	1	US-08-477-728-86	Sequence 86, Appl
32	508	91.0	108	1	US-08-474-040-86	Sequence 86, Appl
33	508	91.0	108	1	US-08-487-200-86	Sequence 86, Appl
34	508	91.0	108	2	US-08-484-537-86	Sequence 86, Appl
35	506.5	90.8	226	2	US-09-456-090A-72	Sequence 72, Appl
36	506.5	90.8	226	2	US-09-453-234-72	Sequence 72, Appl
37	506	90.7	107	2	US-08-635-109-7	Sequence 7, Appl
38	506	90.7	107	2	US-08-844-215-10	Sequence 10, Appl
39	505	90.5	150	2	US-08-862-124-5	Sequence 5, Appl
40	505	90.5	287	2	US-08-862-124-17	Sequence 17, Appl
41	505	90.5	304	2	US-08-862-124-14	Sequence 14, Appl
42	504.5	90.4	107	1	US-08-107-669D-14	Sequence 14, Appl
43	504.5	90.4	107	1	US-08-472-788A-14	Sequence 14, Appl
44	504.5	90.4	107	1	US-08-477-531B-14	Sequence 14, Appl
45	504.5	90.4	107	1	US-08-082-842A-14	Sequence 14, Appl

ALIGNMENTS

RESULT 1
US-08-232-081B-42
; Sequence 42, Application US/08232081B
; Patent No. 5886152
; GENERAL INFORMATION:
; APPLICANT: NAKATANI, TOMOYUKI
; APPLICANT: GOMI, HIDEYUKI
; APPLICANT: WIJDENES, JOHN
; APPLICANT: NOGUCHI, HIROSHI
; TITLE OF INVENTION: HUMANIZED B-B10
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIRCH, STEWART, KOLASCH AND BIRCH
; STREET: PO BOX 747
; CITY: FALLS CHURCH
; STATE: VA
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/232,081B
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: SVENSSON, LEONARD R
; REGISTRATION NUMBER: 30,330
; REFERENCE/DOCKET NUMBER: 20-3484
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 205-8000
; TELEFAX: (703) 205-8050
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 108 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-232-081B-42

Query Match 95.0%; Score 530; DB 1; Length 108;
Best Local Similarity 94.4%; Pred. No. 1.5e-42;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPCQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPCQAPRLLIYATSSRATGIP 60


```
; FILING DATE: 19-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/787,567
; FILING DATE: 04-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: McNicholas, Janet M.
; REGISTRATION NUMBER: 32,918
; REFERENCE/DOCKET NUMBER: 11022US07/200-70.P3.C2A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/707-8889
; TELEFAX: 312/707-9155
; TELEX: 650 388-1248
; INFORMATION FOR SEQ ID NO: 150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 108 amino acids
; TYPE: amino acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-488-113B-150

Query Match          94.1%; Score 525; DB 1; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGGTDFTLISRLEPEDFAVYYCQYGGSPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLISRLEPEDFAVYYCQYGGSPXTFGQGTKVEIK 108

RESULT 7
US-08-477-484B-150
; Sequence 150, Application US/08477484B
; Patent No. 5756659
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; APPLICANT: Carroll, Stephen F.
; APPLICANT: Studnika, Gary M.
; TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
; TITLE OF INVENTION: Proteins
; NUMBER OF SEQUENCES: 169
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street, 34th floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/477,484B
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/425,336
; FILING DATE: 18-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/064,691
; FILING DATE: 12-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,430
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/901,707
; FILING DATE: 19-JUN-1992
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/787,567
; FILING DATE: 04-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: McNicholas, Janet M.
; REGISTRATION NUMBER: 32,918
; REFERENCE/DOCKET NUMBER: 11022US07/200-70.P3.C2A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/707-8889
; TELEFAX: 312/707-9155
; TELEX: 650 388-1248
; INFORMATION FOR SEQ ID NO: 150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 108 amino acids
; TYPE: amino acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-477-484B-150

Query Match          94.1%; Score 525; DB 1; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGGTDFTLISRLEPEDFAVYYCQYGGSPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLISRLEPEDFAVYYCQYGGSPXTFGQGTKVEIK 108

RESULT 8
US-08-646-360-150
; Sequence 150, Application US/08646360
; Patent No. 5837491
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; APPLICANT: Carroll, Stephen F.
; APPLICANT: Studnika, Gary M.
; TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
; TITLE OF INVENTION: Proteins
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street, 34th floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/646,360
; FILING DATE: 13-MAY-1996
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05348
; FILING DATE: 12-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/064,691
; FILING DATE: 12-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,430
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/901,707
; FILING DATE: 19-JUN-1992
; PRIOR APPLICATION DATA:
```

```
/ APPLICATION NUMBER: US 07/787,567
/ FILING DATE: 04-NOV-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: McNicholas, Janet M.
/ REGISTRATION NUMBER: 32,918
/ REFERENCE/DOCKET NUMBER: 200-70.P4
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312/707-8889
/ TELEFAX: 312/707-9155
/ TELEX: 650 388-1248
/ INFORMATION FOR SEQ ID NO: 150:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 108 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-08-646-360-150

Query Match          94.1%; Score 525; DB 1; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
QY 61 DRFGSGSGTDTLTISRLEPDAFVYYCQYGSSPCSFQGTKEIK 108
Db 61 DRFGSGSGTDTLTISRLEPDAFVYYCQYGSSPCSFQGTKEIK 108

RESULT 9
US-08-839-765-150
; Sequence 150, Application US/08839765
; Patent No. 6146631
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; APPLICANT: Carroll, Stephen F.
; APPLICANT: Studnika, Gary M.
; TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
; TITLE OF INVENTION: Proteins
; NUMBER OF SEQUENCES: 169
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street, 34th floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/839,765
; FILING DATE: 15-APR-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/425,336
; FILING DATE: 18-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/064,691
; FILING DATE: 12-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,430
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/901,707
; FILING DATE: 19-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/787,567
```

```
/ FILING DATE: 04-NOV-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: McNicholas, Janet M.
/ REGISTRATION NUMBER: 32,918
/ REFERENCE/DOCKET NUMBER: 11022US09/200-70.P3.C3
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312/707-8889
/ TELEFAX: 312/707-9155
/ TELEX: 650 388-1248
/ INFORMATION FOR SEQ ID NO: 150:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 108 amino acids
/ TYPE: amino acid
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: protein
/ US-08-839-765-150

Query Match          94.1%; Score 525; DB 2; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
QY 61 DRFGSGSGTDTLTISRLEPDAFVYYCQYGSSPCSFQGTKEIK 108
Db 61 DRFGSGSGTDTLTISRLEPDAFVYYCQYGSSPCSFQGTKEIK 108

RESULT 10
US-09-136-389-150
; Sequence 150, Application US/09136389
; Patent No. 6146850
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; APPLICANT: Carroll, Stephen F.
; APPLICANT: Studnika, Gary M.
; TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
; TITLE OF INVENTION: Proteins
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street, 34th floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/136,389
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/646,360
; FILING DATE: 13-MAY-1996
; APPLICATION NUMBER: PCT/US94/05348
; FILING DATE: 12-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/064,691
; FILING DATE: 12-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,430
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/901,707
; FILING DATE: 19-JUN-1992
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US 07/787,567
; FILING DATE: 04-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: McNicholas, Janet M.
; REGISTRATION NUMBER: 32,918
; REFERENCE/DOCKET NUMBER: 200-70.P4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/707-8889
; TELEFAX: 312/707-9155
; TELEX: 650 388-1248
; INFORMATION FOR SEQ ID NO: 150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 108 amino acids
; TYPE: amino acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-136-389-150

Query Match          94.1%; Score 525; DB 2; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60

Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYYCQYGSSPCSFQGQTKLEIK 108
Db 61 DRFGSGSGTDFTLTISRLEPEDFAVYYCQYGSSPCSFQGQTKVEIK 108

RESULT 11
US-09-610-838-150
; Sequence 150, Application US/09610838
; Patent No. 6376217
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; APPLICANT: Carroll, Stephen F.
; APPLICANT: Studnika, Gary M.
; TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
; TITLE OF INVENTION: Proteins
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street, 34th floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 06-JUL-2000
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/136,389
; FILING DATE: 18-AUG-1998
; APPLICATION NUMBER: 08/646,360
; FILING DATE: 13-MAY-1996
; APPLICATION NUMBER: PCT/US94/05348
; FILING DATE: 12-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/064,691
; FILING DATE: 12-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,430
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US 07/901,707
; FILING DATE: 19-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/787,567
; FILING DATE: 04-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: McNicholas, Janet M.
; REGISTRATION NUMBER: 32,918
; REFERENCE/DOCKET NUMBER: 200-70.P4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/707-8889
; TELEFAX: 312/707-9155
; TELEX: 650 388-1248
; INFORMATION FOR SEQ ID NO: 150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 108 amino acids
; TYPE: amino acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-09-610-838-150

Query Match          94.1%; Score 525; DB 2; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLLIYATSSRATGIP 60

Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYYCQYGSSPCSFQGQTKLEIK 108
Db 61 DRFGSGSGTDFTLTISRLEPEDFAVYYCQYGSSPCSFQGQTKVEIK 108

RESULT 12
US-09-711-485-150
; Sequence 150, Application US/09711485
; Patent No. 6649742
; GENERAL INFORMATION:
; APPLICANT: Better, Marc D.
; APPLICANT: Carroll, Stephen F.
; APPLICANT: Studnika, Gary M.
; TITLE OF INVENTION: Immunotoxins Comprising Ribosome-Inactivating
; TITLE OF INVENTION: Proteins
; NUMBER OF SEQUENCES: 169
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: McAndrews, Held & Malloy, Ltd.
; STREET: 500 West Madison Street, 34th floor
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60661
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: US/09/711,485
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/839,765
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/064,691
; FILING DATE: 12-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,430
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/901,707
```

```
; FILING DATE: 19-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/787,567
; FILING DATE: 04-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: McNicholas, Janet M.
; REGISTRATION NUMBER: 32,918
; REFERENCE/DOCKET NUMBER: 11022US09/200-70.P3.C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/707-8889
; TELEX: 312/707-9155
; TELEFAX: 650 388-1248
; INFORMATION FOR SEQ ID NO: 150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 108 amino acids
; TYPE: amino acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-09-711-485-150

Query Match          94.1%; Score 525; DB 2; Length 108;
Best Local Similarity 94.4%; Pred. No. 4.3e-42; Indels 0; Gaps 0;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSSPCSFQGGTKLEIK 108
DB 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSSPCSFQGGTKLEIK 108

RESULT 13
US-09-456-090A-50
; Sequence 50, Application US/09456090A
; Patent No. 6680209
; GENERAL INFORMATION:
; APPLICANT: Buechler, Joe
; APPLICANT: Valkirs, Gunars
; APPLICANT: Gray, Jeff
; APPLICANT: Lonberg, Nils
; APPLICANT: Genpharm International
; TITLE OF INVENTION: HUMAN ANTIBODIES AS DIAGNOSTIC REAGENTS
; FILE REFERENCE: 020015-000200US
; CURRENT APPLICATION NUMBER: US/09/456,090A
; CURRENT FILING DATE: 1999-12-06
; PRIOR APPLICATION NUMBER: US 60/157,415
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
; LENGTH: 226
; TYPE: PRT
; ORGANISM: Homo sapiens
; OTHER INFORMATION: MI-23L
; US-09-456-090A-50

Query Match          94.0%; Score 524.5; DB 2; Length 226;
Best Local Similarity 95.4%; Pred. No. 1.1e-41; Indels 1; Gaps 1;
Matches 104; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSS-PCSFQGGTKLEIK 108
DB 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSSPPYTFQGGTKLEIK 109

RESULT 14
US-09-456-090A-86
; Sequence 86, Application US/09456090A
; Patent No. 6680209
```

```
; GENERAL INFORMATION:
; APPLICANT: Buechler, Joe
; APPLICANT: Valkirs, Gunars
; APPLICANT: Gray, Jeff
; APPLICANT: Lonberg, Nils
; TITLE OF INVENTION: HUMAN ANTIBODIES AS DIAGNOSTIC REAGENTS
; FILE REFERENCE: 020015-000200US
; CURRENT APPLICATION NUMBER: US/09/456,090A
; CURRENT FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 86
; LENGTH: 226
; TYPE: PRT
; ORGANISM: Homo sapiens
; OTHER INFORMATION: M2-33L
; US-09-456-090A-86

Query Match          94.0%; Score 524.5; DB 2; Length 226;
Best Local Similarity 95.4%; Pred. No. 1.1e-41; Indels 1; Gaps 1;
Matches 104; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSS-PCSFQGGTKLEIK 108
DB 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSSPPYTFQGGTKLEIK 109

RESULT 15
US-09-453-234-50
; Sequence 50, Application US/09453234
; Patent No. 6794132
; GENERAL INFORMATION:
; APPLICANT: Buechler, Joe
; APPLICANT: Valkirs, Gunars
; APPLICANT: Gray, Jeff
; APPLICANT: Lonberg, Nils
; APPLICANT: Biosite Diagnostics, Inc.
; APPLICANT: Genpharm International
; TITLE OF INVENTION: Human Antibodies
; FILE REFERENCE: 020015-000110US
; CURRENT APPLICATION NUMBER: US/09/453,234
; CURRENT FILING DATE: 1999-12-01
; PRIOR APPLICATION NUMBER: US 60/157,415
; PRIOR FILING DATE: 1999-10-02
; NUMBER OF SEQ ID NOS: 112
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 50
; LENGTH: 226
; TYPE: PRT
; ORGANISM: Homo sapiens
; OTHER INFORMATION: MI-23L
; US-09-453-234-50

Query Match          94.0%; Score 524.5; DB 2; Length 226;
Best Local Similarity 95.4%; Pred. No. 1.1e-41; Indels 1; Gaps 1;
Matches 104; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSS-PCSFQGGTKLEIK 108
DB 61 DRFGSGSGTDTLTISRLEPDPFVAVYCCQYGSSPPYTFQGGTKLEIK 109

Search completed: May 15, 2006, 17:06:01
Job time : 31.5923 secs
```

NO PAGE LEFT BLANK

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: May 15, 2006, 17:19:47 ; Search time 108.927 Seconds
(without alignments)
414.273 Million cell updates/sec
Title: US-10-041-860-49
Perfect score: 558
Sequence: 1 EIVLTQSPGTLSPGERAT.....CQVGSFPCSFQGTQKLEIK 108
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 1867569 seqs, 417829326 residues
Total number of hits satisfying chosen parameters: 1867569
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA Main:
1: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US10A_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US10B_PUBCOMB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US11_PUBCOMB.pep.*
Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES			
Result No.	Score	Query Match Length DB ID	Description
1	558	100.0	108 4 US-10-041-860-49 Sequence 49, Appl
2	558	100.0	108 4 US-10-041-860-225 Sequence 225, App
3	558	100.0	108 4 US-10-041-860-259 Sequence 259, App
4	558	100.0	108 4 US-10-041-860-375 Sequence 375, App
5	558	100.0	108 4 US-10-665-383-4 Sequence 4, Appli
6	535	95.9	108 5 US-10-658-84 Sequence 84, Appl
7	535	95.9	108 5 US-10-891-658-131 Sequence 131, App
8	535	95.9	108 5 US-10-910-901-18 Sequence 18, Appl
9	533	95.5	108 4 US-10-309-762-156 Sequence 156, App
10	533	95.5	108 4 US-10-693-629-46 Sequence 46, Appl
11	532	95.3	108 4 US-10-307-724-123 Sequence 123, App
12	532	95.3	108 5 US-10-737-290-123 Sequence 123, App
13	532	95.3	109 5 US-10-725-962-27 Sequence 27, Appl
14	532	95.3	120 5 US-10-506-743-2 Sequence 2, Appli
15	532	95.3	130 5 US-10-737-290-161 Sequence 161, App
16	532	95.3	125 4 US-10-307-724-122 Sequence 122, App
17	532	95.3	215 5 US-10-737-290-122 Sequence 122, App
18	532	95.3	239 5 US-10-737-290-142 Sequence 142, App
19	530	95.0	384 4 US-10-291-265-804 Sequence 804, App
20	530	95.0	384 4 US-10-291-265-805 Sequence 805, App
21	530	95.0	384 4 US-10-291-265-806 Sequence 806, App
22	530	95.0	384 4 US-10-291-265-807 Sequence 807, App
23	529	94.8	108 4 US-10-269-711-21 Sequence 21, Appl
24	529	94.8	108 4 US-10-684-109-21 Sequence 21, Appl
25	528	94.6	108 3 US-09-948-939-9 Sequence 9, Appli
26	528	94.6	108 6 US-11-040-846-9 Sequence 9, Appli
27	526	94.3	108 4 US-10-338-366-4 Sequence 4, Appli

28	526	94.3	109 4 US-10-371-942-112 Sequence 112, App
29	526	94.3	109 5 US-10-726-332-210 Sequence 210, App
30	526	94.3	109 5 US-10-938-353-114 Sequence 114, App
31	526	94.3	235 5 US-10-938-353-60 Sequence 60, Appl
32	525.5	94.2	131 4 US-10-478-056-27 Sequence 27, Appl
33	525	94.1	106 4 US-10-309-762-163 Sequence 163, App
34	525	94.1	108 4 US-10-127-890-150 Sequence 150, App
35	525	94.1	108 5 US-10-171-243-150 Sequence 150, App
36	524.5	94.0	109 4 US-10-073-644C-8 Sequence 8, Appli
37	524.5	94.0	109 6 US-11-009-731-94 Sequence 94, Appl
38	524.5	94.0	226 3 US-09-453-234-50 Sequence 50, Appl
39	524.5	94.0	226 3 US-09-453-234-86 Sequence 86, Appl
40	524	93.9	108 4 US-10-309-762-43 Sequence 43, Appl
41	524	93.9	109 5 US-10-477-830-89 Sequence 89, Appl
42	524	93.9	109 5 US-10-989-462-267 Sequence 267, App
43	524	93.9	255 5 US-10-989-462-278 Sequence 278, App
44	523	93.7	108 4 US-10-292-088-113 Sequence 113, App
45	523	93.7	108 6 US-11-102-403-19 Sequence 19, Appl

ALIGNMENTS

RESULT 1
US-10-041-860-49
; Sequence 49, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gad
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; FILE REFERENCE: ARGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041,860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 108
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-49
Query Match 100.0%; Score 558; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.5e-40;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGAPRLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGAPRLIYATSSRATGIP 60
Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYSSPCSFQGTQKLEIK 108
Db 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYSSPCSFQGTQKLEIK 108
RESULT 2
US-10-041-860-225
; Sequence 225, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gad

```
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 225
; LENGTH: 108
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-225

Query Match      100.0%; Score 558; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.5e-40;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108

RESULT 3
US-10-041-860-259
; Sequence 259, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 259
; LENGTH: 108
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-259

Query Match      100.0%; Score 558; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.5e-40;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108

RESULT 4
US-10-041-860-375
; Sequence 375, Application US/10041860
; Publication No. US20030157109A1
; GENERAL INFORMATION:
; APPLICANT: Corvalan, Jose R.F.
```

```
; APPLICANT: Jia, Xiao-Chi
; APPLICANT: Feng, Xiao
; APPLICANT: Yang, Xiao-Dong
; APPLICANT: Chen, Francine
; APPLICANT: Gazit, Gadi
; APPLICANT: Weber, Richard
; APPLICANT: Bezabeh, Binyam
; TITLE OF INVENTION: ANTIBODIES DIRECTED TO PDGFD AND USES
; TITLE OF INVENTION: THEREOF
; FILE REFERENCE: AGENIX.051A
; CURRENT APPLICATION NUMBER: US/10/041.860
; CURRENT FILING DATE: 2002-01-07
; NUMBER OF SEQ ID NOS: 377
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 375
; LENGTH: 108
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-041-860-375

Query Match      100.0%; Score 558; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.5e-40;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108

RESULT 5
US-10-665-383-4
; Sequence 4, Application US/10665383
; Publication No. US20040141969A1
; GENERAL INFORMATION:
; APPLICANT: Floege, Juergen
; APPLICANT: Gazit, Gadi
; APPLICANT: Keyt, Bruce
; APPLICANT: LaRoche, William
; APPLICANT: Lichenstein, Henri
; TITLE OF INVENTION: METHOD FOR THE TREATMENT OF NEPHRITIS
; TITLE OF INVENTION: USING ANTI-PDGF-DD ANTIBODIES
; FILE REFERENCE: AGENIX.052A
; CURRENT APPLICATION NUMBER: US/10/665.383
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: 60/411,137
; PRIOR FILING DATE: 2002-09-16
; NUMBER OF SEQ ID NOS: 97
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 108
; TYPE: PRT
; ORGANISM: homo sapiens
US-10-665-383-4

Query Match      100.0%; Score 558; DB 4; Length 108;
Best Local Similarity 100.0%; Pred. No. 4.5e-40;
Matches 108; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQKPKGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYYCQYGSPPCSFGQGTKLEIK 108

RESULT 6
US-10-891-658-84
```


Sequence 84, Application US/10891658
Publication No. US20050074821A1
GENERAL INFORMATION:
APPLICANT: Kenneth, Wild
APPLICANT: Treanor, James
APPLICANT: Huang, Haichun
APPLICANT: Inoue, Heather
APPLICANT: Zhang, Tie J.
APPLICANT: Martin, Frank
TITLE OF INVENTION: Human anti-NGF Neutralizing Antibodies as Selective NGF Pathway
TITLE OF INVENTION: Inhibitors
FILE REFERENCE: 02-1240
CURRENT APPLICATION NUMBER: US/10/891,658
CURRENT FILING DATE: 2004-07-15
PRIOR APPLICATION NUMBER: US 60/487,431
PRIOR FILING DATE: 2003-07-15
NUMBER OF SEQ ID NOS: 138
SOFTWARE: PatentIn version 3.0
SEQ ID NO 84
LENGTH: 108
TYPE: PRT
ORGANISM: homo sapien
US-10-891-658-84

Query Match 95.9%; Score 535; DB 5; Length 108;
Best Local Similarity 96.3%; Pred. No. 4.1e-38;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYASSRATGIP 60

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108
DB 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108

RESULT 7
US-10-891-658-131
Sequence 131, Application US/10891658
Publication No. US20050074821A1
GENERAL INFORMATION:
APPLICANT: Kenneth, Wild
APPLICANT: Treanor, James
APPLICANT: Huang, Haichun
APPLICANT: Inoue, Heather
APPLICANT: Zhang, Tie J.
APPLICANT: Martin, Frank
TITLE OF INVENTION: Human anti-NGF Neutralizing Antibodies as Selective NGF Pathway
TITLE OF INVENTION: Inhibitors
FILE REFERENCE: 02-1240
CURRENT APPLICATION NUMBER: US/10/891,658
CURRENT FILING DATE: 2004-07-15
PRIOR APPLICATION NUMBER: US 60/487,431
PRIOR FILING DATE: 2003-07-15
NUMBER OF SEQ ID NOS: 138
SOFTWARE: PatentIn version 3.0
SEQ ID NO 131
LENGTH: 108
TYPE: PRT
ORGANISM: homo sapien
US-10-891-658-131

Query Match 95.9%; Score 535; DB 5; Length 108;
Best Local Similarity 96.3%; Pred. No. 4.1e-38;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYGNSSRATGIP 60

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108
DB 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108

Db 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108

RESULT 8
US-10-910-901-18
Sequence 18, Application US/10910901
Publication No. US20050054019A1
GENERAL INFORMATION:
APPLICANT: MICHAUD, NEIL R., et al.
TITLE OF INVENTION: ANTIBODIES TO c-MET
FILE REFERENCE: ABX-PFS
CURRENT APPLICATION NUMBER: US/10/910,901
CURRENT FILING DATE: 2004-08-03
PRIOR APPLICATION NUMBER: US 60/492,432
PRIOR FILING DATE: 2003-08-04
NUMBER OF SEQ ID NOS: 34
SOFTWARE: PatentIn Ver. 3.2
SEQ ID NO 18
LENGTH: 128
TYPE: PRT
ORGANISM: Homo sapiens
US-10-910-901-18

Query Match 95.9%; Score 535; DB 5; Length 128;
Best Local Similarity 96.3%; Pred. No. 4.8e-38;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYATSSRATGIP 60
DB 21 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYGNSSRATGIP 80

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108
DB 81 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 128

RESULT 9
US-10-309-762-156
Sequence 156, Application US/10309762
Publication No. US20040018198A1
GENERAL INFORMATION:
APPLICANT: Gudas, Jean
APPLICANT: Foltz, Ian
APPLICANT: Handa, Masahisa
APPLICANT: Gallo, Michael
TITLE OF INVENTION: ANTIBODIES AGAINST CARBOXYIC ANHYDRASE IX
TITLE OF INVENTION: (CA IX) TUMOR ANTIGEN
FILE REFERENCE: ABGENIX.027A
CURRENT APPLICATION NUMBER: US/10/309,762
CURRENT FILING DATE: 2002-12-02
PRIOR APPLICATION NUMBER: 60/337275
PRIOR FILING DATE: 2001-12-03
NUMBER OF SEQ ID NOS: 246
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 156
LENGTH: 108
TYPE: PRT
ORGANISM: Homo sapiens
US-10-309-762-156

Query Match 95.5%; Score 533; DB 4; Length 108;
Best Local Similarity 95.4%; Pred. No. 6.1e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLLIYGNSSRATGIP 60

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108
DB 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGGQTKLEIK 108

```
RESULT 10
US-10-693-629-46
; Sequence 46, Application US/10693629
; Publication No. US20040120948A1
; GENERAL INFORMATION:
; APPLICANT: KIRIN BEER KABUSHIKI KAISHA
; APPLICANT: MIKAYAMA, Toshifumi
; APPLICANT: YOSHIDA, Hitoshi
; APPLICANT: FORCE, Walker, R.
; APPLICANT: CHEN, Xingjie
; APPLICANT: TAKAHASHI, Nobuaki
; TITLE OF INVENTION: ANTI CD40 MONOCLONAL ANTIBODY
; FILE REFERENCE: 021286-0306473
; CURRENT APPLICATION NUMBER: US/10/693,629
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: PCT/US01/13672
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: US09/844,684
; PRIOR FILING DATE: 2001-04-27
; PRIOR APPLICATION NUMBER: JP2001/142482
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: JP2001/310535
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: US10/040,244
; PRIOR FILING DATE: 2001-10-26
; NUMBER OF SEQ ID NOS: 66
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 46
; LENGTH: 130
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-693-629-46

Query Match          95.5%; Score 533; DB 4; Length 130;
Best Local Similarity 95.4%; Pred. No. 7.3e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 80

Qy 61 DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPFCFGQGTKLEIK 108
Db 81 DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTKLEIK 128

RESULT 11
US-10-307-724-123
; Sequence 123, Application US/10307724
; Publication No. US20030232972A1
; GENERAL INFORMATION:
; APPLICANT: Bowdish, Katherine S.
; APPLICANT: Frederickson, Shana
; APPLICANT: Renshaw, Mark
; TITLE OF INVENTION: RATIONALLY DESIGNED ANTIBODIES
; FILE REFERENCE: 1087-2c1p
; CURRENT APPLICATION NUMBER: US/10/307,724
; CURRENT FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/251,448
; PRIOR FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/288,889
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/294,068
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/006,593
; NUMBER OF SEQ ID NOS: 134
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 123
; LENGTH: 108
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antibody light chain variable region
US-10-307-724-123

Query Match          95.3%; Score 532; DB 5; Length 108;
Best Local Similarity 95.4%; Pred. No. 7.4e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPFCFGQGTKLEIK 108
Db 61 DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTKLEIK 108

RESULT 12
US-10-737-290-123
; Sequence 123, Application US/10737290
; Publication No. US20040253242A1
; GENERAL INFORMATION:
; APPLICANT: Bowdish, Katherine S.
; APPLICANT: Frederickson, Shana
; APPLICANT: Renshaw, Mark
; APPLICANT: Orenchia, Cecilia
; TITLE OF INVENTION: RATIONALLY DESIGNED ANTIBODIES
; FILE REFERENCE: 1087-2 CIP III
; CURRENT APPLICATION NUMBER: US/10/737,290
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 10/452,590
; PRIOR FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: US 10/307,724
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 10/006,593
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/251,448
; PRIOR FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/288,889
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/294,068
; PRIOR FILING DATE: 2001-05-29
; NUMBER OF SEQ ID NOS: 193
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 123
; LENGTH: 108
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antibody light chain variable region
US-10-737-290-123

Query Match          95.3%; Score 532; DB 5; Length 108;
Best Local Similarity 95.4%; Pred. No. 7.4e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60

Qy 61 DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPFCFGQGTKLEIK 108
Db 61 DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPITFGQGTKLEIK 108

RESULT 13
US-10-725-962-27
; Sequence 27, Application US/10725962
; Publication No. US20050013809A1
; GENERAL INFORMATION:
; APPLICANT: Samuel M. Owens
; APPLICANT: Frank I. Carroll
; APPLICANT: Philip Abraham
; APPLICANT: Melinda G. Gunnell
```

```

; APPLICANT: Mary Haak-Frendscho
; APPLICANT: Xiao Feng
; TITLE OF INVENTION: ANTIBODIES AGAINST DRUGS OF ABUSE
; FILE REFERENCE: ABGENIX 071A
; CURRENT APPLICATION NUMBER: US/10/725,962
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: 60/430717
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 141
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 109
; TYPE: PRT
; ORGANISM: Mus musculus
; US-10-725-962-27

Query Match          95.3%; Score 532; DB 5; Length 109;
Best Local Similarity 95.4%; Pred. No. 7.4e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPGQAPRLLIYAGASSRATGIP 60

QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGSSPSCSFQGTQKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGSSPWTFGQTKVEIK 108

RESULT 14
US-10-506-743-2
; Sequence 2, Application US/10506743
; Publication No. US20050106140A1
; GENERAL INFORMATION:
; APPLICANT: Lancaster, Joanne Sloan
; TITLE OF INVENTION: Antagonistic Anti-hFas Ligand Human Antibodies and Fragments
; FILE REFERENCE: X15450 - National Stage
; CURRENT APPLICATION NUMBER: US/10/506,743
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: 60/367,054
; PRIOR FILING DATE: 2002-03-21
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 120
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-506-743-2

Query Match          95.3%; Score 532; DB 5; Length 120;
Best Local Similarity 95.4%; Pred. No. 8.2e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPGQAPRLLIYAGASSRATGIP 60

QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGSSPSCSFQGTQKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGSSPWTFGQTKVEIK 108

RESULT 15
US-10-737-290-161
; Sequence 161, Application US/10737290
; Publication No. US20040253242A1
; GENERAL INFORMATION:
; APPLICANT: Bowdish, Katherine S.
; APPLICANT: Frederickson, Shana
; APPLICANT: Renshaw, Mark
; APPLICANT: Orecia, Cecilia
; TITLE OF INVENTION: RATIONALLY DESIGNED ANTIBODIES
```

```

; FILE REFERENCE: 1087-2 CIP III
; CURRENT APPLICATION NUMBER: US/10/737,290
; CURRENT FILING DATE: 2003-12-15
; PRIOR APPLICATION NUMBER: US 10/452,590
; PRIOR FILING DATE: 2003-06-02
; PRIOR APPLICATION NUMBER: US 10/307,724
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 10/006,593
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/251,448
; PRIOR FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/288,889
; PRIOR FILING DATE: 2001-05-04
; PRIOR APPLICATION NUMBER: US 60/294,068
; PRIOR FILING DATE: 2001-05-29
; NUMBER OF SEQ ID NOS: 193
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 161
; LENGTH: 130
; TYPE: PRT
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: recombinant Ab Vκ
; US-10-737-290-161

Query Match          95.3%; Score 532; DB 5; Length 130;
Best Local Similarity 95.4%; Pred. No. 8.8e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPGQAPRLLIYATSSRATGIP 60
Db 23 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKQPGQAPRLLIYAGASSRATGIP 82

QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGSSPSCSFQGTQKLEIK 108
Db 83 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGSSPWTFGQTKVEIK 130

Search completed: May 15, 2006, 17:25:05
Job time : 109.927 secs
```

THIS PAGE LEFT BLANK

GenCore version 5.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 17:21:22 ; Search time 17.1502 Seconds
(without alignments)
295.651 Million cell updates/sec

Title: US-10-041-860-49
Perfect score: 558
Sequence: 1 BIVLTQSPGTLISLSPGERAT.....CQQYGGSPCSFGQGTFLKLIK 108

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 250354 seqs, 4694837 residues

Total number of hits satisfying chosen parameters: 250354

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA_New.*
1: /SIDSS/ptodata/1/pubpaa/US08_NEW_PUB.pep1.*
2: /SIDSS/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
3: /SIDSS/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
4: /SIDSS/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
5: /SIDSS/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
6: /SIDSS/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
7: /SIDSS/ptodata/1/pubpaa/US09_NEW_PUB.pep1.*
8: /SIDSS/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
9: /SIDSS/ptodata/1/pubpaa/US10_NEW_PUB.pep1.*
10: /SIDSS/ptodata/1/pubpaa/US11_NEW_PUB.pep.*
11: /SIDSS/ptodata/1/pubpaa/US11_NEW_PUB.pep1.*
12: /SIDSS/ptodata/1/pubpaa/US60_NEW_PUB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	530	95.0	384	11	US-11-000-463-804
2	530	95.0	384	11	US-11-000-463-805
3	530	95.0	384	11	US-11-000-463-806
4	530	95.0	384	11	US-11-000-463-807
5	529	94.8	109	9	US-10-834-397-16
6	528	94.6	247	11	US-11-056-825-8
7	528	94.6	249	11	US-11-056-825-4
8	526	94.3	108	9	US-10-850-635-6
9	525.5	94.2	131	9	US-10-721-763-27
10	524	93.9	108	9	US-10-850-635-4
11	524	93.9	108	11	US-11-051-453-58
12	524	93.9	128	11	US-11-051-453-60
13	523	93.7	108	10	US-11-211-317-113
14	521	93.4	235	11	US-11-128-900-14
15	521	93.4	235	11	US-11-128-900-65
16	520	93.2	108	9	US-10-982-440-32
17	520	93.2	108	9	US-10-982-440-36
18	518	92.8	108	11	US-11-064-174-178
19	514.5	92.2	113	11	US-11-049-536-104
20	514.5	92.2	113	11	US-11-199-739-104
21	513	91.9	291	11	US-11-041-095-60

Sequence 134, App
Sequence 74, Appl
Sequence 332, App
Sequence 334, App
Sequence 168, App
Sequence 168, App
Sequence 1499, App
Sequence 1499, App
Sequence 1264, App
Sequence 1264, App
Sequence 58, Appl
Sequence 1219, App
Sequence 1219, App
Sequence 592, App
Sequence 592, App
Sequence 16, Appl
Sequence 236, App
Sequence 296, App
Sequence 82, Appl
Sequence 82, Appl
Sequence 368, App
Sequence 368, App
Sequence 31, Appl
Sequence 32, Appl

ALIGNMENTS

RESULT 1
US-11-000-463-804
; Sequence 804, Application US/11000463
; Publication No. US20050266423A1
; GENERAL INFORMATION:
; APPLICANT: Tang, Y Tom
; APPLICANT: Liu, Chenghua
; APPLICANT: Asundi, Vinod
; APPLICANT: Chen, Rui-hong
; APPLICANT: Qian, Xuehong B.
; APPLICANT: Wang, Zhiwei
; APPLICANT: Wehrman, Tom
; APPLICANT: Zhang, Jie
; APPLICANT: Zhou, Ping
; APPLICANT: Cao, Yi-Cheng
; APPLICANT: Drmanac, Radoje T.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 785CIP4CN
; CURRENT APPLICATION NUMBER: US/11/000,463
; CURRENT FILING DATE: 2004-11-29
; PRIOR APPLICATION NUMBER: 10/291,265
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: PCT/US01/02623
; PRIOR FILING DATE: 2001-01-25
; PRIOR APPLICATION NUMBER: 09/922,279
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 09/491,404
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 09/617,746
; PRIOR FILING DATE: 2000-07-17
; PRIOR APPLICATION NUMBER: 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/633,870
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 944
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 804
; LENGTH: 384
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-000-463-804

Query Match 95.0%; Score 530; DB 11; Length 384;
Best Local Similarity 94.4%; Pred. No. 8.5e-37;

Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYATSSRATGIP 60
|||||
Db 170 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYGASSRATGIP 229
|||||

Qy 61 DRFSGSGGTDTLTISRLEPDAFYVYCOQYGSPPCSFGQGTKEIK 108
|||||
Db 230 DRFSGSGGTDTLTISRLEPDAFYVYCOQYGSPTTFGGQTKVDIK 277
|||||

RESULT 2

US-11-000-463-805

; Sequence 805, Application US/110000463

; Publication No. US20050266423A1

; GENERAL INFORMATION:

; APPLICANT: Tang, Y Tom

; APPLICANT: Liu, Chenghua

; APPLICANT: Asundi, Vinod

; APPLICANT: Chen, Rui-hong

; APPLICANT: Qian, Xiaohong B.

; APPLICANT: Wang, Zhiwei

; APPLICANT: Wehrman, Tom

; APPLICANT: Zhang, Jie

; APPLICANT: Zhou, Ping

; APPLICANT: Cao, Yi-Cheng

; APPLICANT: Drmanac, Radoje T.

; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides

; FILE REFERENCE: 785CIP4CN

; CURRENT APPLICATION NUMBER: US/11/000,463

; CURRENT FILING DATE: 2004-11-29

; PRIOR APPLICATION NUMBER: 10/291,265

; PRIOR FILING DATE: 2002-11-08

; PRIOR APPLICATION NUMBER: PCT/US01/02623

; PRIOR FILING DATE: 2001-01-25

; PRIOR APPLICATION NUMBER: 09/922,279

; PRIOR FILING DATE: 2001-08-03

; PRIOR APPLICATION NUMBER: 09/491,404

; PRIOR FILING DATE: 2000-01-25

; PRIOR APPLICATION NUMBER: 09/617,746

; PRIOR FILING DATE: 2000-07-17

; PRIOR APPLICATION NUMBER: 09/631,451

; PRIOR FILING DATE: 2000-08-03

; PRIOR APPLICATION NUMBER: 09/633,870

; PRIOR FILING DATE: 2000-09-15

; NUMBER OF SEQ ID NOS: 944

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 805

; LENGTH: 384

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-11-000-463-805

Query Match 95.0%; Score 530; DB 11; Length 384;
Best Local Similarity 94.4%; Pred. No. 8.5e-37;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYATSSRATGIP 60
|||||
Db 170 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYGASSRATGIP 229
|||||

Qy 61 DRFSGSGGTDTLTISRLEPDAFYVYCOQYGSPPCSFGQGTKEIK 108
|||||

Db 230 DRFSGSGGTDTLTISRLEPDAFYVYCOQYGSPTTFGGQTKVDIK 277
|||||

RESULT 3

US-11-000-463-806

; Sequence 806, Application US/110000463

; Publication No. US20050266423A1

; GENERAL INFORMATION:

; APPLICANT: Tang, Y Tom

; APPLICANT: Liu, Chenghua

; APPLICANT: Asundi, Vinod
; APPLICANT: Chen, Rui-hong
; APPLICANT: Qian, Xiaohong B.
; APPLICANT: Wang, Zhiwei
; APPLICANT: Wehrman, Tom
; APPLICANT: Zhang, Jie
; APPLICANT: Zhou, Ping
; APPLICANT: Cao, Yi-Cheng
; APPLICANT: Drmanac, Radoje T.
; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides
; FILE REFERENCE: 785CIP4CN

; CURRENT APPLICATION NUMBER: US/11/000,463

; CURRENT FILING DATE: 2004-11-29

; PRIOR APPLICATION NUMBER: 10/291,265

; PRIOR FILING DATE: 2002-11-08

; PRIOR APPLICATION NUMBER: PCT/US01/02623

; PRIOR FILING DATE: 2001-01-25

; PRIOR APPLICATION NUMBER: 09/922,279

; PRIOR FILING DATE: 2001-08-03

; PRIOR APPLICATION NUMBER: 09/491,404

; PRIOR FILING DATE: 2000-01-25

; PRIOR APPLICATION NUMBER: 09/617,746

; PRIOR FILING DATE: 2000-07-17

; PRIOR APPLICATION NUMBER: 09/631,451

; PRIOR FILING DATE: 2000-08-03

; PRIOR APPLICATION NUMBER: 09/633,870

; PRIOR FILING DATE: 2000-09-15

; NUMBER OF SEQ ID NOS: 944

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 806

; LENGTH: 384

; TYPE: PRT

; ORGANISM: Homo sapiens

; US-11-000-463-806

Query Match 95.0%; Score 530; DB 11; Length 384;
Best Local Similarity 94.4%; Pred. No. 8.5e-37;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYATSSRATGIP 60
|||||
Db 170 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYGASSRATGIP 229
|||||

Qy 61 DRFSGSGGTDTLTISRLEPDAFYVYCOQYGSPPCSFGQGTKEIK 108
|||||

Db 230 DRFSGSGGTDTLTISRLEPDAFYVYCOQYGSPTTFGGQTKVDIK 277
|||||

RESULT 4

US-11-000-463-807

; Sequence 807, Application US/110000463

; Publication No. US20050266423A1

; GENERAL INFORMATION:

; APPLICANT: Tang, Y Tom

; APPLICANT: Liu, Chenghua

; APPLICANT: Asundi, Vinod

; APPLICANT: Chen, Rui-hong

; APPLICANT: Qian, Xiaohong B.

; APPLICANT: Wang, Zhiwei

; APPLICANT: Wehrman, Tom

; APPLICANT: Zhang, Jie

; APPLICANT: Zhou, Ping

; APPLICANT: Cao, Yi-Cheng

; APPLICANT: Drmanac, Radoje T.

; TITLE OF INVENTION: Novel Nucleic Acids and Polypeptides

; FILE REFERENCE: 785CIP4CN

; CURRENT APPLICATION NUMBER: US/11/000,463

; CURRENT FILING DATE: 2004-11-29

; PRIOR APPLICATION NUMBER: 10/291,265

; PRIOR FILING DATE: 2002-11-08

; PRIOR APPLICATION NUMBER: PCT/US01/02623

; PRIOR FILING DATE: 2001-01-25

; PRIOR APPLICATION NUMBER: 09/922,279

```
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: 09/491,404
; PRIOR FILING DATE: 2000-01-25
; PRIOR APPLICATION NUMBER: 09/617,746
; PRIOR FILING DATE: 2000-07-17
; PRIOR APPLICATION NUMBER: 09/631,451
; PRIOR FILING DATE: 2000-08-03
; PRIOR APPLICATION NUMBER: 09/633,870
; PRIOR FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 944
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 807
; LENGTH: 384
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-000-463-807

Query Match          95.0%; Score 530; DB 11; Length 384;
Best Local Similarity 94.4%; Pred. No. 8.5e-37;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
   |||||
Db 170 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYATSSRATGIP 229
   |||||

QY 61 DRFSGSGGTDTLTISRLEPEDFAVYCCQYGSPPCSFGQGTKLEIK 108
   |||||
Db 230 DRFSGSGGTDTLTISRLEPEDFAVYCCQYGSPPCSFGQGTKVDIK 277
   |||||

RESULT 5
US-10-834-397-16
; Sequence 16, Application US/10834397
; Publication No. US200600033441
; GENERAL INFORMATION:
; APPLICANT: Knappik, Achim
; Pack, Peter
; Ilag, Vic
; Ge, Liming
; Moroney, Simon
; Plueckthun, Andreas
; TITLE OF INVENTION: Protein/(Poly)peptide libraries
; NUMBER OF SEQUENCES: 373
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: James F. Haley, Jr., Esq. c/o Fish & Neave
; STREET: 1251 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10021
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/834,397
; FILING DATE: 29-Apr-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/490,324
; FILING DATE: 24-Jan-2000
; APPLICATION NUMBER: US/09/025,769
; FILING DATE: 18-FEB-1998
; APPLICATION NUMBER: EP 95 11 3021.0
; FILING DATE: 18-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: James F. Haley, Jr., Esq.
; REGISTRATION NUMBER: 27,794
; REFERENCE/DOCKET NUMBER: MORPHO/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212)596-9000
; TELEFAX: (212)596-9090
; INFORMATION FOR SEQ ID NO: 16:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 109 amino acids
; TYPE: amino acid
; STRANDEDNESS: <Unknown>
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-834-397-16

Query Match          94.8%; Score 529; DB 9; Length 109;
Best Local Similarity 94.4%; Pred. No. 3.4e-37;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
   |||||
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
   |||||

QY 61 DRFSGSGGTDTLTISRLEPEDFAVYCCQYGSPPCSFGQGTKLEIK 108
   |||||
Db 61 DRFSGSGGTDTLTISRLEPEDFAVYCCQYGSPPCSFGQGTKVEIK 108
   |||||

RESULT 6
US-11-056-825-8
; Sequence 8, Application US/11056825
; Publication No. US20050255109A1
; GENERAL INFORMATION:
; APPLICANT: Felding-Habermann, Brunhilde
; APPLICANT: Janda, Kim D.
; APPLICANT: Saven, Alan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR INHIBITION OF METASTASIS
; FILE REFERENCE: SCRP-0042
; CURRENT APPLICATION NUMBER: US/11/056,825
; CURRENT FILING DATE: 2005-02-11
; PRIOR APPLICATION NUMBER: US 60/626,726
; PRIOR FILING DATE: 2004-11-10
; PRIOR APPLICATION NUMBER: US 60/544,807
; PRIOR FILING DATE: 2004-02-13
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: Patent In version 3.3
; SEQ ID NO 8
; LENGTH: 247
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-056-825-8

Query Match          94.6%; Score 528; DB 11; Length 247;
Best Local Similarity 94.4%; Pred. No. 8.5e-37;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYATSSRATGIP 60
   |||||
Db 127 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYATSSRATGIP 186
   |||||

QY 61 DRFSGSGGTDTLTISRLEPEDFAVYCCQYGSPPCSFGQGTKLEIK 108
   |||||
Db 187 DRFSGSGGTDTLTISRLEPEDFAVYCCQYGSPPCSFGQGTKVDIK 234
   |||||

RESULT 7
US-11-056-825-4
; Sequence 4, Application US/11056825
; Publication No. US20050255109A1
; GENERAL INFORMATION:
; APPLICANT: Felding-Habermann, Brunhilde
; APPLICANT: Janda, Kim D.
; APPLICANT: Saven, Alan
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR INHIBITION OF METASTASIS
; FILE REFERENCE: SCRP-0042
; CURRENT APPLICATION NUMBER: US/11/056,825
; CURRENT FILING DATE: 2005-02-11
```

```
; PRIOR APPLICATION NUMBER: US 60/626,726
; PRIOR FILING DATE: 2004-11-10
; PRIOR APPLICATION NUMBER: US 60/544,807
; PRIOR FILING DATE: 2004-02-13
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 249
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-11-056-825-4

Query Match          94.6%; Score 528; DB 11; Length 249;
Best Local Similarity 94.4%; Pred. No. 8.5e-37;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 186

Qy 61 DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPCSFGQGTKLEIK 108
Db DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPRTFGQGTKVDIK 234

RESULT 8
US-10-850-635-6
; Sequence 6, Application US/10850635
; Publication No. US20050287149A1
; GENERAL INFORMATION:
; APPLICANT: Keler, Tibor
; APPLICANT: Lowy, Israel
; APPLICANT: Vitale, Laura
; APPLICANT: Blanset, Diane
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES AGAINST
; TITLE OF INVENTION: BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
; FILE REFERENCE: MXI-305
; CURRENT APPLICATION NUMBER: US/10/850,635
; PRIOR FILING DATE: 2004-05-21
; PRIOR APPLICATION NUMBER: 60/472636
; PRIOR FILING DATE: 2003-05-21
; PRIOR APPLICATION NUMBER: 60/512336
; PRIOR FILING DATE: 2003-10-16
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-850-635-6

Query Match          94.3%; Score 526; DB 9; Length 108;
Best Local Similarity 95.4%; Pred. No. 6e-37;
Matches 103; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60

Qy 61 DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPCSFGQGTKLEIK 108
Db DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSMYTFGQGTKLEIK 108

RESULT 9
US-10-721-763-27
; Sequence 27, Application US/10721763
; Publication No. US20050249729A1
; GENERAL INFORMATION:
; APPLICANT: KIRIN BEER KABUSHIKI KAISHA
; TITLE OF INVENTION: ANTI TRAIL-R ANTIBODY
```

```
; FILE REFERENCE: PH-1573-PCT
; CURRENT APPLICATION NUMBER: US/10/721,763
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: JP2001-150213
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: JP2001-243040
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: JP2001-314489
; PRIOR FILING DATE: 2001-10-11
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 27
; LENGTH: 131
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-721-763-27

Query Match          94.2%; Score 525.5; DB 9; Length 131;
Best Local Similarity 95.4%; Pred. No. 7.8e-37;
Matches 104; Conservative 1; Mismatches 3; Indels 1; Gaps 1;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 80

Qy 61 DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPC-SFGQGTKLEIK 108
Db DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPPLYTFGQGTKLEIK 129

RESULT 10
US-10-850-635-4
; Sequence 4, Application US/10850635
; Publication No. US20050287149A1
; GENERAL INFORMATION:
; APPLICANT: Keler, Tibor
; APPLICANT: Lowy, Israel
; APPLICANT: Vitale, Laura
; APPLICANT: Blanset, Diane
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES AGAINST
; TITLE OF INVENTION: BACILLUS ANTHRACIS PROTECTIVE ANTIGEN
; FILE REFERENCE: MXI-305
; CURRENT APPLICATION NUMBER: US/10/850,635
; PRIOR FILING DATE: 2004-05-21
; PRIOR APPLICATION NUMBER: 60/472636
; PRIOR FILING DATE: 2003-05-21
; PRIOR APPLICATION NUMBER: 60/512336
; PRIOR FILING DATE: 2003-10-16
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-850-635-4

Query Match          93.9%; Score 524; DB 9; Length 108;
Best Local Similarity 94.4%; Pred. No. 8.8e-37;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60
Db EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLIIYATSSRATGIP 60

Qy 61 DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPCSFGQGTKLEIK 108
Db DRFSGSGSDTFTLTISRLEPEDFAVYYCQYGGSPPTFGGGTKVEIK 108

RESULT 11
US-11-051-453-58
; Sequence 58, Application US/11051453
; Publication No. US20050287150A1
```


GENERAL INFORMATION:
; APPLICANT: AMBROSINO, DONNA
; APPLICANT: BABCOCK, GREGORY J.
; APPLICANT: BROERING, THERESA
; APPLICANT: GRAZIANO, ROBERT
; APPLICANT: HERNANDEZ, HECTOR JAVIER
; APPLICANT: LOWY, ISRAEL
; APPLICANT: MANDELL, ROBERT
; APPLICANT: MOLRINE, DEBORAH
; APPLICANT: THOMAS, JR., WILLIAM D.
; APPLICANT: ZHANG, HUI-PEN
; TITLE OF INVENTION: ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND
; FILE REFERENCE: MJI-001
; CURRENT APPLICATION NUMBER: US/11/051,453
; PRIOR FILING DATE: 2005-02-04
; PRIOR APPLICATION NUMBER: 60/542,357
; PRIOR FILING DATE: 2004-02-06
; PRIOR APPLICATION NUMBER: 60/613,854
; PRIOR FILING DATE: 2004-09-28
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 58
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-051-453-58

Query Match 93.9%; Score 524; DB 11; Length 108;
Best Local Similarity 94.4%; Pred. No. 8.8e-37;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKPKQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKPKQAPRLLIYATSSRATGIP 60
QY 61 DRFGSGSGTDTFTLTISRLEPEDFAVYCCQYGGSPSCFSGQGTKEIK 108
Db 61 DRFGSGSGTDTFTLTISRLEPEDFAVYCCQYGGSPSCFSGQGTKEIK 108

RESULT 12
US-11-051-453-60
; Sequence 60, Application US/11051453
; Publication No. US20050287150A1
; GENERAL INFORMATION:
; APPLICANT: AMBROSINO, DONNA
; APPLICANT: BABCOCK, GREGORY J.
; APPLICANT: BROERING, THERESA
; APPLICANT: GRAZIANO, ROBERT
; APPLICANT: HERNANDEZ, HECTOR JAVIER
; APPLICANT: LOWY, ISRAEL
; APPLICANT: MANDELL, ROBERT
; APPLICANT: MOLRINE, DEBORAH
; APPLICANT: THOMAS, JR., WILLIAM D.
; APPLICANT: ZHANG, HUI-PEN
; TITLE OF INVENTION: ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND
; FILE REFERENCE: MJI-001
; CURRENT APPLICATION NUMBER: US/11/051,453
; PRIOR FILING DATE: 2005-02-04
; PRIOR APPLICATION NUMBER: 60/542,357
; PRIOR FILING DATE: 2004-02-06
; PRIOR APPLICATION NUMBER: 60/613,854
; PRIOR FILING DATE: 2004-09-28
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 60
; LENGTH: 128
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-051-453-60

Query Match 93.9%; Score 524; DB 11; Length 128;
Best Local Similarity 94.4%; Pred. No. 1e-36;
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKPKQAPRLLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKPKQAPRLLIYATSSRATGIP 80
QY 61 DRFGSGSGTDTFTLTISRLEPEDFAVYCCQYGGSPSCFSGQGTKEIK 108
Db 81 DRFGSGSGTDTFTLTISRLEPEDFAVYCCQYGGSPSCFSGQGTKEIK 128

RESULT 13
US-11-211-917-113
; Sequence 113, Application US/11211917
; Publication No. US20060093600A1
; GENERAL INFORMATION:
; APPLICANT: BEDIAN, VAHE
; APPLICANT: GLADUE, RONALD P.
; APPLICANT: CORVALAN, JOSE
; APPLICANT: JIA, XIAO-CHI
; APPLICANT: FENG, XIAO
; TITLE OF INVENTION: ANTIBODIES TO CD40
; FILE REFERENCE: ABX-PF/3 US
; CURRENT APPLICATION NUMBER: US/11/211,917
; CURRENT FILING DATE: 2005-08-25
; PRIOR APPLICATION NUMBER: US/10/292,088
; PRIOR FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: 60/348,980
; PRIOR FILING DATE: 2001-11-09
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 113
; LENGTH: 108
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-211-917-113

Query Match 93.7%; Score 523; DB 10; Length 108;
Best Local Similarity 93.5%; Pred. No. 1.1e-36;
Matches 101; Conservative 3; Mismatches 4; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKPKQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAAYQKPKQAPRLLIYATSSRATGIP 60
QY 61 DRFGSGSGTDTFTLTISRLEPEDFAVYCCQYGGSPSCFSGQGTKEIK 108
Db 61 DRFGSGSGTDTFTLTISRLEPEDFAVYCCQYGGSPSCFSGQGTKEIK 108

RESULT 14
US-11-128-900-14
; Sequence 14, Application US/11128900
; Publication No. US20050287136A1
; GENERAL INFORMATION:
; APPLICANT: HANSON, DOUGLAS C.
; APPLICANT: NEVEU, MARK J.
; APPLICANT: MUELLER, EILEEN E.
; APPLICANT: HANKE, JEFFREY H.
; APPLICANT: GILMAN, STEVEN C.
; APPLICANT: DAVIS, C. GEOFFREY
; APPLICANT: CORVALAN, JOSE R.
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
; FILE REFERENCE: ABX-PF1 DIV3
; CURRENT APPLICATION NUMBER: US/11/128,900
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 10/776649
; PRIOR FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 10/612497
; PRIOR APPLICATION NUMBER: 2003-07-01
; PRIOR APPLICATION NUMBER: US 09/472087

```
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: US 60/113647
; PRIOR FILING DATE: 1998-12-23
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 235
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-128-900-14

Query Match          93.4%; Score 521; DB 11; Length 235;
Best Local Similarity 91.7%; Pred. No. 3.1e-36;
Matches 99; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKQAPRLLIYATSSRATGIP 60
   |||||
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKQAPRLLIYATSSRATGIP 80
   |||||

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGSPCSFGQGTKLEIK 108
   |||||
Db 81 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGSPCSFGQGTKLEIK 128
   |||||

RESULT 15
US-11-128-900-65
; Sequence 65, Application US/11128900
; Publication No. US20050287136A1
; GENERAL INFORMATION:
; APPLICANT: HANSON, DOUGLAS C.
; APPLICANT: NEVEU, MARK J.
; APPLICANT: MUELLER, EILEEN E.
; APPLICANT: HANKE, JEFFREY H.
; APPLICANT: GILMAN, STEVEN C.
; APPLICANT: DAVIS, C. GEOFFREY
; APPLICANT: CORVALAN, JOSE R.
; TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES TO CTLA-4
; FILE REFERENCE: ABX-PFI DIV3
; CURRENT APPLICATION NUMBER: US/11/128,900
; CURRENT FILING DATE: 2005-05-12
; PRIOR APPLICATION NUMBER: US 10/776649
; PRIOR FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: US 10/612497
; PRIOR APPLICATION NUMBER: 2003-07-01
; PRIOR APPLICATION NUMBER: US 09/472087
; PRIOR FILING DATE: 1999-12-23
; PRIOR APPLICATION NUMBER: US 60/113647
; PRIOR FILING DATE: 1998-12-23
; NUMBER OF SEQ ID NOS: 147
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 65
; LENGTH: 235
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-128-900-65

Query Match          93.4%; Score 521; DB 11; Length 235;
Best Local Similarity 91.7%; Pred. No. 3.1e-36;
Matches 99; Conservative 6; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKQAPRLLIYATSSRATGIP 60
   |||||
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKQAPRLLIYATSSRATGIP 80
   |||||

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGSPCSFGQGTKLEIK 108
   |||||
Db 81 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGSPCSFGQGTKLEIK 128
   |||||
```

Search completed: May 15, 2006, 17:25:49
Job time : 18.1502 secs

GenCore version 5.1.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: May 15, 2006, 16:59:17 ; Search time 21.7854 Seconds
(without alignments)
476.989 Million cell updates/sec

Title: US-10-041-860-49
Perfect score: 558
Sequence: 1 EIVLTQSPGTLSPGERAT.....CQQYGSPPCSFGQGTKLEIK 108
Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283416 segs, 96216763 residues
Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	535	95.9	108	2	Ig kappa chain V-I
2	535	95.9	109	2	Ig kappa chain V-I
3	534	95.7	109	2	Ig kappa chain V-I
4	533	95.5	109	2	Ig kappa chain V-I
5	531	95.2	109	2	Ig kappa chain V-I
6	531	95.2	109	2	Ig kappa chain V-I
7	530	95.0	109	2	Ig kappa chain V-I
8	530	95.0	129	2	Ig light chain var
9	530	95.0	134	2	Ig kappa chain V-I
10	529	94.8	109	2	Ig kappa chain V-I
11	529	94.8	129	2	anti-5m antibody V
12	528	94.6	129	1	Ig kappa chain V-I
13	527	94.4	128	2	Ig kappa chain V-I
14	526	94.3	129	1	Ig kappa chain V-I
15	524	93.9	109	1	Ig kappa chain V-I
16	524	93.9	109	2	Ig kappa chain V-I
17	523.5	93.8	114	2	Ig kappa chain V-I
18	521	93.4	109	1	Ig kappa chain V-I
19	520	93.2	109	2	Ig kappa chain V-I
20	515	92.3	109	2	Ig kappa chain V-I
21	514	92.1	107	2	Ig kappa chain V-I
22	514	92.1	108	2	Ig kappa chain V-I
23	513	91.9	124	2	Ig kappa chain - h
24	511	91.6	121	2	Ig kappa chain - h
25	508	91.0	109	1	Ig kappa chain V-I
26	507	90.9	110	2	Ig kappa chain V-I
27	504.5	90.4	108	2	Ig kappa chain V-I
28	503.5	90.2	110	2	Ig kappa chain V-I
29	503	90.1	108	1	Ig kappa chain V-I

30 502 90.0 109 2 F44151 Ig kappa chain V r
31 501.5 89.9 108 2 H44151 Ig kappa chain V r
32 500 89.6 109 1 K3HUGO Ig kappa chain V-I
33 500 89.6 130 2 S20637 Ig kappa chain V r
34 499 89.4 129 2 A32274 Ig kappa chain pre
35 497.5 89.2 110 2 S44120 Ig kappa chain V-J
36 495 88.7 109 2 S47181 Ig kappa chain - h
37 488.5 87.5 104 2 PH0964 Ig kappa chain V r
38 488 87.5 215 2 JE0242 Ig kappa chain NIG
39 486.5 87.2 129 2 S40325 Ig kappa chain - h
40 485 86.9 96 2 A30601 Ig kappa chain V-I
41 485 86.9 116 2 B27594 Ig kappa chain pre
42 484 86.7 215 2 A23746 Ig kappa chain V-I
43 479 85.8 118 2 T03036 Ig light chain - h
44 477 85.5 108 2 S33988 Ig kappa chain V r
45 475 85.1 116 2 C27594 Ig kappa chain pre

ALIGNMENTS

RESULT 1

C30608
Ig kappa chain V-III region (Pie) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 09-Jul-2004
C:Accession: C30608
R:Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Solc
J. Immunol. 142, 3158-3163, 1989
A:Title: Structural and idiotypic characterization of the L chains of human IgM autoantibodies
A:Reference number: A30601; MUID:89215279; PMID:2496160
A:Accession: C30608
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-108 <GON>
A:Cross-references: UNIPROT:Q9UL78; UNIPARC:UPI0000176AE3
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:16-91/Domain: immunoglobulin homology <IMM>

Query Match 95.9%; Score 535; DB 2; Length 108;
Best Local Similarity 96.3%; Pred. No. 3.8e-38;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSYLAWYQKPGQAPRLIYGNSSRATGIP 60
QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCYQYGSPPCSFGQGTKLEIK 108
Db 61 DRFGSGSGTDTLTISRLEPEDFAVYCYQYGSPPCSFGQGTKLEIK 108

RESULT 2

H30601
Ig kappa chain V-III region (Gar and Flo) - human (fragment)
C:Species: Homo sapiens (man)
C:Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 21-Jan-2000
C:Accession: H30601; E30601
R:Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Solc
J. Immunol. 142, 3158-3163, 1989
A:Title: Structural and idiotypic characterization of the L chains of human IgM autoantibodies
A:Reference number: A30601; MUID:89215279; PMID:2496160
A:Accession: H30601
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-109 <GON1>
A:Cross-references: UNIPARC:UPI0000011B930
A:Accession: E30601
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-109 <GON2>
A:Cross-references: UNIPARC:UPI0000011B930

C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-91/Domain: immunoglobulin homology <IMM>

Query Match 95.9%; Score 535; DB 2; Length 109;
Best Local Similarity 96.3%; Pred. No. 3.8e-38;
Matches 104; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPYTFGQGTKLEIK 108

RESULT 3

F30601
Ig kappa chain V-III region (Nuc) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 21-Jan-2000
C;Accession: F30601
J;Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Soldo
R;Immunol. 142, 3158-3163, 1989
A;Title: Structural and idiotypic characterization of the L chains of human IgM autoanti
A;Reference number: A30601; MUID:89215279; PMID:2496160
A;Accession: F30601
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-109 <GON>
A;Cross-references: UNIPARC:UPI0000176AE8
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-91/Domain: immunoglobulin homology <IMM>

Query Match 95.7%; Score 534; DB 2; Length 109;
Best Local Similarity 93.5%; Pred. No. 4.6e-38;
Matches 101; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSRYLAWYQKPGQAPRLLIYATSSRATGIP 60
Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPCSFGQGTKLEIK 108
Db 61 DRFTGSGGTDFTLVSRLEPEDFAVYCCQYGGSPCTFGQGTKLEIK 108

RESULT 4

B30601
Ig kappa chain V-III region (Glo) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 09-Jul-2004
C;Accession: B30601
J;Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Soldo
R;Immunol. 142, 3158-3163, 1989
A;Title: Structural and idiotypic characterization of the L chains of human IgM autoanti
A;Reference number: A30601; MUID:89215279; PMID:2496160
A;Accession: B30601
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-109 <GON>
A;Cross-references: UNIPARC:UPI0000176AE7
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-91/Domain: immunoglobulin homology <IMM>

Query Match 95.5%; Score 533; DB 2; Length 109;
Best Local Similarity 95.4%; Pred. No. 5.6e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60

Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPPLTFGQGTKVEIK 108

RESULT 5

PH0963
Ig kappa chain V region (G6+ CLL-SMI) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 17-Apr-1993 #sequence_revision 17-Apr-1993 #text_change 09-Jul-2004
C;Accession: PH0963
R;Martin, T.; Duffy, S.F.; Carson, D.A.; Kipps, T.J.
J. Exp. Med. 175, 983-991, 1992
A;Title: Evidence for somatic selection of natural autoantibodies.
A;Reference number: PH0952; MUID:92202880; PMID:1552291
A;Accession: PH0963
A;Status: nucleic acid sequence not shown
A;Molecule type: DNA
A;Residues: 1-109 <MAR>
A;Cross-references: UNIPROT:Q9UL78; UNIPARC:UPI0000176A29
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;1-23/Region: framework 1
F;16-91/Domain: immunoglobulin homology <IMM>
F;24-34/Region: complementarity-determining 1
F;35-50/Region: framework 2
F;51-56/Region: complementarity-determining 2
F;57-89/Region: framework 3
F;90-97/Region: complementarity-determining 3

Query Match 95.2%; Score 531; DB 2; Length 109;
Best Local Similarity 95.4%; Pred. No. 8.2e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Qy 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPCSFGQGTKLEIK 108
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPPAFGQGTKVEIK 108

RESULT 6

D30601
Ig kappa chain V-III region (Cur) - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 09-Jul-2004
C;Accession: D30601
J;Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Soldo
R;Immunol. 142, 3158-3163, 1989
A;Title: Structural and idiotypic characterization of the L chains of human IgM autoanti
A;Reference number: A30601; MUID:89215279; PMID:2496160
A;Accession: D30601
A;Status: preliminary
A;Molecule type: protein
A;Residues: 1-109 <GON>
A;Cross-references: UNIPROT:Q9UL78; UNIPARC:UPI0000176AE9
C;Superfamily: immunoglobulin V region; immunoglobulin homology
C;Keywords: heterotetramer; immunoglobulin
F;16-91/Domain: immunoglobulin homology <IMM>

Query Match 95.2%; Score 531; DB 2; Length 109;
Best Local Similarity 95.4%; Pred. No. 8.2e-38;
Matches 103; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60

QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSSPCSFQGQTKLEIK 108
|||||
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPRTFGQTKVEIK 108

RESULT 7

C30601
Ig kappa chain V-III region (Pay) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 09-Jul-2004
C:Accession: C30601
R:Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Sold
J. Immunol. 142, 3158-3163, 1989
A:Title: Structural and idiotypic characterization of the L chains of human IgM autoanti
A:Reference number: A30601; MUID:89215279; PMID:2496160
A:Accession: C30601
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-109 <GON>
A:Cross-references: UNIPROT:Q9UL78; UNIPARC:UPI0000176ABE
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:16-91/Domain: immunoglobulin homology <IMM>

Query Match 95.0%; Score 530; DB 2; Length 109;
Best Local Similarity 94.4%; Pred. No. 9.9e-38;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 60
|||||
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 60
|||||
QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSSPCSFQGQTKLEIK 108
|||||
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPRTFGQTKVEIK 108

RESULT 8

S46369
IG light chain variable region (VJ) - human
C:Species: Homo sapiens (man)
C>Date: 07-May-1995 #sequence_revision 21-Jul-1995 #text_change 21-Jan-2000
C:Accession: S46369
R:Bensimon, C.; Chastagner, P.; Zouali, M.
EMBO J. 13, 2951-2962, 1994
A:Title: Human lupus anti-DNA autoantibodies undergo essentially primary V(chi) gene re
A:Reference number: S46369; MUID:94313975; PMID:8039491
A:Accession: S46369
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-129 <BEN>
A:Cross-references: UNIPARC:UPI0000176CA5; EMBL:227170
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: immunoglobulin
P:36-111/Domain: immunoglobulin homology <IMM>

Query Match 95.0%; Score 530; DB 2; Length 129;
Best Local Similarity 95.4%; Pred. No. 1.2e-37;
Matches 103; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 60
|||||
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 80
|||||
QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSSPCSFQGQTKLEIK 108
|||||
Db 81 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPRTFGQTKLEIK 128

RESULT 9

S38643
Ig kappa chain V region - human (fragment)
C:Species: Homo sapiens (man)

C>Date: 06-Jan-1995 #sequence_revision 06-Jan-1995 #text_change 21-Jan-2000
C:Accession: S38643
R:Bensimon, C.; Chastagner, P.; Zouali, M.
submitted to the EMBL Data Library, November 1993
A:Description: Low rate of receptor-editing in human lupus anti-DNA autoantibodies.
A:Reference number: S38643
A:Accession: S38643
A>Status: preliminary
A:Molecule type: mRNA
A:Residues: 1-134 <BEN>
A:Cross-references: UNIPARC:UPI00001165A2; EMBL:227170; NID:g415955; PIDN:CAA81694.1; PI
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:41-116/Domain: immunoglobulin homology <IMM>

Query Match 95.0%; Score 530; DB 2; Length 134;
Best Local Similarity 95.4%; Pred. No. 1.2e-37;
Matches 103; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 60
|||||
Db 26 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 85
|||||
QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSSPCSFQGQTKLEIK 108
|||||
Db 86 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPRTFGQTKLEIK 133

RESULT 10

G30601
Ig kappa chain V-III region (Got) - human (fragment)
C:Species: Homo sapiens (man)
C>Date: 29-Jun-1989 #sequence_revision 29-Jun-1989 #text_change 09-Jul-2004
C:Accession: G30601
R:Goni, F.R.; Chen, P.P.; McGinnis, D.; Arjonilla, M.L.; Fernandez, J.; Carson, D.; Sold
J. Immunol. 142, 3158-3163, 1989
A:Title: Structural and idiotypic characterization of the L chains of human IgM autoant
A:Reference number: A30601; MUID:89215279; PMID:2496160
A:Accession: G30601
A>Status: preliminary
A:Molecule type: protein
A:Residues: 1-109 <GON>
A:Cross-references: UNIPROT:Q9UL78; UNIPARC:UPI0000176ABE
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer; immunoglobulin
P:16-91/Domain: immunoglobulin homology <IMM>

Query Match 94.8%; Score 529; DB 2; Length 109;
Best Local Similarity 95.4%; Pred. No. 1.2e-37;
Matches 103; Conservative 1; Mismatches 4; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 60
|||||
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAAYQKQKQAPRLIYATSSRATGIP 60
|||||
QY 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSSPCSFQGQTKLEIK 108
|||||
Db 61 DRFSGSGGTDFTLTISRLEPEDFAVYCCQYGGSPRTFGQTKLEIK 108

RESULT 11

S49532
anti-Sm antibody VL chain (V kappa 3/J kappa 2) - human
C:Species: Homo sapiens (man)
C>Date: 01-Feb-1995 #sequence_revision 12-May-1995 #text_change 21-Jan-2000
C:Accession: S49532
R:Mahmoudi, M.; Edwards, J.; Cairns, E.; Bell, D.
submitted to the EMBL Data Library, October 1994
A:Description: Molecular characterization of natural human anti-Sm autoantibodies.
A:Reference number: S48797
A:Accession: S49532
A>Status: preliminary
A:Molecule type: mRNA

C:Accession: A01895
R:Suter, L.; Barnikol, H.U.; Watanabe, S.; Hilschmann, N.
Hoppe-Seyler's Z. Physiol. Chem. 353, 189-208, 1972
A:Title: Die Primaerstruktur einer monoklonalen Immunglobulin-L-Kette vom kappa-Typ, Sub
A:Reference number: A91651; MUID:72188439; PMID:5027703
A:Accession: A01895
A:Molecule type: protein
A:Residues: 1-109 <SUT>
A:Cross-references: UNIPROT:P01622; UNIPARC:UPI000012E15D
A:Note: the sequence of the C region, which has the Inv (3) marker, is also given
C:Comment: This is a Bence Jones protein.
C:Genetics:
A:Gene: GDB:IGKV3
A:Cross-references: GDB:136266
A:Map position: 2p12-2p11
C:Complex: An immunoglobulin heterotetramer subunit consists of two identical light (kap
hain disulfide bonds. In some cases, such as IgA and IgM, the subunits associate into la
C:Superfamily: immunoglobulin V region; immunoglobulin homology
C:Keywords: heterotetramer
F:16-91/Domain: immunoglobulin homology <IMM>
F:23-89/Disulfide bonds: #status predicted

Query Match	93.9%	Score 524;	DB 1;	Length 109;
Best Local Similarity	92.6%	Pred. No. 3.2e-37;	Mismatches 3;	Indels 0; Gaps 0;
Matches 100;	Conservative 5;			
QY	1	EIVLTQSPPTLSLSPGERATLSCRASQSVSSYLAWYQKQAPRLIIYATSSRATGIP	60	
Db	1	EIVLTQSPPTLSLSPGERATLSCRASQSVNSFLAWYQKQAPRLIIYVASSRATGIP	60	
QY	61	DRFGSGSGTDPTLTISRLEPEDFAVYCCQYGSFPCSPGQGTKLEIK	108	
Db	61	DRFGSGSGTDPTLTISRLEPEDFAVYCCQYGSFPCSPGQGTKVELK	108	

Search completed: May 15, 2006, 17:04:49
Job time : 22.7854 secs

HIS PAGE LEFT BLANK

GenCore version 5.1.1.8
Copyright (c) 1993 - 2006 Bioceleration Ltd.
OM protein - protein search, using sw model
Run on: May 15, 2006, 16:54:27 ; Search time 138.592 Seconds
(without alignments)
549.793 Million cell updates/sec
Title: US-10-041-860-49
Perfect score: 558
Sequence: 1 EIVLTQSPGTLISLSPERAT.....CQQYSSPCSFQGTQKLEIK 108

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5
Searched: 2166443 seqs, 705528306 residues
Total number of hits satisfying chosen parameters: 2166443
Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries
Database : UniProt 05.80.*
1: uniprot_sprot.*
2: uniprot_trembl.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	528	94.6	129	1 KV3L HUMAN	P18135 homo sapien
2	526	94.3	129	1 KV3M HUMAN	P18136 homo sapien
3	524	93.9	109	1 KV3D HUMAN	P01622 homo sapien
4	521	93.4	109	1 KV3B HUMAN	P01620 homo sapien
5	518	92.8	109	2 Q9UL78 HUMAN	Q9UL78 homo sapien
6	508	91.0	109	1 KV3E HUMAN	P01623 homo sapien
7	506.5	90.8	236	2 Q6PIL8 HUMAN	Q6PIL8 homo sapien
8	504	90.3	109	2 Q9UL86 HUMAN	Q9UL86 homo sapien
9	503	90.1	108	1 KV3A HUMAN	P01619 homo sapien
10	500	89.6	109	1 KV3G HUMAN	P04206 homo sapien
11	493	88.4	235	2 Q6PJF2 HUMAN	Q6PJF2 homo sapien
12	491	88.0	235	2 Q6GMV9 HUMAN	Q6GMV9 homo sapien
13	481.5	86.3	236	2 Q6P5S8 HUMAN	Q6P5S8 homo sapien
14	466	83.5	100	1 KV3C HUMAN	P01621 homo sapien
15	465.5	83.4	128	1 KV3K HUMAN	P06311 homo sapien
16	446	79.9	109	1 KV3F HUMAN	P01624 homo sapien
17	445.5	78.8	234	2 Q569I9 HUMAN	Q569I9 homo sapien
18	439	78.7	129	1 KV3H HUMAN	Q64207 homo sapien
19	435.5	78.0	108	2 Q9UL83 HUMAN	Q9UL83 homo sapien
20	426	76.3	109	2 Q9UL85 HUMAN	Q9UL85 homo sapien
21	420.5	75.4	115	1 KV31 HUMAN	P04433 homo sapien
22	420	75.3	235	2 Q6GMW0 HUMAN	Q6GMW0 homo sapien
23	415.5	74.5	114	1 KV4A HUMAN	P01625 homo sapien
24	414	74.2	116	1 KV3J HUMAN	P04434 homo sapien
25	399.5	71.6	134	1 KV4C HUMAN	P06314 homo sapien
26	398.5	71.4	108	2 Q9UL79 HUMAN	Q9UL79 homo sapien
27	397.5	71.2	108	1 KV1H HUMAN	P01600 homo sapien
28	394.5	70.7	236	2 Q6PIH7 HUMAN	Q6PIH7 homo sapien
29	390.5	70.0	108	2 Q9UL77 HUMAN	Q9UL77 homo sapien
30	387	69.4	133	1 KV4B HUMAN	P06313 homo sapien
31	386.5	69.3	108	2 Q9UL70 HUMAN	Q9UL70 homo sapien

32	386.5	69.3	236	2 Q6GMX8 HUMAN	Q6GMX8 homo sapien
33	384	68.8	114	2 Q8K1F1 MOUSE	Q8K1F1 mus musculus
34	383.5	68.7	131	2 Q811C3 MOUSE	Q811C3 mus musculus
35	382.5	68.5	108	1 KV1M HUMAN	P01605 homo sapien
36	382.5	68.5	236	2 Q723Y4 HUMAN	Q723Y4 homo sapien
37	382.5	68.5	236	2 Q6GMX3 HUMAN	Q6GMX3 homo sapien
38	381.5	68.4	244	2 Q85ZC8 HUMAN	Q85ZC8 homo sapien
39	381	68.3	107	2 Q96SA9 HUMAN	Q96SA9 homo sapien
40	380.5	68.2	108	1 KV1F HUMAN	P01598 homo sapien
41	379.5	68.0	108	1 KV1K HUMAN	P01603 homo sapien
42	378.5	67.8	234	2 Q72473 HUMAN	Q72473 homo sapien
43	377.5	67.7	236	2 Q8P1T5 HUMAN	Q8P1T5 homo sapien
44	377.5	67.7	240	2 Q85ZC9 HUMAN	Q85ZC9 homo sapien
45	376.5	67.5	255	2 Q6KB05 MOUSE	Q6KB05 mus musculus

ALIGNMENTS

RESULT 1
KV3L HUMAN STANDARD; PRT; 129 AA.
AC P18135;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DE 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-III region HAH precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
EX MEDLINE=89171307; PubMed=3127527; DOI=10.1084/jem.167.3.840;
RA Kipps T.J., Tomhave E., Chen P.P., Carson D.A.;
RT "Antibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy.";
RL J. Exp. Med. 167:840-852 (1988).
CC -I- DISEASE: The protein is one of the surface immunoglobulin M autoantibodies expressed in patients with chronic lymphocytic leukemia.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use as long as its content is in no way modified and this statement is not removed.
CC -----
CC PIR; PLO022; K3HUHA.
CC HSSP; P01625; 1BBQ.
CC SMR; P18135; 21-129.
CC Ensembl; ENSG00000169769; Homo sapiens.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; P:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; Igv; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 129
FT REGION 21 43
FT REGION 44 55
FT REGION 56 70
FT REGION 71 77
FT REGION 78 109
FT REGION 110 118
FT REGION 119 129
FT DISULFID 43 109
FT NON_TER 129 129
FT -----
FT Ig kappa chain V-III region HAH.
FT Framework-1.
FT Complementarity-determining-1.
FT Framework-2.
FT Complementarity-determining-2.
FT Framework-3.
FT Complementarity-determining-3.
FT JKL segment.
FT By similarity.

```
SQ SEQUENCE 129 AA; 14073 MW; D3C52927272774D0 CRC64;
Query Match 94.6%; Score 528; DB 1; Length 129;
Best Local Similarity 94.4%; Pred. No. 6.8e-47;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 80

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 80

Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSCSFQGGTKLEIK 108
Db 81 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSPRTFGGQTKVEIK 128

Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSCSFQGGTKLEIK 108
Db 81 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSPRTFGGQTKVEIK 128

RESULT 2
KV3M HUMAN
ID KV3M HUMAN STANDARD; PRT; 129 AA.
AC P18136;
DT 01-NOV-1990 (Rel. 16, Created)
DT 01-NOV-1990 (Rel. 16, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-III region HIC precursor.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=88171307; PubMed=3127527; DOI=10.1084/jem.167.3.840;
RA Kipps T.J., Tomhave E., Chen P.P., Carson D.A.;
RT "Autoantibody-associated kappa light chain variable region gene
RT expressed in chronic lymphocytic leukemia with little or no somatic
RT mutation. Implications for etiology and immunotherapy.";
RL J. Exp. Med. 167:840-852 (1988).
CC -!- DISEASE: The protein is one of the surface immunoglobulin M
CC autoantibodies expressed in patients with chronic lymphocytic
CC leukemia.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; P18021; K3HUH1.
CC HSSP; P01625; 1EQ.
CC SMR; P18136; 21-129.
CC
CC Ensembl; ENSG00000169769; Homo sapiens.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS0835; IG LIKE; 1.
CC Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 129 Ig kappa chain V-III region HIC.
FT REGION 21 43 Framework-1.
FT REGION 44 55 Complementarity-determining-1.
FT REGION 56 70 Framework-2.
FT REGION 71 77 Complementarity-determining-2.
FT REGION 78 109 Framework-3.
FT REGION 110 118 Complementarity-determining-3.
FT REGION 119 129 JKL segment.
FT DISULFID 43 109 By similarity.
FT NON TER 129 129
SQ SEQUENCE 129 AA; 14071 MW; 7395528EA2BB74D6 CRC64;
Query Match 94.3%; Score 526; DB 1; Length 129;
Best Local Similarity 94.4%; Pred. No. 1.1e-46;
Matches 102; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
```

```
Matches 102; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 80

Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSCSFQGGTKLEIK 108
Db 81 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSPRTFGGQTKVEIK 128

RESULT 3
KV3D HUMAN
ID KV3D HUMAN STANDARD; PRT; 109 AA.
AC P01622;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-III region TI.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=72188439; PubMed=5027703;
RA Suter L., Barnikol H.U., Watanabe S., Hilschmann N.;
RT "Rule of antibody structure. The primary structure of a monoclonal
RT immunoglobulin L-chain of kappa-type, subgroup 3 (Bence-Jones protein
RT Ti). IV. The complete amino acid sequence and its significance for the
RT mechanism of antibody production.";
RL Hoppe-Seyler's Z. Physiol. Chem. 353:189-208 (1972).
CC -!- MISCELLANEOUS: The C region of this chain has the INV (3) marker.
CC -!- MISCELLANEOUS: This is a Bence-Jones protein.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A01895; K3HUT1.
CC HSSP; P01625; 1LVE.
CC SMR; P01622; 1-109.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; IG-like.
CC InterPro; IPR003596; IG_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS0835; IG LIKE; 1.
CC Bence-Jones protein; Direct protein sequencing; Immunoglobulin domain;
CC Immunoglobulin V region.
FT DISULFID 23 89 By similarity.
FT NON TER 109 109
SQ SEQUENCE 109 AA; 11788 MW; 8C35058CDC7749BC CRC64;
Query Match 93.9%; Score 524; DB 1; Length 109;
Best Local Similarity 92.6%; Pred. No. 1.5e-46;
Matches 100; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

Qy 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQOKPGQAPRLIYATSSRATGIP 60

Qy 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSCSFQGGTKLEIK 108
Db 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGGSPSPRTFGGQTKVEIK 108

RESULT 4
KV3B_HUMAN
```

```
ID KV3B HUMAN STANDARD; PRT; 109 AA.
AC P01620;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-III region SIE.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP PROTEIN SEQUENCE.
RX MEDLINE=82046598; PubMed=6794615;
RA Andrews D.W., Capra J.D.;
RT "Amino acid sequence of the variable regions of light chains from two
RT idiotypically cross-reactive human IgM anti-gamma-globulins of the Wa
RT group.";
RL Biochemistry 20:5816-5822(1981).
RC -!- MISCELLANEOUS: This chain was isolated from an IgM with anti-gamma
CC globulin activity.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
CC PIR; A01892; K3HUSI.
DR HSP; P01625; LLVE.
DR SMR; P01620; 1-109.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; P:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT DISULFID 23 89 By similarity.
FT NON TER 109 109
SQ SEQUENCE 109 AA; 11775 MW; 76893EC6D646FFB4 CRC64;

Query Match 93.4%; Score 521; DB 1; Length 109;
Best Local Similarity 92.6%; Pred. No. 3e-46; 3; Indels 0; Gaps 0;
Matches 100; Conservative 5; Mismatches 3;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCYQQYGSPPCFSGQGTKEIK 108
Db 61 DRFGSGSGTDTLTISRLEPEDFAVYCYQQYGSPPCFSGQGTKEIK 108

RESULT 5
Q9UL78 HUMAN PRELIMINARY; PRT; 109 AA.
AC Q9UL78;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-MAY-2004 (TrEMBLrel. 26, Last annotation update)
DE Myosin-reactive immunoglobulin light chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]_TaxID=9606;
RP NUCLEOTIDE SEQUENCE.
```

```
RX MEDLINE=98277139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berney S.M.,
RA Young D.C.;
RT "Myosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1373487;
RA Zebedee S.L., Barbas C.P. 3rd, Hom Y.L., Caothien R.H., Graff R.,
RA DeGraw J., Pyati J., LaPolla R., Burton D.R., Lerner R.A.;
RT "Human combinatorial antibody libraries to hepatitis B surface
RT antigen.";
RL Proc. Natl. Acad. Sci. U.S.A. 89:3175-3179(1992).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=8436174;
RA Wagner S.D., Luzzatto L.;
RT "v kappa gene segments rearranged in chronic lymphocytic leukemia are
RT distributed over a large portion of the v kappa locus and do not show
RT somatic mutation.";
RL Eur. J. Immunol. 23:391-397(1993).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RX PubMed=1552291;
RA Martin T., Duffy S.F., Carson D.A., Kipps T.J.;
RT "Evidence for somatic selection of natural autoantibodies.";
RL J. Exp. Med. 175:983-991(1992).
DR EMBL; AF035036; AAD56272.1; -, mRNA.
DR PIR; A30601; A30601.
DR PIR; A30608; A30608.
DR PIR; B30601; B30601.
DR PIR; B30607; B30607.
DR PIR; C30601; C30601.
DR PIR; C30607; C30607.
DR PIR; C30608; C30608.
DR PIR; D30601; D30601.
DR PIR; D30607; D30607.
DR PIR; D30608; D30608.
DR PIR; F30601; F30601.
DR PIR; F30607; F30607.
DR PIR; F30608; F30608.
DR PIR; G30601; G30601.
DR PIR; G30607; G30607.
DR PIR; H30601; H30601.
DR PIR; H30607; H30607.
DR PIR; H30608; H30608.
DR PIR; H44151; H44151.
DR PIR; I30601; I30601.
DR PIR; PH0963; PH0963.
DR PIR; PH0964; PH0964.
DR PIR; PH0965; PH0965.
DR PIR; S33988; S33988.
DR PIR; S34096; S34096.
DR HSP; P01625; IEX3.
DR SMR; Q9UL78; 1-109.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
FT NON TER 1 1
FT NON TER 109 109
SQ SEQUENCE 109 AA; 11646 MW; 5F675C52EC7BE197 CRC64;

Query Match 92.8%; Score 518; DB 2; Length 109;
Best Local Similarity 93.5%; Pred. No. 6.1e-46; 5; Indels 0; Gaps 0;
Matches 101; Conservative 2; Mismatches 5;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQKPKQAPRLLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCYQQYGSPPCFSGQGTKEIK 108
Db 61 DRFGSGSGTDTLTISRLEPEDFAVYCYQQYGSPPCFSGQGTKEIK 108
```

```
RESULT 6
KV3E_HUMAN
ID KV3E_HUMAN STANDARD; PRT; 109 AA.
AC P01623;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DT 05-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-III region WOL.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=82046598; PubMed=6794615;
RA Andrews D.W., Capra J.D.;
RT "Amino acid sequence of the variable regions of light chains from two
RT idiotypically cross-reactive human IgM anti-gamma-globulins of the Wa
RT group.";
RL Biochemistry 20:5816-5822(1981).
CC -!- MISCELLANEOUS: This chain was isolated from an IgM with anti-gamma
CC globulin activity.
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR PIR; A01896; K3HULW.
DR HSSP; P01625; ILVE.
DR SMR; P01623; 1-109.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig v.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 1.
KW Direct protein sequencing; Immunoglobulin domain;
KW Immunoglobulin V region.
FT DISULFID 23 89 By similarity.
FT NON TER 109 109
SQ SEQUENCE 109 AA; 11746 MW; 566C115B6B9CBEE CRC64;
Query Match 91.0%; Score 508; DB 1; Length 109;
Best Local Similarity 91.7%; Pred. No. 6.7e-45;
Matches 99; Conservative 2; Mismatches 7; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIYATSSRATGIP 60
DB 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIYATSSRATGIP 60
QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYVYCCQYGSPPCSFGQTKLEIK 108
DB 61 DRFGSGSGTDFTLTISRLEPEDFAVYVYCCQYGSPPCSFGQTKLEIK 108
RESULT 7
Q6PIL8_HUMAN
ID Q6PIL8_HUMAN PRELIMINARY; PRT; 236 AA.
AC Q6PIL8;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
```

```
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullah S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalls D.B.,
RA Schenck A., Schein J.B., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX TISSUE=Brain;
RA Strausberg R.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC032451; AAH32451.1; -, mRNA.
DR HSSP; P01837; 1KCU.
DR SMR; Q6PIL8; 21-236.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig ci.
DR InterPro; IPR003006; Ig MHC.
DR InterPro; IPR003596; Ig v.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS0835; IG LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN 1.
KW Hypothetical protein_
SQ SEQUENCE 236 AA; 25834 MW; 6647A9E77A3C0053 CRC64;
Query Match 90.8%; Score 506.5; DB 2; Length 236;
Best Local Similarity 90.8%; Pred. No. 2.4e-44;
Matches 99; Conservative 5; Mismatches 4; Indels 1; Gaps 1;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIYATSSRATGIP 60
DB 21 ENVLTSQPGTSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLIYGVSSRATGIP 80
QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYVYCCQYGSPPCSFGQTKLEIK 108
DB 81 DRFGSGSGTDFTLTISRLEPEDFAVYVYCCQYGSPPCSFGQTKLEIK 129
RESULT 8
Q9UL86_HUMAN
ID Q9UL86_HUMAN PRELIMINARY; PRT; 109 AA.
AC Q9UL86;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Myosin-reactive immunoglobulin kappa chain variable region
DE (Fragment).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
```

```

OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=9827139; PubMed=9614934; DOI=10.1006/clin.1998.4531;
RA Wu X., Liu B., Van der Merwe P.L., Kalis N.N., Berny S.M.,
RT "Yosin-reactive autoantibodies in rheumatic carditis and normal
RT fetus.";
RL Clin. Immunol. Immunopathol. 87:184-192(1998).
DR EMBL; AF035028; AAD56264.1; -; mRNA.
DR PIR; B30607; B30607.
DR PIR; I30601; I30601.
DR HSP; P01625; 1EK3.
DR SMR; Q9UL86; 1-109.
DR Ensemble; ENSG00000169769; Homo sapiens.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_v.
DR SMART; SM00406; IGV; 1_v.
DR PROSITE; PS50835; IG_LIKE; 1.
FT NON_TER 1
FT NON_TER 109
SQ SEQUENCE 109 AA; 11928 MW; 243325F72C7DAC83 CRC64;

Query Match 90.3%; Score 504; DB 2; Length 109;
Best Local Similarity 91.7%; Pred. No. 1.8e-44;
Matches 99; Conservative 3; Mismatches 6; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGQAPRLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGQAPRLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSSPCSFQGTGKLEIK 108
Db 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSSIFTEGPKTKVDIK 108

RESULT 9
KV3A_HUMAN STANDARD; PRT; 108 AA.
AC P01619;
DT 21-JUL-1986 (Rel. 01, Created)
DT 21-JUL-1986 (Rel. 01, Last sequence update)
DE 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-II region B6.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX PubMed=11946339;
RA Milstein C.;
RT "The basic sequences of immunoglobulin kappa chains: sequence studies
RT of Bence Jones proteins Rad, Fr4 and B6.";
RL FEBS Lett. 2:301-304(1969).
CC -!- MISCELLANEOUS: This is a Bence-Jones protein.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A01891; K3HUB6.
CC HSP; P01625; 1EQ.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Bence-Jones protein; Direct protein sequencing; Immunoglobulin domain;
CC Immunoglobulin V region.
CC DISULFID 23 89 By similarity.
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC Query Match 89.6%; Score 500; DB 1; Length 109;
CC Best Local Similarity 89.8%; Pred. No. 4.6e-44;
CC Matches 97; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGQAPRLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRAALISRGYLAWYQQKPKGQAPRLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSSPCSFQGTGKLEIK 108
Db 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSPRFSFGQTKRVEIK 108

DISULFID 23 89 By similarity.
```

```

FT NON_TER 108
SQ SEQUENCE 108 AA; 11636 MW; 8BC14FF07A419E3D CRC64;

Query Match 90.1%; Score 503; DB 1; Length 108;
Best Local Similarity 86.1%; Pred. No. 2.2e-44;
Matches 93; Conservative 9; Mismatches 6; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGQAPRLIYATSSRATGIP 60
Db 1 ZIVLTZSPGTLSPGZRAALSCLASQSLSGYLAWYQQKPKGQAPRLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSSPCSFQGTGKLEIK 108
Db 61 DRFGSGSGADFTLTISRLEPEDFAVYCCQYGGSPFTFGQSGKLEIK 108

RESULT 10
KV3G_HUMAN STANDARD; PRT; 109 AA.
AC P04206;
DT 20-MAR-1987 (Rel. 04, Created)
DT 20-MAR-1987 (Rel. 04, Last sequence update)
DT 10-MAY-2005 (Rel. 47, Last annotation update)
DE Ig kappa chain V-III region GOL (Rheumatoid factor).
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Euthera; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP PROTEIN SEQUENCE.
RX MEDLINE=86230578; PubMed=3086710; DOI=10.1016/0161-5890(86)90049-0;
RA Newkirk M., Chen P.P., Carson D.A., Posnett D., Capra J.D.;
RT "Amino acid sequence of a light chain variable region of a human
RT rheumatoid factor of the Wa idiotype group, in part predicted by its
RT reactivity with anti-peptide antibodies.";
RL Mol. Immunol. 23:239-244(1986).
CC
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC
CC PIR; A01893; K3HUGO.
CC HSP; P01625; 1EK3.
CC SMR; P04206; 1-109.
CC GO; GO:0005576; C:extracellular region; NAS.
CC GO; GO:0003823; F:antigen binding; NAS.
CC GO; GO:0006955; P:immune response; NAS.
CC InterPro; IPR007110; Ig-like.
CC InterPro; IPR003596; Ig_v.
CC SMART; SM00406; IGV; 1.
CC PROSITE; PS50835; IG_LIKE; 1.
CC Direct protein sequencing; Immunoglobulin domain;
CC Immunoglobulin V region.
CC DISULFID 23 89 By similarity.
CC
CC Query Match 89.6%; Score 500; DB 1; Length 109;
CC Best Local Similarity 89.8%; Pred. No. 4.6e-44;
CC Matches 97; Conservative 3; Mismatches 8; Indels 0; Gaps 0;

QY 1 EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPKGQAPRLIYATSSRATGIP 60
Db 1 EIVLTQSPGTLSPGERATLSCRAALISRGYLAWYQQKPKGQAPRLIYATSSRATGIP 60

QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSSPCSFQGTGKLEIK 108
Db 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYGGSPRFSFGQTKRVEIK 108
```

RESULT 11

Q6PJF2_HUMAN
ID Q6PJF2_HUMAN PRELIMINARY; PRT; 235 AA.
AC Q6PJF2;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Lung;
RA Strausberg R.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC016380; AAH16380.1; -, mRNA.
DR HSSP; P01837; IKCU.
DR SMR; Q6PJF2; 21-235.
DR InterPro; IPR003599; Ig.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 235 AA; 25520 MW; F33A145A396BA285 CRC64;

Query Match 88.4%; Score 493; DB 2; Length 235;
Best Local Similarity 88.0%; Pred. No. 6e-43;
Matches 95; Conservative 7; Mismatches 6; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Db 21 EIVLTQSPATLSLSPGERATLSCRAQIVSSAYLAWYQKPGQAPRLIMFGSSSRATGIP 80
QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYQYGGSPCSFGQGTKEIK 108
Db 81 DRFGSGSGTDTLTISRLEPEDFAVYCCQYQYGGSGTGFPGTKVDIK 128

RESULT 12

Q6GMV9_HUMAN
ID Q6GMV9_HUMAN PRELIMINARY; PRT; 235 AA.
AC Q6GMV9;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RX MEDLINE=2238257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Heieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Spleen;
RA Strausberg R.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC073793; AAH73793.1; -, mRNA.
DR SMR; Q6GMV9; 21-235.
DR GO; GO:0016021; C: integral to membrane; IEA.
DR InterPro; IPR003599; Ig-like.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003597; Ig cl.
DR InterPro; IPR003006; Ig_MHC.
DR InterPro; IPR003596; Ig_v.
DR Pfam; PF07654; CI-set; 1.
DR SMART; SM00409; IG; 2.
DR SMART; SM00407; IGcl; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 2.
DR PROSITE; PS00290; IG_MHC; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 235 AA; 25646 MW; DF32B580BAD19E4B CRC64;

Query Match 88.0%; Score 491; DB 2; Length 235;
Best Local Similarity 87.0%; Pred. No. 9.7e-43;
Matches 94; Conservative 7; Mismatches 7; Indels 0; Gaps 0;
QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSSYLAWYQKPGQAPRLLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLISLSPGERAALSCRASQSVNSKYLAWYQKPGQAPRLIMYASIRATGIP 80
QY 61 DRFGSGSGTDTLTISRLEPEDFAVYCCQYQYGGSPCSFGQGTKEIK 108
Db 81 DRFGSGSGTDTLTISRLEPEDFALYFCQYQYISPLTFGGGTVKEIK 128
RESULT 13
Q6P5S8_HUMAN


```

RA Klobeck H.G., Meindl A., Combriato G., Solomon A., Zachau H.G.;
RT "Human immunoglobulin kappa light chain genes of subgroups II and
RL III.";
RL Nucleic Acids Res. 13:6499-6513(1985).
CC -----
CC This Swiss-Prot entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use as long as its content is in no way modified and this statement is not
CC removed.
CC -----
DR EMBL; Z00021; CAA77316.1; -; Genomic DNA.
DR PIR; A01899; K3HU41.
DR HSP; P01625; 1ERQ.
DR SMR; P06311; 21-128.
DR GO; GO:0005576; C:extracellular region; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; Ig-like.
DR InterPro; IPR003596; Ig_V.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG_LIKE; 1.
KW Immunoglobulin domain; Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 128 Ig kappa chain V-III region IARC/BL41.
FT REGION 21 43 Framework-1.
FT REGION 44 54 Complementarity-determining-1.
FT REGION 55 69 Framework-2.
FT REGION 70 76 Complementarity-determining-2.
FT REGION 77 108 Framework-3.
FT REGION 109 117 Complementarity-determining-3.
FT REGION 118 128 JkI segment.
FT DISULFID 43 108 By similarity.
FT NON_TER 128 128
SQ SEQUENCE 128 AA; 14070 MW; CC8957F0FE3B9012 CRC64;

Query Match 83.4%; Score 465.5; DB 1; Length 128;
Best Local Similarity 87.0%; Pred. No. 2.1e-40;
Matches 94; Conservative 4; Mismatches 9; Indels 1; Gaps 1;

QY 1 EIVLTQSPGTLISLSPGERATLSCRASQSVSSYLAWYQQKPKQAPRLIYATSSRATGIP 60
Db 21 EIVLTQSPGTLISLSPGESATLSCRASQSVSSN-LAWYQQKQSPRLIIRDASSRANGIP 79

QY 61 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYGSFPCSPGQGTKLEIK 108
Db 80 DRFGSGSGTDFTLTISRLEPEDFAVYCCQYSTSPYTFGQGTKLEIK 127

```

Search completed: May 15, 2006, 17:03:56
Job time : 139.592 secs